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ABSTRACT
The survival of bacteraemic isolates of viridans streptococci, 
after the administration to subjects of prophylactic antibiotic 
cover, has been widely reported in the literature. This study 
demonstrated that the cause of bacteraemia was as a result of 
phenotypic tolerance amongst populations of bacteria, and both 
proposed a mechanism responsible for the appearance of this form of 
tolerance and the design of a model to evaluate candidate drugs for 
infective endocarditis (IE) prophylaxis.
Dental plaque material from 67 subjects not previously exposed to 
S-lactam antibiotics (UE-group) and from 50 individuals who 
received either rheumatic fever prophylaxis (RF-subgroup) (41) or 
were given high therapeutic doses of ampicillin (A-subgroup) (9), 
was inoculated into Todd-Hewitt broth containing 0.125 mg/ml 
penicillin G, 1.0 mg/ml penicillin G and a combination of 0.125 
mg/ml penicillin G plus 5 mg/ml gentamicin. After overnight in­
cubation, the selection broth cultures were subinoculated onto 
blood agar plates. Alpha-haemolytic colonies were selected for 
identification according to taxonomic principals of Kilian with a 
minor modification proposed by Coykendal to accommodate Strep­
tococcus vestibularis. The isolates were further investigated by 
determination of minimum inhibitory (MICs) and bactericidal con­
centrations (MBCs) to penicillin V, amoxycillin, erythromycin, 
roxithromycin, clindamycin and vancomycin. This approach permitted 
the demonstration of genotypic tolerance and the presence of 
persisters, while survival of streptococci with MBCs less than the 
equivalent selection concentration of penicillin G allowed for the 
demonstration of phenotypic tolerance
Results
The ex vivo model clearly demonstrated selection of S-lactam 
resistant and phenotypically tolerant isolates. S. oralis. S. mitis
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biovar 1 and S. mitis biovar 2 were most commonly isolated from 
both the antibiotic exposed group (E-group) and the group previous­
ly unexposed to S-lactam agents (UE-group). S. oralis was signifi­
cantly more common in the E-group than in the UE-group while S . 
mitis biovar 2 was relatively more plentiful in the UE-group 
compared with the E-group. Considering the combined findings of the 
three selection groups, 66 out of 140 isolates (47%) were 
phenotypically tolerant to penicillin V and 68 (63%) to amoxycill­
in, ie. survived despite equivalent MBCs being lower than the 
selection concentrations in broth. The rest of the surviving 
isolates, following in vitro selection, were obviously resistant 
with MBCs in excess of the selection concentrations. Significantly 
more isolates had MBCs for either penicillin V or amoxycillin of 
>1.0 mg/1 antibiotic (highest selection concentration of penicillin 
G) in the group previously exposed to S-lactam antibiotics than in 
the UE-group (p values <0.0001). When the isolates from patients in 
the rheumatic fever and high-dose ampicillin treatment subgroups 
were examined for S-lactam resistance and compared with the 
isolates from the UE-group, significantly more strains from the 
exposure groups demonstrated low-level resistance to both penicil­
lin V and amoxycillin. When selection in penicillin G-only (without 
gentamicin) was analysed, only resistance at a higher level (>.1.0 
mg/1) showed a significant difference between the E- and UE-groups 
in the case of penicillin V (p=0.02) and approached statistical 
significance in the case of amoxycillin (p=0.06)
Except for vancomycin to which all isolates were consistently 
susceptible, there were notable differences in the upper limits of 
susceptibility between the two penicillin exposure groups. Neither 
the MICs nor the MBCs exceeded 4 mg/1 in the UE-group while in the 
E-group, both the MICs and MBCs for the macrolides and clindamycin
xv
were greater than 64 mg/1 antibiotic, and were greater than 8 mg/1 
for penicillin V and amoxycillin. Exposure to high doses of 
ampicillin and prolonged exposure to penicillin V resulted in 
viridans bacteria which were not only more resistant to £-lactam 
agents, but also to the macrolides and clindamycin. Erythromycin 
and clindamycin showed the greater activity with the lowest MICs 50 
in both the UE- and E-groups (both 0.007 and 0.015 mg/1, respectiv­
ely) . Roxithromycin was only marginally less active than the latter 
agents (MICs 50 of 0.015 and 0.06 mg/1, respectively). MIC and MBC 
ranges were consistently higher in the ampicillin exposure 
E-subgroup (A-subgroup) than the rheumatic fever E-subgroup 
(RF-subgroup). Upper limit MIC and MBC concentrations of isolates 
were often greater than 64 mg/1 antibiotic in the A-subgroup, 
especially against the macrolides and clindamycin, but isolates 
remained fully susceptible to vancomycin. MICs 50 and MBCs 50 were, 
for most agents, approximately twice to four times higher in the 
A-subgroup compared with the RF-subgroup
Only four S. oralis isolates, all in the E-group, were genotypi­
cally tolerant with MBC:MIC ratios of >10. Of these, three were 
also tolerant to erythromycin and one to clindamycin (ratios 
>16:1). MBC:MIC ratios were clearly higher in the E-group than in 
the UE-group, including genotypic tolerance to erythromycin in the 
E-group. There was no tolerance to vancomycin
Persisters were most commonly found in the UE-group amongst S . 
mitis biovar 2 (33.3%) strains and least commonly amongst S. oralis 
(17.9%). In the E-group, S. mitis biovar 2 again produced 
proportionately the greatest number of persisters (27.8%) but, in 
contrast to the above, S. mitis biovar 1 had the least (13.3%) . Of 
all species in the study, S. oralis (which was also the most 
commonly isolated species) produced the greatest number of per­
sisters overall in the E-group (50 of a possible 444; 14%) compared 
with 7% in the UE-group
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Results of susceptibility tests of viridans streptococci to 
penicillin V and amoxycillin after selection in penicillin 
G-containing broth can be summarised as follows:
i) S. oralis and S. mitis biovars 1 and 2 were the most 
common survivors in this model
ii) Amoxycillin was more active than penicillin V amongst 
viridans streptococci in general, with the differences 
between the activities of these antibiotics being 
most marked against S. mitis biovar 1 and 2 strains
iii) There was a larger proportion of susceptible strains of 
S. oralis and S. mitis biovar 1 in the UE-group 
surviving in vitro than in the E-group but this trend 
was less marked in the strains surviving the penicillin 
G-only selection procedure
iv) Peak MICs and MBCs were highest in the E-group isolates 
and were most clearly observed in S. oralis and S. mitis 
biovar 2 strains
Further important aspects related to the susceptibility of viridans 
isolates were also studied. The observed antibiotic insensitivity 
of certain bacterial subpopulations within dental plaque deposits 
(microbial biofilms) was discussed. It was noted that current 
experimental animal models of IE prophylaxis are inadequate in as 
much as they only test candidate agents against bacteria while in 
their usually most susceptible exponential growth phase. Bacterial 
fractions disregarded by such tests are the phenotypically tolerant 
dormant or near-dormant bacteria found normally within mature (or 
stable) dental plaque deposits and other biofilms on mucosae in the 
body (bacteria exhibiting this form of tolerance would also be 
found within infected heart valve nodules)
vi
Of note was the susceptibility behaviour exhibited by certain 
isolates to the macrolide antibiotics. This appeared remarkably 
similar to phenotypic tolerance recognised traditionally only 
amongst bacterial exposed to effect of S-lactam antibiotic agents
Conclusions
The ex vivo selection broth model used in the present study clearly 
demonstrated the phenotypic tolerance phenomenon which also 
features in bacteraemias following blood-letting dental procedures 
performed under protection of S-lactam antibiotic prophylaxis. A 
mechanism is described which may be responsible not only for 
aforementioned bacteraemia but also for the presence of strains 
which subsequently test susceptible to the agent of prophylaxis 
intended to control such occurrences.
The model was useful in showing the likely effect of previous an­
tibiotic exposure on the resistance profiles of bacteraemic 
streptococci based on the in vitro selection procedure.
These positive aspects auger well for the usefulness of the model 
in evaluating candidate animicrobial agents for IE prophylaxis, 
including phenotypically tolerant subpopulations
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EFFECT ON ORAL STREPTOCOCCI OF EXPOSURE TO PENICILLIN AND ITS 
RELEVANCE IN INFECTIVE ENDOCARDITIS PROPHYLAXIS
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Chapter 1
INTRODUCTION
1.1 Some historical landmarks in the understanding of infective 
endocarditis
A detailed description of infective endocarditis (IE) appeared 
near the turn of the century in the classical writings of William 
Osier who linked viridans streptococci to subacute or "chronic" 
endocarditis. In his famous textbook "Principals and Practice of 
Medicine" published early this century (1912), Osier suggested 
that Streptococcus mitior was the most common cause of this dis­
ease. Rushton (1930) reported a direct link between dental ex­
traction (and tonsillectomy) and the development of IE while, 
five years later in 1935, Okell and Elliot were the first to show 
clearly that bacteria from the oral cavity may cause this infec­
tion
1.2 Prophylaxis against infective endocarditis
1.2.1 The link between oral streptococci and infective
endocarditis
Viridans streptococci are micro-organisms indigenous to the oral 
cavity and oropharynx and are important aetiological agents of IE 
(Roberts et al, 1979; American Heart Association Report (AHA), 
1981; Cotran et al, 1989; Hall and Heimdahl, 1989)
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1.2.2 Emergence of B—lactam resistance in viridans 
streptococci
Oral streptococci have traditionally been regarded as being sus­
ceptible to penicillin (Hall and Heimdahl, 1989) but resistant 
strains have been isolated from the oral cavity (Longman et al, 
1991) and blood (Hess et al, 1983b) of IE-susceptible patients. 
However, antibiotic use is known to select for bacterial resis­
tance in oral streptococci (Southall et al, 1983; Harrison, 
Stross et al, 1985; Herbert et al, 1988; Smith et al, 1989; Mas- 
kell et al, 1990)
Additionally, exposure has been shown to select for resistance 
soon after the initial contact between the streptococci and an 
antibacterial agent and resistant strains emerge readily in in­
dividuals with either recent or frequent exposure to such agents 
Southall et al, 1983; Harrison, Rubin et al, 1985; Woodman et al, 
1985). Leviner et al, (1987) detected resistant strains after six 
hours in 9 (31%) of 29 volunteers following ingestion of the 
first of three doses of phenoxymethylpenicillin (penicillin V) 
administered within a 10-hour period. Acquisition of resistant 
strains may, however, occur without direct antibiotic exposure, 
especially in hospital settings (Leviner et al, 1984). Persons 
with no previous exposure to antibacterial agents are known to 
carry small numbers of antibiotic-resistant bacteria as part of 
their normal oral flora (Woodman et al, 1985; Longman et al, 
1991). It has been shown that bacteraemia with B-lactam 
(penicillin)-resistant oral streptococci and IE may follow 
prophylaxis in animals, and may possibly constitute a threat of 
prophylaxis failure in humans susceptible to this infection 
(Longman et al, 1992). As early as 1947, Krumwiede recorded the 
failure of prophylaxis and the development of IE in a young 
patient in whom a penicillin-resistant streptococcal strain was 
isolated from the oral cavity
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1.3 The present study
A major feature of the present study is an in vitro model 
designed to mimic IE prophylaxis. In this model, the identity of 
strains of viridans streptococci within dental plaque (see Sec­
tion 8.5 for description) and their susceptibility to candidate 
agents for IE prophylaxis were determined following in vitro 
selection in benzylpenicillin (penicillin G) and results dis­
cussed. Plaque specimens were collected from volunteers who were 
at the time receiving B-lactam antibiotics or were without an­
tibiotic exposure for a minimum period of three months prior to 
sampling. Isolates were speciated and tested for antimicrobial 
susceptibility at concentrations of antibiotics appropriate to 
the treatment of IE (breakpoint concentrations). All strains 
originated from plaque specimens which were subjected to in vitro 
exposure and selection in penicillin G-containing broth
Antibiotic susceptibility levels in viridans streptococci from 
dental plaque following in vitro exposure to penicillin G, espe­
cially with regard to 6-lactams but also other candidates for IE 
prophylaxis, including erythromycin, roxithromycin clindamycin 
and vancomycin, will be described and explanations for the ob­
served deviations from expected patterns proposed. The anomaly of 
streptococci surviving in the presence of 6-lactam concentrations 
expected to have a bactericidal effect, which has been described 
as phenotypic tolerance (Tuomanen, 1986), feature prominently in 
this dissertation
In the introductory chapters, background information relevant to 
the dissertation, and which has a bearing on IE prophylaxis, are 
discussed. Aspects to be included relate to the pathogenesis of 
IE (including risk factors), the reputed importance of dental
4
procedures as a major cause of IE, as well as the role of proce­
dures unrelated to dentistry which affect bacterial niches other 
than those in the oral cavity. Finally, based on the findings of 
this study, the use of in vitro models to more accurately 
evaluate candidate antimicrobial agents for IE prophylaxis are 
discussed
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Chapter 2
OVERVIEW OF INFECTIVE ENDOCARDITIS
2.1 Definition
Infective endocarditis (IE) is an inflammatory disease of the en­
docardium and "one of the most serious of all infections" (Back 
and Svanbom, 1980; Cotran et al, 1989). The disease is charac­
terised by the colonisation or invasion of heart valves or mural 
endocardium by microbiological agents leading to the formation of 
friable vegetations laden with organisms
Prior to the antibiotic era, IE invariably exhibited an extremely 
high mortality - in the region of 100% (Hayward, 1972a); Tanner 
and Durack, 1990). However, even with the availabilty of modern 
therapeutic compounds, it remains a life-threatening condition 
(Anonymous, 1981; Cotran et al, 1989; Hayward, 1973a). The in­
cidence of new cases of IE appears not to have decreased 
(Hayward, 1973a) but has actually risen markedly with a longer 
survival rate and an increase in median age of onset and number 
of recurrent cases (Tanner and Durack, 1990) (see below)
The infection has been classified on clinical grounds into acute 
and subacute IE types. The former more severe form is caused by 
highly virulent organisms which, characteristically, tend to at­
tack the previously normal heart. Necrotising, ulcerative and in­
vasive lesions of heart valves are produced. This process results 
in the death of patients, often within days. Subacute or chronic 
IE shows a longer clinical course, is caused by commensal or­
ganisms which tend to be less virulent and which affect pre-
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viously damaged or scarred endocardium (Cotran et al, 1989) or 
those with either chronic valvular disease or congenital malfor­
mations of the heart (Hayward, 1973a)
2.2 Epidemiology of infective endocarditis
The incidence of IE is difficult to determine accurately since 
differing diagnostic and reporting criteria exist and only a 
relatively small number of clinically diagnosed cases, using 
strict definitions, are proven IE (von Reym et al, 1981)
In a post-mortem investigation, Hayward (1973a) found no defini­
tive reduction in the number of IE cases in the UK from the 1930s 
through to the early 1970s. He suggested that an alteration in 
the general clinical picture had occurred and noted that IE still 
carried a high (30%) mortality rate. He suggested that tradi­
tional diagnostic criteria were inadequate - an aspect handled in 
much greater detail by other authors (von Reyn and Arbeit, 1994) 
(see later)
Durack and Petersdorf (1977) indicated that the average age of 
onset had risen from 34 years of age in 1944 to 50 years of age 
in 1977. They postulated that possible reasons for this include 
an increased prevalence of arteriovascular and cardiovascular 
disease in the elderly. This latter proposal was supported by 
Friedlander and Yoshikawa (1990) who also noted that lesions in 
the elderly which predispose patients to IE do tend to be age- 
related degenerative or atherosclerotic valvular defects. In ad­
dition, chronic rheumatic heart disease led to the development of 
IE in this age group - with a few notable exceptions (Veasy et 
al, 1987). An explanation for the observed trend may be a general 
decreased incidence of rheumatic fever (Morris, 1985) especially 
amongst the youth in Western countries. An escalation in the use
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of intravenous devices on hospital in-patients could be another 
contributing factor to the observed later onset of IE
Von Reyn and Arbeit (1994) believe that accurate IE case defini­
tion and clinical patterns in this disease should emphasize four 
fundamental features, ie. (i) predisposing heart disease, (ii) 
distinctive persistent bacteraemia, (iii) vascular phenomena 
(cutaneous and visceral) and (iv) evidence of "active intracar­
diac pathology" ie. active endocardial processes. This diagnostic 
approach, they contend, may better equip clinicians to compare 
the results of previous treatments and lead to more accurate 
diagnoses than was the case in the past. In a multicentre study 
to determine (amongst others), IE incidence, an optimal 
therapeutic approach and duration of therapy, Fang et al (1993) 
divided episodes of IE into "definitive", "presumptive" or 
"suspicious". Each form of IE was strictly defined
New proposals contained in the Duke schema have been examined 
critically and are claimed to be an improvement over proposals 
used currently for the diagnosis of IE (Bayer et al, 1994). The 
Duke schema involves three major factors for IE diagnosis (not 
noted here) and, following these, a diagnosis is either 
"definite", "possible" or a diagnosis is "rejected". A "definite" 
case of IE, for example, is one which has to satisfy specific 
pathological and clinical criteria. Each of the two major 
pathological and clinical criteria is defined as are factors 
which constitute a definitive or positive IE diagnosis
Hayward (1973b) stated that although often quoted figures on IE 
mortality appear to indicate a particularly poor prognosis, it 
is not necessarily the case as the figures include both acute IE 
and surgically induced cases. A clearer pattern is said to emerge 
were only bacterially positive cases to be considered. In the 
author's 300-case series, survival increased as mortality
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decreased from 27% prior to 1956 to 14% in the period 1966-72. 
With the inclusion of all acute and surgical IE cases into the 
sample, there was a much greater overall mortality figure of 31% 
for the same period
It appears certain however, that the development of IE tends to 
occur amongst those with pre-existing cardiac abnormalities (70- 
75%), some of which may be unknown to those at risk (Durack, 
1995). Bayliss et al, (1983) highlighted the incidence of IE 
amongst the elderly with supposedly normal hearts
2.3 Aetiology and pathogenesis of infective endocarditis
2.3.1 Vegetation development and structure
The accepted (traditional) manner of vegetation development is 
described by Hayward (1973a) as follows: "minute platelet thrombi 
settle on valves roughened by congenital or acquired defects or 
(on) areas of endocardium damaged by jet effects, and that bac­
teria of low virulence enter from the mouth or genitourinary 
tract become established and grow in the platelet thrombi and 
produce the (typical) proliferative and fragile vegetations..."
IE vegetations are single or multiple, vary in size from a few 
millimetres to several centimetres in diameter and are located 
along (but not restricted to) the line of valve closure (Lode, 
1982. Although this author stressed that lesions found in acute 
and chronic IE were more similar than dissimilar, Cotran et al 
(1989) detailed differences in size, site and complications 
(consequent to their presence) of these structures between the 
two clinical entities. In the acute form of IE, vegetations are 
located on previously healthy valves, tend to be larger 
("bulkier") and perforate or erode underlying leaflets. Abscesses
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may develop within underlying endocardial tissue. Chronic IE on 
the other hand exhibits smaller vegetations which less commonly 
produce leaflet erosions or damage but which tend to extend onto 
adjacent endocardial walls. Such vegetations are commonly as­
sociated with the presence of congenital heart defects (Cotran et 
al, 1989). On prostheses, vegetative lesions tend to occur on the 
margin of the suture ring
The typical microscopic structure of the endocarditis vegetation 
consists of an amorphous fibrin mass in which platelets, red 
blood cells and large numbers of bacteria are imbedded, the lat­
ter being centrally placed (Hayward, 1973b). These nodules may 
"heal" and undergo progressive sterilisation, reorganisation, 
fibrosis and calcification (Cotran et al, 1989)
As bacteria are present in the valvular lesions of IE, bac- 
teraemia and the resultant seeding of bacteria (into small ves­
sels of the spleen, kidneys and skin leading to vascular changes) 
are a fundamental requirement for the development of IE (Back and 
Svanbom, 1980)
2.3.2 Sequence of events in the pathogenesis of infective
endocarditis
For subacute (chronic) IE to develop, a number of predisposing 
(and often unrelated) factors need to be present. Those which 
play a role include: *
* pre-existing congenital or acquired heart defects
* eddy currents and "jet streams" in the flow of blood
* formation of sterile fibrin-platelet deposits
* infective bacteraemic elements
* bacterial adhesion
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infection of sterile vegetations
i) Pre-existing congenital or acquired heart defects
A number of acquired or congenital cardiac abnormalities 
tend to predispose patients to IE (Back and Svanbom, 1980, and 
particularly in the young (Cotran et al, 1989). Rheumatic heart 
disease tended, in the past, to be the most important predispos­
ing factor which lessened considerably in importance in the 
1960's and 1970's (Cotran et al, 1989; Jaspers and Little, 1984; 
Special Report, 1984) but recent reports have indicated an un­
characteristic resurgence of rheumatic fever in the USA (Veasy et 
al, 1987), occurring in the classical 5-15 year age group
Particular congenital and acquired abnormalities of the heart 
strongly predispose patients to IE (Cotran et al, 1989) and 
various categories are tabulated below. Important among these are 
small shunts formed as a result of limited interventricular 
defects and which produce jet streams in the blood flow (see 
below). Others include forms of valvular disease (stenoses), 
patent ductus arteriosus, tetralogy of Fallot, mitral valve 
prolapse, degenerative calcific valvular stenoses and bicuspid 
aortic valve, as well as cardiac valve prostheses and indwelling 
pulmonary artery catheters. With the observed general decline in 
rheumatic fever and an increase in the elderly population, Morris 
(1985) noted the appearance of new groups of high-risk patients 
with prosthetic heart valve replacements. Cardiac scar tissue at 
sites of previous injury (damage) or degenerative or inflammatory 
changes may play a contributory role (Cotran et al, 1989)
*
Underlying conditions predisposing to infective endocarditis 
Congenital:
Ductus arteriosus, ventricular septal defects, co-arctation of 
the aorta, bicuspid aortic valve, tetralogy of Fallot and pulmo­
nary artery stenosis
Rheumatic:
Mitral valve (85%) and aortic valve stenosis 
Degenerative:
Calcified mitral annulus, arteriosclerotic heart disease includ­
ing calcified nodular stenosis and post-myocardial infarction - 
mainly in elderly patients
Nosocomial:
Haemodyalsis shunts, pace-maker wires, intracardiac prostheses 
Others:
Syphilitic aortitis, idiopathic hypertrophic subaortic stenosis 
(IHSS), mitral valve prolapse
Non-cardiovascular predisposing factors include neutropaenia, im­
munodeficiency and -suppression, and IV drug abuse. The latter 
two are particularly important at the present time (Cotran, 1989)
ii) Haemodynamic factors
Cardiac abnormalities tend to affect the smooth and even 
flow of blood through the heart chambers and vasculature. Jet
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streams and eddy currents generated as a result of valvular or 
small septal constrictions initiate the early nonbacterial throm- 
bic stage in the formation of vegetations on the endothelial 
lining of the heart wall
Interestingly, patients with cardiac lesions with less severe 
haemodynamic problems are especially at risk of IE while those 
with severe heart disease (failure) are rarely affected (Hayward, 
1973a). Hearts with markedly deficient blood pumping abilities 
would produce smaller pressure gradients in the blood and would, 
consequently, be unable to form jet streams etc. severe enough to 
precipitate thrombus formation and thus initiate vegetation for­
mation
iii) Sterile platelet and fibrin deposits
Platelets and fibrin are deposited onto areas of pre­
existing endothelial damage, or where haemodynamic or other in­
jury has occurred (Hayward 1973a; Cotran et al, 1989). This 
traditional approach was, however, questioned by Hayward in 1973 
(1973a) who stated that the exact mechanism of why vegetations 
form under these conditions is unclear (see later). Cotran et al 
(1989) appears to lay rather more stress on the haemodynamic 
changes which occur in heart disease than •. the presence of en­
docardial scar tissue and the effect, if any, which this tissue 
would have on vegetation formation and subsequent infection of 
the endocardium
Apart from the inductive ability of damaged endothelium, the 
presence of growing bacteria in the thrombi overlying endothelial 
lesions acts to further stimulate deposition of fibrin and 
platelets - albeit deposition under non-sterile conditions. 
Removal of bacteria from the circulation during therapy removes 
the catalyst for further such deposition (Hayward, 1973b)
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iv) Infective bacteraemic elements
The immediate and essential source of bacteria able to in­
fect the endocardium are those present in the blood. Entry of or­
ganisms into the vasculature may occur by way of two mechanisms 
(Cotran et al, 1989). Firstly, directly as a result of mechanical 
manipulation of tissues (dental or surgical treatment, the IV 
route as in drug addiction) or infective processes (sepsis) else­
where in the body. Secondly, covertly by means of transient bac- 
teraemias after minor injuries of the gut, oral cavity, skin or 
other areas in the body. These sources tend to seed the blood 
with organisms of low virulence
Almost any blood-borne microbe has the potential to produce IE. 
However, like viridans streptococci, some appear have a greater 
propensity than others. Aetiological agents may be bacterial, 
fungal, rickettsial, chlamydial and (possibly) viral (Cotran et 
al, 1989), Hayward, 1973a in origin
A noticable change has also occurred in the type of infective or­
ganism responsible for the disease over the years (Hayward, 
1973a). In the pre-penicillin era, 95% of cases were caused by 
viridans streptococci while in their 1969 investigation, 
Shinebourne et al (Hayward is a co-author) noted that only 44% 
were caused by these organisms. In a more recent study, Sussman 
et al (1986) reported that 65% of all cases to be caused by 
streptococci including the viridans group, as well as S. bovis, 
Enterococcus faecalis and others
Although oral streptococci may be less common aetiological agents 
of IE today than in the past, this bacterial group is still the 
most common associated with diseased heart valves. The severity 
of viridans endocarditis is illustrated by the findings of 
Bayliss and his co-workers (1983). In their study of 74 patients 
who died from IE, at least 15 (20%) were infected with viridans
streptococci. Five of these patients had some form of cardiac ab­
normality while the rest (67%) experienced infection of a pre­
viously "healthy" endocardium. Sussman et al (1986) noted that 
the clinical course of a number of patients in their 1986 study 
of viridans endocarditis was comparable to that associated with 
organisms such as Staphylococcus aureus which tended to be con­
siderably more virulent. They postulated that oral streptococci 
with enhanced virulence may also have infected healthy hearts in 
some patients in the study of Bayliss et al (1983) and mimiced 
staphylococcal IE of previously normal (healthy) endocardium
A recent publication (Douglas et al, 1993) attempted to clarify 
the confusion relating to different classification schemes and 
named viridans streptococcal species causing endocarditis in 
Britain. This was performed according to the most recent 
taxonomic concepts. Employing a scheme by Beighton et al (1991), 
of 47 strains collected from 42 confirmed cases of this disease, 
S. sanguis was found by Douglas et al to be the most common in­
fecting viridans Streptococcus at 32%, S. oralis followed with 
30% and S. qordonii with 13%. Other species such as S. mitis were 
less commonly isolated
v) Bacterial adhesion
Adhesion of bacteria to substrates plays an important 
physiological role in normal microbe-host interactions, and a 
critical one in the initiation and progression of disease 
processes involving these organisms
a) Physiological adherence. A natural biological interaction 
exists between micro-organisms themselves as well as between 
micro-organisms and exposed inanimate objects introduced into the 
vascular system, or between micro-organisms and various anatomi­
cal structures in animals and humans. Colonisation of specific 
areas of the human body involves the inherent attachment
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properties of micro-organisms and host tissues (Gibbons and van 
Houte, 1975). In the mouth, species of oral streptococci are 
specific in their ability to colonise particular areas. Their 
particular mechanism of tissue attachment is selective and in­
fluenced by a number of factors which includes compatibility with 
other microbes, host age, saliva composition and diet (Ellen,
1982) . Typical colonisatory behaviour which begins immediately 
post-partum, is observed in the new-born during pioneer colonisa­
tion of commensal flora of the skin and mucosae (Hardie, 1983)
b) Adhesion in IE. Adhesion plays a pivotal role in the ini­
tial stages of IE. Any property which increases the ease with 
which organisms attach to target substrates (tissues) prior to 
colonisation (infection) would serve as a virulence factor under 
conditions such as those prevailing in the health-compromised 
cardiac patient. The ability of specific bacterial species to ad­
here to fibrin and platelet elements present during endocarditis 
and nonbacterial thrombic endocarditis (NBTE) is important in the 
pathogenesis of IE (Scheld et al, 1981). Adhesive ability is ex­
hibited by bacteria which colonise damaged or defective endocar- 
diums of patients with congenital or acquired heart disease (van 
der Bijl, 1992)
Viridans streptococci adhere more strongly to platelet and fibrin 
thrombi than, for example, E. coli (Cotran et al, 1989). Oral 
streptococci are also known, under certain conditions, to produce 
substances which increase their adherence capabilities eg: long, 
extra-cellular polysaccharide polymers called glucans (Hardie,
1983) . Polysaccharides synthesised in the presence of sucrose by 
S . mutans enhance initial bacterial attachment onto certain sur­
faces (dental) (Socransky and Morganiello, 1971). This feature 
may, however, not be relevant once strains with the ability to 
synthesise polysaccharides have reproduced themselves in the 
bloodstream where nutrients such as sucrose are no longer
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present. For attachment of the original bacteraemic bacteria 
which still carry presynthesised exopolysaccharides, this 
property may be highly beneficial initially (see below)
Beachey (1981) investigated specificity of bacterial adherence to 
mucosal surfaces. He noted that bacterial species preferencially 
populate different tissues - "tissue tropism" - and described the 
normal habitats of two oral streptococcal species. S. mutans was 
abundant in "dental plaque" and sparse elsewhere in the oral 
cavity while S. salivarius was found on tongue epithelium but un­
common elsewhere
Attachment of bacteria to mucosal surfaces is the initial event 
in the pathogenesis of most infectious diseases in animals and 
humans (Beachey, 1981) and organisms with an increased ability to 
do so would exhibit a greater virulence under specific condi­
tions. Lipoteichoic acid (LTA), a cell-membrane constituent in 
most streptococci, acts as an "adhesin" or receptor for bacterial 
attachment to target substrates (Beachey, 1981; Courtney et al, 
1983). Adhesins, a term first coined by Duguid in 1959, are 
"adhesive molecules on the surfaces of bacteria". Streptococcal 
binding sites have been identified on serum albumin, blood 
platelets, lymphocytes, whole erythrocytes and oral epithelium 
(Beachey, 1981). LTA has been implicated in a number of inflam­
matory reactions and other processes (Courtney et al, 1983)
Fibronectin, a glycoprotein, is a normal soluble constituent of 
blood plasma and other fluids and an insoluble component of ex­
tracellular matrix of various cells (buccal mucosal cells) and 
tissues. It binds to a number of bodily materials and includes 
collagen, heparin, actin, plasma membranes and certain micro­
organisms (Staphylococcus aureus) (Akiyama et al, 1981). It plays 
a role in bacterial attachment processes in the oral cavity and 
elsewhere. It is present in saliva and gingival fluid and is in­
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corporated into the acquired dental pellicle during its forma­
tion. The acquired pellicle is the first structure (or coating) 
to form on teeth and onto which oral bacteria can adhere after 
all bacterial and other deposits have been cleaned mechanically 
from the teeth. It is composed of salivary proteins and 
glycoproteins (Marsh, 1992). The pellicle has been described 
(Gahnberg et al, 1982; Malamud et al, 1981 and Rosan et al, 1982) 
as consisting of a variety of salivary products of host and bac­
terial origin, for example: "high molecular weight glycoproteins 
(salivary mucins), lysozyme, salivary agglutinins, IgA and bac­
terial extracellular polymeric substances" including fibronec- 
tin. Fibronectin contains fatty acid-binding sites for LTA and 
may act as a receptor for bacteria with LTA-containing cell- 
membranes to permit attachment to mucosal cells (Courtney et al, 
1983)
The role of LTA was illustrated when it was found to inhibit, to 
some degree, binding of viridans streptococci to fibronectin- 
coated hydroxyapatite beads (Hogg and Manning, 1988). In this ex­
periment, a S. sanquis-derived LTA-containing solution was able 
to attach to and block (or partially block) fibronectin-adherence 
receptors on the beads before the membrane-bound LTA receptors of 
bacteria used in the experiment were able to interact. Binding 
between LTA and fibronectin appears to be of an hydrophobic na­
ture. Hogg and Manning suggest that as both LTA and bacterial 
cells competed for the same or neighbouring sites on the coated 
beads, this provided further evidence of the involvement of LTA 
in viridans streptococcal adhesion. Species were tested for adhe­
sion and no significant difference was apparent between species. 
However, in this experiment the percentage of adhesion varied in 
four strains of S . mutans between 66.6-83.2% with one strain 
<50%, while in the case of S. salivarius 4 isolates varied be­
tween 50-90.7% bound, one <50%. Six strains of S. sanguis I were 
75.5-92.5% bound. Binding of six strains of S. sanguis II varied
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from 69.3-79.3% with one strain <50% and in S. mitis three
strains showed binding of 61.4-93.9%. The appearance of a strain 
each of S . mutans and S. salivarius with LTA-mediated binding 
percentages of below 50% and lower values is evidence, the 
authors claimed, for the the involvement of other fibronectin 
mechanisms. The effect of LTA may be less specific as S. sanguis 
II and S. mitis were inhibited by LTA although the species do not 
synthesise LTA
Recent research, employing molecular genetics techniques, has 
discovered that important virulence factors exist amongst gram­
positive bacteria producing experimental endocarditis. Mutant S . 
sanguis were developed with a reduced ability to bind with immo­
bilised fibronectin and were found to be markedly less virulent 
in a rat model than the strain with intact fibronectin-binding 
characteristics. The virulence of the former was infective dose- 
dependent while the latter was unaffected by inoculum size. 
Similar tests were performed on S . aureus strains. From data in 
these studies, it appears that adherence of Gram-positive bac­
teria to fibronectin is "pivotal" in the pathogenesis of ex­
perimental endocarditis (Baddour, 1994)
The ability to synthesise extra-cellular (exo)polysaccharides in 
S , mutans, for example, and its possible contribution to 
virulence this species may display has been studied. Through 
manipulation of its genome, strains with a deficient abilty to 
produce this substance were markedly less able to produce en­
docardial disease. What played a definitive role in infectivity 
was the prior exposure of "normal" test strains to sucrose. 
Without such exposure, the latter strain exhibited the same (very 
reduced) degree of infectivity as the mutant strain with such ex­
posure (Baddour, 1994)
In Baddour1s 1994 review of virulence factors in IE, he noted
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that when S. qordonii was subjected to the same mutagenic 
manipulation as S . mutans as regards its production of ex­
opolysaccharides and its effect on cariogenicity, it showed no 
difference in infectivity in the rat endocarditis model. Re­
searchers were unable to explain this phenomenon but it may be 
that the two processes are unrelated. One is relevant to ad­
herence of strains to hard, dental tissue (and attached protein- 
rich dental pellicle, bacteria and their products and food debris 
- see elsewhere) and an ability to produce tooth-dissolving 
acids, while the other applies to attachment to tissues and sub­
structures of the endocardium. Adherence in cariogenicity and its 
role in cardiac infectivity are not necessarily comparable
Manning et al (1994) recognised the role which adherence to 
fibronectin (plentiful at sites of endothelial injury and repair, 
and also on surfaces of thrombic lesions on platelets) and sub­
sequent platelet aggregation by S. sanquis-group bacteria play in 
the development of endocarditis
Certain unrelated factors are, however, known to discourage bac­
terial substrate adherence. Examples include the phenomenon of 
species specificity - where certain bacteria tend only to infect 
specific host species (N . qonorrhoeae . infects only humans), 
genetic specificity (susceptibility to certain infections is a 
genetic trait), the presence of non-specific protective 
mechanisms on host mucosae (antibodies, protective enzymes, 
cleansing/flushing action of secretions etc.) and receptor 
specificity (of bacterial cells for host receptor)
vi) Infection of sterile vegetations
Fibrin-platelet aggregates are initially sterile. Before in­
fection is possible, adhesion to and colonisation of vegetations 
by micro-organisms circulating in the blood-stream has to occur 
(Cotran et al, 1989) to produce the typical "infective
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vegetations" found in IE
2.3.3 A possible immunological link in the development of 
infective endocarditis
A strong immunological link in the pathogenesis of IE has been 
suggested by Hayward (1973a). Leucocytes are absent from vegeta­
tions and organisms tend to be centrally placed within the 
vegetations. He suggested that factors like the (stimulatory) im­
munological response of the host to the introduction into the 
blood-stream of organisms of low virulence, could play a role in 
the development and the complications of IE. In most IE-patients, 
high levels of circulating antibody to the infecting organism are 
present and high antibody titre levels may play a major in­
itiatory role in the formation of vegetations, for example. It 
was found experimentally that chronic bacterial endocarditis is 
inducible in animals used for the commercial production of an­
tisera after re-introduction of bacteria into the blood-stream 
during the phase of elevated antibody titres in the immune 
response. The presence of circulating agglutinating antibodies 
enables the spread of immune complexes to other areas of the body 
where they become attached, amongst other sites, to the en­
dothelium of small blood vessels (Hayward, 1973a. Fragile in­
fected vegetations are known to fragment and to spread to other 
parts of the body in a similar fashion (Hayward 1973a; Cotran et 
al, 1989)
2.3.4 Summary
Cotran et al (1989) divided the pathogenesis of IE into distinct 
events. In the presence of bacteraemia, three are important: (i) 
the formation of sterile platelet-fibrin deposits or non-
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bacterial thrombic endocarditis (NBTE), (ii) the seeding of 
sterile vegetations by clumps of agglutinating antibodies and 
bacteria, and (iii) the important role which bacterial adhesion 
plays. Development of the acute form of IE is more difficult to 
describe except in cases with obvious and frequent bacterial con­
tamination of the blood such as is found in IV drug abusers, or 
in those with indwelling vascular catheters
An observation by Hayward in 1973 (Hayward, 1973a) during a lec­
ture before the Royal College of Surgeons is particularly apt. 
When dealing with the confusion and uncertainties of IE, its 
pathogenesis, why it should develop in the first instance and the 
reputed involvement of dental procedures, he said the following: 
"It is difficult to understand why the introduction over a short 
period of time, such as during a dental extraction, of organisms 
of low virulence should, in a well patient often with trivial 
heart trouble, initiate a disease so relentless in its course and 
destructive in its effects"
It is recognised today that micro-organisms that commonly produce 
endocarditis in humans, particularly staphylococci, streptococci 
and enterococci, exploit the wound and wound healing process of 
the host to produce endocardial infection (see below). Infection 
would be impossible were there not (i) early colonisation of en­
dothelial wounds by bacteraemic isolates able to survive the hos­
tile conditions present within the bloodstream, and (ii) attach­
ment by bacterial elements to exposed sub-endothelial extracel­
lular matrix proteins within the wounds (Baddour, 1994)
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Chapter 3
SOURCES, ROUTES OF INFECTION, AND BACTERAEMIA IN RELATION TO
INFECTIVE ENDOCARDITIS
3.1 Indigenous oral flora
3.1.1 Bacteria of the oral cavity
Indigenous populations of micro-organisms inhabiting the skin and 
mucosal surfaces provide protection against colonisation and/or 
invasion by pathogenic organisms. However, the organisms need 
not always serve a protective function and, under certain cir­
cumstances, the same microbes may destroy a natural host, either 
by their own action or together in a mixed infection with ex­
ogenous pathogens (Mackowiak, 1982). Opportunistic infections oc­
cur commonly in patients with impared immunological defences
The oral cavity in healthy individuals supports one of the "most 
concentrated and varied of microbial populations of any area of 
the body" (Hardie, 1983) and numbers of resident organisms in the 
mouth are extremely great. Gordon et al (1971) state that a 
"periodontally normal" adult gingival crevice would contain ap­
proximately 270 thousand million recoverable micro-organisms per 
gramme of dental plaque and debris. They determined that aerobic 
and cultivable anaerobic bacteria made up between 22- and 179 
thousand million bacteria per gramme of wet dental plaque depend­
ing upon which culture techniques were employed. These figures 
would include viridans streptococci and other facultatively 
anaerobic organisms. The sulcus contains a complex, mixed popula­
tion of organisms the general make-up of which has been found to
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be similar in most individuals (Kornman, 1982). The total count 
in saliva of (mostly tongue derived) organisms is between 430- to 
550 million per millilitre with an average sample count of ap­
proximately 750 million and 200 000 million cells per gramme for 
the gingival sulcus (Hardie, 1983)
A difficulty in determining the total viable count is the dis­
crepancy between this figure and the total microscopic count, 
especially for substances such as dental plaque (used in this 
study only as a source of streptococci), an aggregate of oral or­
ganisms growing within a gelatinous organic matrix (Hardie, 
1983). By mechanical disruption of specimens, eg. ultrasonic dis­
persal, the viable count can be increased significantly 
(especially of streptococci and actinomyces) or decreased 
(certain Gram-negative strains)
Microbiological variation amongst oral bacteria is great. Moore 
et al (1982) found 264 morphologically and biochemically distinct 
bacterial groups or species amongst 6800 isolates colonising the 
mouth and dental sites of volunteers with varying degrees of 
periodontal disease. From a small control sample of four people 
with healthy periodontia, 316 distinct isolates were cultured. 
The indigenous flora of the healthy mouth is populated by over 40 
named species (Hardie, 1983)
3.1.2 Environmental niches within the oral cavity
Microflora-host relationships are both important and complex and 
not fully understood (Heimdahl and Nord, 1979). Mechanisms exist 
which play an important role in the selection of sites where par­
ticular organisms tend to be more plentiful. The specific 
locality of a bacterium type in the host is dependent initially 
upon the physical ability of that organism to attach or "anchor"
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itself to a particular tissue (Gibbons and van Houte, 1975) and 
for its retention there thereafter (Hardie, 1983). Under 
favourable conditions, the bacterium will remain at that site and 
multiply
Different but anatomically related micro-environments or habitats 
exist in the mouth. Each is chararcterised by, for example, 
specific pHs, oxygen tensions and nutrient concentrations 
(Kornman, 1982; Hardie, 1983). Bacteria are more plentiful in 
areas of the mouth able to provide ideal conditions of growth for 
that specific strain. The composition of the microflora, there­
fore, is an indication of the nature of the oral environment from 
which bacteria are sampled (Hardie, 1983)
Oral niches include the salivary environment, gingival crevice, 
tongue, dental surfaces and the buccal mucosa (Chow et al, 1978) 
and colonisation of such sites by oral streptococci is influenced 
by factors which affect their selective ability to attachment to 
dental and mucosal surfaces (Ellen, 1982)
S. salivarius is found principally on the tongue and in suspen­
sion in saliva where it accounts for approximately 50% of all 
bacteria. It forms less than 1% of the species identified in 
either plague or the gingival crevice (Hardie, 1983). Its 
presence in saliva in high numbers is likely to be as a result of 
mechanical dislodgement from its site of attachment (Socransky 
and Manganiello, 1971). S. salivarius is not dependent upon the 
presence of teeth for its survival in the mouth (Socransky and 
Manganiello, 1971). Saliva serves simply as a carrier for this 
organism
Three strains, S. oralis, S. mitis biovar 1 and S. salivarius 
were the most abundant species in a study of pioneer oral strep­
tococci undertaken on neonates (Pearce et al, 1995). Samples from
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specified sites in the mouth were taken from babies at 1-3 days, 
2 weeks and 1 month post-partum. The former species, the most 
plentiful at the first sampling (41%), was the least common of 
the three species after a month (20%) while the latter strain 
rose from an initial 10% to a final 28% after four weeks. There 
was little change to S. mitls biovar 1 numbers. Other identified 
species included S. mitis biovar 2, S. sanguis, S. gordonii, and 
S. anginosis
In the first months of life, microbe populations are relatively 
unstable (Socransky and Manganiello, 1971). A constant introduc­
tion of different species to the baby from other sources (mother) 
occurs but few will remain and proliferate if environmental con­
ditions are unsuitable. With the eruption of teeth after ap­
proximately six months, new micro-environments develop and other 
aerobic and new anaerobic species are able to colonise the gin­
gival groove and various structures in and on dental hard tissue. 
The presence of dental caries in the child and adolescent has a 
marked effect on micobe populations and their composition 
(Socransky and Manganiello, 1971)
Composition of bacterial populations in the mouth (dental plaque) 
alters as a result of changes to the oral environment and the in­
tegrity of host tissues. This is noticable in the presence of 
gingival inflammation or during carious processes of teeth. Ellen 
(1982) examined populations in patients with periodontal disease. 
The author noted that although Gram-positive bacteria are numeri­
cally important oral organisms, they tended to play a lesser role 
in those with advanced periodontitis and form only a minor (but 
important) proportion of subgingival microflora at affected 
sites. Gram-negative anaerobic organisms become more plentiful as 
the disease process progresses while Gram-positive bacteria tend 
to increase in number as tissues heal during treatment. The lat­
ter are however, like Gram-negative species, also capable of in­
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ducing inflammation of the gingiva as they proliferate in dental 
plaque (Actinomyces species). Even in the "healthy" mouth, signs 
of gingival inflammation (gingivitis) are evident in concealed 
locations
The comparative composition of streptococcal populations in 
caries-active and caries-inactive individuals was examined by 
Nyvad and Kilian (1990). Seven hundred viridans strains in 4-hour 
old plaque from 14 adolescent children (median age 14 years, 
range 12-23 years) were identified. All isolates were taken from 
identical pieces of human enamel (of identical size etc.) carried 
in the mouths of volunteers. Streptococci dominated the 
microflora in 61 and 78% of the viable counts in caries-active 
and -inactive individuals respectively. Of 700 streptococcal iso­
lates, the predominant isolates consisted of Streptococcus oralis 
(31.8%), S. mitis biovar I (29.3%) and S. sanguis (21.3%) with 
S. mitis biovar 2, S. salivarius, S. qordonii and S. mutans 
making up 5% or less of the total streptococcal count. The first 
three species accounted for 95% of all streptococci and 56% of 
the total number of cultivated oral bacteria. The authors found a 
significantly higher proportion of S. sanguis amongst caries- 
inactive than caries-active children. Two species, S. oralis and 
S. qordonii, predominate in health (Marsh, 1992). (Viridans 
speciation in this study followed the proposals of Kilian et al 
(1989)
As in the neonate investigation (Pearce et al, 1995), S. oralis, 
and S. mitis biovar I were plentiful but S. salivarius numbers 
were substantially reduced. The two to three day difference in 
sampling times of the two projects may account for this dis­
parity, or the presence of and the attachment to dental hard- 
tissue by certain other species in the older volunteers, may have 
played a role
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As an adult ages, further floral changes take place. One of the 
most striking occurs after the loss of teeth (Socransky and Man- 
ganiello, 1971)
Proportions of various viridans species may differ in plaque 
specimens of older (but unspecified) ages. MacFarlane et al 
(1983) cultured 24 viridans isolates from the plaque of 15 
patients about to undergo a molar extraction. Identified or­
ganisms (method not noted) consisted of 10 S. mitior, 6 S . san­
guis, 5 S. mutans, and 3 S. salivarius isolates. S. mitior (under 
which S. mitis is also classified) and S . sanguis together formed 
the majority of isolates in this study of (probably) older plaque 
but a difference in classification makes comparison difficult
3.1.3 Bacterial interactions in the oral cavity
Certain bacteria may inhance or retard the growth of other 
species in close proximity (Kuramitsu and Paul, 1980). The growth 
behaviour of Actinomyces viscosus (isolate T14V) and viridans 
strains was investigated in an in vitro system designed to mimic 
bacterial compatibility and attachment to dental surfaces. 
Hydroxy-apatite beads were coated with one strain and the ac­
tivity of both organisms was observed when a second was permitted 
to attempt attachment. Two S . mutans strains, in the presence or 
absensce of sucrose, were found not inhibit A. viscosus attach­
ment. S sanguis (2 strains) tended to inhibit A. viscosus attach­
ment to a marked degree. A. viscosus noticeably increased attach­
ment of one S. sanguis strain and weakly inhibited attachment of 
the other. The authors postulated that S. sanguis and A. viscosus 
competed for similar hydroxyapatite attachment sites. S . 
salivarius and a lactobacillus species exerted little if any ef­
fect on A. viscosus while S. mitis possessed activity which was a 
weakly inhibitory
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In another in vitro study, behaviour of an antagonistic nature 
was apparent amongst certain plaque bacteria (Hardie, 1983). S . 
sanguis displayed a broad inhibitory effect on all other strep­
tococci, filamentous organisms and rods. S . mutans produced bac- 
teriocins which endowed it with a competitive advantage against 
neighbouring species in the mouth
3.2 Involvement in bacteraemias of oral streptococci
3.2.1 Transient bacteraemias
Since Okell and Elliot's reported link between dental treatment, 
transitory bacteraemias, the bacteraemic source and the develop­
ment of IE (1935), much clinical and microbiological research has 
been undertaken. The transient bacteraemia which follows dental 
extractions permits oral bacteria to colonise pre-existing car­
diac endothelial lesions and is likely to place patients with 
underlying valvular heart disease at risk of developing IE 
(Littner et al, 1986; Durack et al, 1983; (British Society for 
Antimicrobial Chemotherapy Working Party, 1990)
The phenomenon of bacteraemia development after operative proce­
dures within the mouth has received a great deal of attention in 
the scientific literature. But the proportion of streptococcal 
bacteria in the blood identified in the literature as being 
viridans strains varies widely - from less than 40% to well over 
60%. In the British Heart Journal, Bayliss et al (1983) analysed 
the cases of 544 episodes of IE diagnosed in 541 patients. They 
found the most commonly isolated organisms to be this group of 
organisms (261 of a 548 isolate total). Sixty-three percent or 
164 of 261 streptococcal isolates were viridans streptococci. Of 
the 544 episodes of I.E., 122 patients (22.65%) had undergone
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treatment of a dentally-related nature or had had dental sepsis 
in the three months prior to the onset of illness. However, 19% 
of the total number of I.E. cases were considered to be of a 
"probable" dental origin; ie. 103 of 544 cases or 84% of 122 of 
patients who presented with a history of either dental treatment 
(with or without antibiotic cover) or dental infection. Two 
hundred and thirty patients (43%) either had normal hearts or an 
unrecognised cardiac abnormality prior to onset of IE
Following a different approach, Durack et al, (1983) found dif­
ferent dental manipulations to be implicated in 48 of 52 (92%) 
endocarditis prophylaxis failures reported to the National 
Registry of the American Heart Association. Aetiological agents 
in almost two-thirds of cases (63.5%) were viridans streptococci
Shanson et al (1984), while investigating a method to better 
detect viridans bacteraemia after dental extraction, reported the 
involvement of viridans streptococci in bacteraemias in at least 
28 of 58 (48.2%) healthy individuals without a known history of 
prior antibiotic use. A 30 ml volume of blood was suggested as 
being of optimal size for detection. Fifteen of 58 persons (41%) 
yielded viridans streptococci with a lesser 15 ml of blood. Later 
in 1987, Shanson et al detected this group of bacteria from 12 ml 
of blood in 32.5% (13 of 40) of volunteers in a comparative study 
to investigate the effectivity of amoxycillin and teicoplanin as 
agents of prophylaxis
Coulter et al (1990) reported much higher isolation rates in 58 
healthy children following dental extraction using 5 ml of blood. 
Sixty-three percent (20 of 32) who were not on any form of an­
tibiotic prophylaxis showed post-extraction bacteraemias. Half of 
88 organisms identified were either aerobic or facultatively 
anaerobic and predominantly streptococcal. Thirty one strep­
tococci isolates, identified chiefly as viridans streptococal
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species S. mitior and S. sanguis, were found in 20 of 29 
children. Other organisms isolated included Actinomyces, Bac- 
teroides (certain of the latter are now classified as 
Porphyromonas) and Veillonella species. A third of blood cultures 
in which streptococci were isolated, were found as pure culture. 
Roberts et al (1987), using an complex culture technique, 
reported a lower incidence of post-extraction bacteraemia. An in­
cidence of 38.3% in a group of 47 patients was noted. Of the bac­
teria isolated, 46.6% were viridans streptococci, a percentage 
almost two thirds that of the 63% of Coulter's et al (1990)
In a trial to assess the efficacy of the prophylactic regimen 
proposed by the American Heart Associaton (AHA, 1977), Hess et al 
(1983a) cultured blood specimens drawn from 82 "at risk" children 
after the extraction of either permanent or primary teeth. Post­
extraction bacteraemia was present in 21% (17 children). Of 
these, 13.4% (10 of 82 or 58.8% of the 17 positive blood 
specimens) yielded viridans isolates in spite of the volunteers 
having received pre-operative penicillin G
A link between the size of a bacteraemia and the extraction of 
certain teeth has been sought. Phillips et al (1976) found no ob­
vious difference in the incidence of bacteraemia in patients un­
dergoing full dental clearance or extraction of wisdom teeth 
alone. Peterson and Peacock (1976) were, however, able to find a 
statistically significant difference (p= <0.001) in the incidence 
of bacteraemia relative to the extraction of teeth as compared to 
non-extraction (restorative) procedures. They were also unable to 
detect differences between the types of dentition (permanent or 
deciduous) or dental health status (the gingival health status 
was not considered)
In an earlier 1968 study, Elliott and Dunbar ran an investigation 
similar to the later 1976 study of Peterson and Peacock. The
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former wished to determine differences, if any, between the oc­
currence of bacteraemias within younger and older age groups 
amongst 100 healthy children between the ages of 2 and 13. Blood 
cultures were performed after extractions. Whether extractions 
were of diseased or undiseased teeth was not specified. Thirty- 
six percent yielded blood cultures positive for alpha-haemolytic 
streptococci - none of which were speciated. Deciduous teeth 
(only) were removed in 79 children and both permanent and 
deciduous in 10. In 32% (25 children) of the former and 4 of the 
latter, viridans streptococci were cultured. In those from whom 
only permanent teeth were removed (11 children), 63.6% (7 of 11) 
had viridans streptococci in their blood post-operatively. When 
ages and positive blood counts were analysed, there was a higher 
incidence of bacteraemia (52%) amongst the older (8 to 13-year 
olds) than the younger group (31%, 2 to 7-year olds). Groups were 
small and no form of statistical analysis was employed
3.2.2 Variation in bacteraemia frequency
The wide variation in the frequency of surgery-linked bac­
teraemias has been noted above and specifically commented upon in 
the literature. Frequencies of bacteraemia range between 15-85% 
(Baltch et al, 1982). Differences in patient selection, times at 
which blood was drawn after the surgical event, types of surgery 
performed (Hall and Heimdahl, 1989) and other factors may account 
for these disparities
Conflicting opinions exist, for example, on what role, if any, 
the oral hygiene and periodontal health status of a patient or 
the number of extracted teeth would play in the appearance or 
magnitude of bacteraemia (Bender et al, 1963). The oral hygiene 
status of participants is often omitted from investigations of 
this nature. The contentiousness surrounding the issue is high­
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lighted by Coulter et al (1990) who found no relationship between 
either the incidence of the bacteraemia and the amount of dental 
plaque, and periodontal (gingival health) status of a patient, or 
between the magnitude and incidence of a bacteraemia and the num­
ber of teeth extracted. However, Wahl (1994) appeared convinced 
that an indifferent oral hygiene status plays a substantive role 
in the development of IE. Bartzokas et al (1994) were able to 
trace to the mouths of patients with extensive periodontal dis­
ease, identical strains of S. sanguis cultured from infected 
material taken from total joint replacement prostheses after 
their failure and subsequent surgical removal
Although the source, locality and portal of entry of oral strep­
tococci into the blood stream from the mouth may be obvious and 
easily identifiable, it is extremely difficult in retrospect to 
establish with any degree of certainty how and when offending 
bacteria entered the vascular system if or when no direct cause 
for the bacteraemia is detectable
3.2.3 Inflammation of the gingiva
Dental plaque, a soft, non-calcified material composed of bac­
teria, their products, food debris and other substances, is 
closely associated with tooth surfaces and the gingival sulcus 
(Hardy, 1983). Proximity to the gingiva of young (two to three 
day-old) plaque deposits on the teeth induces mild inflammatory 
processes in the gingiva after stimulation of the host's immune 
system (see also later) with accompanied vasodilatation, oedema 
and vascular fragility. Gingivitis develops initially and is 
restricted to the soft tissues of the gingival apparatus. Later, 
with prolonged exposure of the gingiva to bacterial metabolic by­
products and toxins produced within older plaque deposits (where 
species of Gram negative bacteria tend to predominate over the
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Gram positive cocci and other species found in gingivitis), 
tissue breakdown occurs and periodontitis develops (Slots, 1979; 
Slots and Genco, 1984). Characteristically, this latter condition 
is not restricted to the gingival apparatus but also affects the 
alveolar bone and other supportive tissues of the periodontium. 
Inflammation of periodontal tissues, therefore, eases entry into 
the blood stream of resident bacteria during forms of physical 
manipulation. An excellent description of the pathogenesis of 
periodontal disease is given by Williams et al (1992)
Normal physiological activity of a mechanical nature (chewing, 
tooth brushing) exerted upon affected gingival tissues may have a 
similar effect and also produce bacteraemias. Silver et al (1977) 
were more specific on the contribution which periodontal inflam­
mation played in the development of bacteraemia. Aerobic and 
anaerobic species of bacteria were cultured in their study in all 
four volunteer groups who had increasing degrees of defined gin­
gival inflammation. After completion of standard tooth- and gin­
gival brushing procedures, the authors reported a significantly 
higher incidence of positive blood cultures amongst volunteers 
with worsening (increased) severities of gingival inflammation: 
16%, 33%, 56% and 68% positivity in groups 1-4 respectively. 
However, like Sconyers et al (1973), any significance between the 
amount of accumulated dental plaque and the number of positive 
blood cultures remained undetected. But they were able to corre­
late an increased number of commensal oral bacterial species oc­
curring in the bloodstream with degrees of specified gingival in­
flammation and worsening plaque indices. Of note in Silver's in­
vestigation was the fact that amongst those volunteers in the 
group with the best possible standard of oral hygiene (and there­
fore presumably the least amount of gingival inflammation), bac­
teraemia was still detected in 16%. None-the -less, early re­
search has shown that the elective removal of teeth does not ap­
pear to be warranted to reduce the likelihood of viridans IE
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(Croxson et al, 1971; Simon and Goodwin, 1971)
Bacteraemia is not a consequence only of traumatic surgical elec­
tive procedures - simple, commonly performed, routine exercises 
are known to lead to the development of bacteraemia. This was ob­
served after tooth-brushing (as noted above), manipulation during 
detailed dental examination and periodontal probing, dental scal­
ing, root-canal treatments and after other non-invasive proce­
dures (Robinson et al, 1950; Bender et al, 1963; Conner et al, 
1967; Speck et al, 1971; Sconyers et al, 1973; Silver et al, 
1 977)
In a review of the accepted importance of dental procedures as 
causes of endocarditis, Guntheroth (1984) found few cases to be 
related specifically to dental extractions only (47 of 1322 cases 
or 3.55%). Earlier (and as commented upon above), Hayward (1973b) 
noted that in many IE cases (two-thirds) neither a precipitating 
cause for the infection nor the time when the bacteraemia oc­
curred could be satisfactorily determined
A complicating factor in the detection of bacteraemia is the fact 
that microbiological methods of investigation may differ and 
dedicated isolation techniques are often required to culture cer­
tain bacteria. For example, the identification of "nutritionally- 
variant" streptococci is only possible if specially supplemented 
growth media are utilised (Roberts et al, 1979; Feder et al, 
1980)
3.2.4 Viridans streptococci and orofacial infection
Viridans and other streptococci need not originate only from 
dentally-associated foci of infection to precipitate IE and other 
serious infections. Strains of these bacteria are associated with
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episodes of septicaemia and purulent infections of both the oral 
cavity (Beighton et al, 1991) and peri-oral structures of the 
human head and neck. Chow et al (1978), noted that (pyogenic) 
orofacial infections are most commonly odontogenic in origin. 
They would tend, therefore, to involve organisms (both aerobic 
and anaerobic) associated with teeth. In exudate cultures from 
oro-facial soft tissue infections collected during surgical 
treatment, 36% were found to be viridans streptococci in pure 
culture (Hunt et al, 1978)
3.3 A dermal source and route of infection
Staphylococci are carried naturally on the skin and on the mucous 
membranes of the naso-pharynx. These areas of the body serve as 
important reservoirs, in carriers, for virulent strains of 
Staphylococcus aureus (von Lichtenstein, 1989). This species is 
"among the hardiest of nonspore-forming bacteria" (Waldevogel, 
1985). It can be cultured from dried clinical material, is able 
to tolerate high salt levels and is relatively heat resistant. S . 
aureus causes inflammatory reactions throughout the body and can 
"invade" the lymphatic and blood systems to give "rise to severe 
septicaemia or endocarditis"
S . aureus is involved in 20-30% of cases of IE (less than the 35- 
65% with viridans streptococci, refer above). Characteristically, 
it is the principal agent in the acute form of endocarditis where 
previously healthy heart valves are infected. It is widely in­
volved in endocarditis of IV-drug users and is the major cause of 
IE in patients with valvular prostheses (Cotran et al, 1989). 
Waldvogel (1985) reports a lower incidence of 10% or less of IE 
in patients with S . aureus septicaemia while early figures were 
60% or higher
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Although favouring the adhesion of S . aureus, mucous membranes 
and the skin form very effective mechanical barriers to tissue 
invasion (Waldvogel, 1985). Were this barrier to be breached as a 
result of trauma or surgery (Waldvogel, 1985), large numbers of 
bacteria would be required for staphylococci to become infective. 
However, once established and no treatment is initiated, the bac­
teria tend to become invasive and the infection progressive (von 
Lichtenstein, 1989). Characteristically, abscess formation is in­
dicative of staphylococcal infection (von Lichtenstein, 1989). If 
located near the body surface, these lesions heal after natural 
or surgical drainage. Deeper lesions tend to rupture into serous 
cavities and suppurative peritonitis or pericarditis may develop. 
Another clinical condition, cellulitis, becomes apparent when, 
instead of forming typical localised, well circumscribed collec­
tions of purulent material, highly virulent staphylococcal 
strains spread into and infect loose connective tissue spaces. 
Staphylococci may disperse throughout the body via the 
bloodstream and metastatic abscesses or endocarditis may develop 
if treatment is not instituted promptly. Regional lymphadenitis 
may develop after S . aureus infection and, with involvement of 
the venous blood vessels, may lead to the complications typical 
of staphylococcal cellulitis: the formation and spread of septic 
emboli which may implant onto heart valves or into other organs 
(brain, kidney, lung) (von Lichtenstein, 1989)
Another staphylococcusal skin inhabitant, S. epidermidis, which 
tends to be less virulent, infects surgical or traumatic wounds 
or prostheses and may be life-threatening in compromised or 
debilitated patients (von Lichtenstein, 1989). In the multicentre 
study of Fang et al (1993), this staphylococcal species was the 
most commonly identified bacterium in all positive blood cultures 
in the investigation (43 of 171, or 25%). Seventy-four patients 
of 171 (43%) were classified as having definite prosthetic valve 
endocarditis and of these, in 30 of 74 patients the organism
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responsible for IE was S. epidermidis. The portal of entry most 
commonly identified in Fangs' study to lead to the development of 
new cases (18) of prosthetic heart valve IE with nosocomial bac­
teria, were intravascular catheters and wound and skin infec­
tions. In six and five patients, the causative organisms were S . 
epidermidis and S. aureus, respectively
S . aureus sepsis shows a high mortality in certain clinical set­
tings in spite of the availability of antibiotic chemotherapy. 
Sepsis with S. epidermidis, on the other hand, is inclined to 
show a more chronic course and be less of a medical emergency 
(von Lichtenstein, 1989)
3.4 Gastro-intestinal source and route of infection
3.4.1 Organisms and some predisposing factors
The entry into the blood-stream of bacteria may be overt and can 
be related directly to some specific and identifiable mechanism, 
or it may occur covertly as a result of causes difficult to iden­
tify (see earlier). Covert transient bacteraemias originate 
frequently in the gut (and oral cavity), (Cotran et al, 1989). 
Seeding of the gut blood supply with bacteria of low virulence 
from the gastro-intestinal tract may occur during normal 
physiological processes such as intestinal peristalsis or mas­
tication. In two-thirds of patients with IE, no identifiable 
cause of the initial bacteraemia is known (Hayward, 1973b) - per­
haps the latter mechanism may be precipitating factors of greater 
importance than is currently acknowledged?
Surgical procedures which breach the physical integrity of 
bacterially-laden mucosal membranes of the (lower) gastro­
intestinal tract, are likely to precipitate bacteraemia (Ashby et
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al, 1978). Wound infection is common after colon or gastric 
resection or hysterectomy (Gorbach, 1982) - all surgical proce­
dures involving bacteria-laden mucosae
E. coli, together with Enterobacter and Proteus organisms, are 
common causes of suppurative infections of the abdominal cavity 
(von Lichtenstein, 1989). Gram-negative bacteraemia is an ex­
tremely serious consequence of infections by these bacteria 
(acute appendicitis, cholecystitis etc.). Patients die as a 
result of endotoxaemic reactions, metastatic dissemination of or­
ganisms, DIC and shock
Von Lichtenstein makes the point that supports those made by 
Cotran et al (1989) and Hayward (1973b) on unidentifiable sources 
of bacteraemic organisms when he wrote that the presence of 
(Gram-negative) bacteraemia is not necessarily the consequence of 
suppurative disease. He continued: "...transient contamination of 
the blood is commonplace in daily life" and is of no consequence 
in the normal individual but only in those with "lowered resis­
tance..". Bacteroides species, like E. coli, are capable of en­
tering the blood stream after sepsis of the gut (B. fraqilis), 
oral cavity (B. melanoqenicus) and associated structures (von 
Lichtenstein, 1989). Debilitated patients commonly become sep- 
ticaemic when affected by these species and have a high mortality
3.4.2 Gastro-intestinal malignancy and bacteraemia
Endocarditis caused by certain bacteria present in the colon has 
been associated with lesions of the large bowel, including colo­
rectal carcinoma. Enterococcus spp. and Streptococcus bovis are 
examples of organisms which have been shown to be associated with 
malignancy. Such neoplasms are responsible for entry of these 
bacteria into the bloodstream with subsequent develoment of en­
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docarditis. An association between disease of the gastro­
intestinal tract (GIT) and S. bovis bacteraemia was sought by 
Murray and Roberts (1978). Thirty-six adults with S. bovis en­
docarditis plus 10 with bacteraemia alone were examined in an at­
tempt to determine possible portals of entry. Of these, 25 had 
lesions of the GIT or had recently undergone manipulation of this 
organ system. Twenty-two patients (14 with endocarditis, 8 with 
bacteraemia) had identifiable lesions in the gut. The authors 
divided these lesions into "probable" sources of bacteraemia (for 
example, colon carcinoma, ulcerations, adenomas, peritonitis) or 
"possible" sources (benign colonic polyps, bleeding 
haemorrhoids). Two symptomless patients (one each with IE or 
bacteraemia) after exploration of the GIT, were later found to 
have previously unidentified villous adenomas
Klein et al (1977) noted a possible link between carriage of S . 
bovis and the presence of carcinoma of the colon. They speculated 
on whether S. bovis may increase in number as a result of altered 
environmental factors in the bowel produced by the malignancy or 
visa versa
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Chapter 4
OVERVIEW OF PROPHYLAXIS OF INFECTIVE ENDOCARDITIS 
4.1 Introduction
"Efforts to prevent the disease (IE) have failed, regret­
tably...." (Morris, 1985)
An important relationship between dental extraction and other 
blood-letting procedures in dentistry and IE has been recognised 
for years and it has become accepted (obligatory) to attempt to 
prevent bacterial endocarditis in patients considered to be at 
risk
4.2 Regimens of antibiotic prophylaxis
Chemoprophylaxis has as its principal aim the protection of com­
promised patients from infection by micro-organisms resident in 
the mouth, nasopharynx and upper respiratory tract. As oral 
(viridans) streptococci are most commonly implicated in I.E. 
(Roberts et al, 1979; Bayliss et al, 1983; Durack et al, 1983; 
Hall and Heimdhal, 1989), safe, practicable methods of protection 
are directed against these bacteria when they appear in the blood 
stream
The exact nature of factors predisposing patients to IE develop­
ment, the disease itself and its prevention may be confusing 
(Jaspers and Little, 1984) but the known involvement of viridans 
streptococci in the aetiology of dentally-associated infective
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endocarditis (Bourgault et al, 1979) is irrefutable. It is ac­
knowledged that dental treatment is potentially hazardous for 
those with cardiac disease and that the development of IE in 
these patients is possible (Durack et al, 1983; Morris, 1985). 
Following current concepts, the administration of prophylactic 
antibiotics to reduce the likelihood of susceptible bacteria in­
fecting existing cardiac lesions in susceptable patients is 
highly advisable. The elective administration of protective an­
tibiotic cover is, however, controversial (Petersdorf, 1978; Mor­
ris, 1985; Durack et al, 1983). IE prevention is complex and in­
volves many "diverse issues" (Durack, 1995). Bayer et al (1990) 
take the view that the administration of antibiotic prophylaxis 
has simply become a "community standard practice" in the highly 
compromised patient to prevent prosthetic valve endocarditis in 
"two major settings": (i) peri-operatively to circumvent opera­
tive development of prosthesis colonisation, and (ii) during
bacteraemia-inducing oral, urogenital, and other medical proce-
/
dures
Numbers of European and American IE prophylaxis regimen proposals 
have been published over the years. The British Society for An­
timicrobial Chemotherapy (BSAC) has released several and include 
the Report of a Working Party in 1982, 1986 and 1990. Those of
the American Heart Association (AHA) include releases in the AHA 
Committee Report (1981), Special Report (1984) and Special State­
ment (1985). Recommendations and summaries from other parties are 
available (Van der Bijl, 1992; Medical Letter, 1989; Federation 
Dentaire Internationale, 1987; Editorial, 1985; Jaspers and 
Little, 1984)
The detail of many regimens differed markedly in earlier ver­
sions and caused considerable confusion amongst dentists and 
medical practitioners, especially regarding patient-risk 
categories and antibiotic regimen selection (van der Bijl, 1992).
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Attempts have been made to both reduce subsequent confusion and 
ease patient compliance. Emphasis earlier on parental administra­
tion made prophylaxis far less acceptable to both recipients and 
dentists (Petersdorf, 1978) and in 1982, in an effort to improve 
compliance, the BSAC proposed a simpler single or double, high- 
dose, peri-operative oral amoxycillin regimen to cover the criti­
cal post-operative risk period
The 1982 BSAC IE-prophylaxis proposal and the AHA (1984) equiv­
alent were the two most commonly used regimens but still, unfor­
tunately, differed sufficiently to prolong confusion. The AHA, 
however, fell in step with the British (BSAC, 1982; BSAC 1984; 
BSAC 1986; BSAC 1990) with the publication in 1990 of their up­
dated and amended recommendations (AHA, 1990)
4.2.1 Oral route
At present, the difference between the BSAC and AHA proposals is 
relatively minor. Both recommend oral erythromycin, clindamycin 
and large doses of amoxycillin with variations in form and dosage 
size. The former group prefer larger, single pre-operative doses 
of antibiotic (except erythromycin, see below) while the AHA tend 
have an initial dose either identical or smaller in size to the 
BSAC, with a second administration 6 hours later. Neither the 
BSAC nor the AHA any longer include penicillin V in their 
protocols and both recommend amoxycillin 3 g per os 1-hour pre- 
operatively in non-sensitive adults, while the latter also use a 
second 1.5 g amoxycillin dose 6 hours later to ensure high post­
operative serum amoxycillin concentrations
For penicillin-allergic patients, both oral protocols contain a 
second erythromycin dose 6 hours after the first but they differ 
marginally in other areas: the British recommend only the
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stearate salt in a 1.5 g stat dose a shorter 1-2 hours prior to 
the procedure with a 500 mg 6-hour dose later while the Americans 
prefer a smaller initial 800 mg erythromycin ethylsuccinate or 1 
g erythromycin stearate 2-hours pre-operatively plus a second 
dose of half the first the same period of 6-hours afterwards
Each regimen has some merit. The 50% larger BSAC 1.5 g -stearate 
dose size ensures higher and more adequate blood levels over a 
longer period (BSAC, 1986; Shanson, 1985 but may induce a higher 
incidence of nausea (BSAC, 1986) while the AHA erythromycin- 
succinate alternative is better tolerated by the patient
Roxithromycin may be a useful alternative to erythromycin (Smith 
et al, 1989). It has excellent pharmacokinetics and an antibac­
terial spectrum which is similar to that of erythromycin. It is 
known to induce less nausea and fewer gastro-intestinal upsets 
(Blanc et al, 1987) than erythromycin ethylsuccinate and has been 
shown to produce higher blood levels (than enteric coated 
erythromycin) from smaller quantities taken by mouth (Nilsen,
1987). Encapsulated enteric-coated erythromycin base produces 
higher serum levels than the -stearate formulation (Josefsson, 
Bergan et al, 1982)
Clindamycin is suitable for those who cannot tolerate either 
penicillin or erythromycin. The total amount of clindamycin ad­
ministered to IE-susceptible patients in the AHA regimen is less 
than that in the BSAC. The former has a smaller loading dose of 
300 mg clindamycin 1 hour prior to surgery plus 150 mg after 6 
hours where the British recommend a single, very much larger 600 
mg pre-operative dose only, also given the same time (1 hour) 
before the blood-letting procedure - without apparent side- 
effects (BSAC, 1990), apart from the "small risk" of pseudo­
membranous colitis (BSAC, 1986)
44
4.2.2 Parenteral route
The BSAC has only one recommendation for parenteral form of IE 
prophylaxis for non-allergic adults: a smaller 1.0 g quantity of 
amoxycillin IM suspended in local anaesthetic plus 120 mg gen­
tamicin is administered initially plus 500 mg amoxycillin orally 
6 hours later. This prophylaxis regimen is used to prevent en- 
terococcal endocarditis following gastro-intestinal tract 
manipulation. The Americans (AHA, 1990) use ampicillin instead of 
parenteral amoxycillin and use amoxycillin only in its oral form: 
ampicillin 2.0 g IM or IV 30 minutes before the procedure plus
1.0 g IM or IV or 1.5 g amoxycillin per os 6 hours later. One of 
three AHA parenteral routes is very similar to that of the BSAC, 
except that a larger 2.0 g ampicillin IV dose is used (instead of
1.0 g amoxycillin IV) and also with gentamicin up to a maximum of 
80 mg. The third adult AHA IV or IM method (non-high-risk 
patients) uses clindamycin in the lower dose (300 mg) IV plus 150 
mg either IV or orally 6 hours later
Both the BSAC and AHA use vancomycin in high-risk, penicillin al­
lergic patients who require treatment under general anaesthesia 
or have had penicillin more than once the previous month (see 
below)
In spite of the pain experienced during injection of IV amoxycil­
lin, it is used instead of ampicillin because of its greater and 
more rapid bactericidal activity (Comber et al, 1975)
For high-risk patients, 1.0 g vancomycin by slow IV infusion 1 
hour before surgery is common to the regimens. The BSAC, however, 
also recommends the additional use of gentamicin (120 mg) IV 
prior to induction or 15 minutes before the procedure
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Paediatric prophylaxis regimens of the BSAC and AHA are adaptions 
of those of the adult
Recommendations of the BSAC and AHA have been summarised with ex­
planatory comments by van der Bijl (1992). His major differention 
is between the oral and parental regimens and between penicillin­
taking and penicillin-allergic patients. Standard- or high-risk 
patients (those who recently took penicillin and those who 
receive treatment under anaesthesia) are included
Since 1982, the BSAC has recommended the use of oral prophylactic 
cover for almost all high-risk patients (including those with 
prosthetic heart valves) and the AHA now concurs, although the 
selection of a particular AHA parenteral prophylaxis regimen is 
still left to the clinician to a large degree. The single BSAC 
parenteral route is recommended for special risk cases such as 
those who have had previous episodes of endocarditis. Included in 
AHA guidelines are recommendations for patients suffering hyper­
trophic cardiomyopathy and mitral valve proplapse
While the AHA recommends chemoprophylaxis during blood-letting 
procedures involving the oral mucosa or gingiva, the BSAC does 
not unless patients are at special risk
The development of resistance amongst viridans strains initially 
prompted the BSAC to recommend a minimum interval for amoxycillin 
of 4 weeks between the last dose and the prophylaxis but later 
shortened this period to 2 weeks (BSAC, 1986) after further re­
search was published indicating that this was not common 
(Harrison, Rubin et al, 1985; Woodman et al, 1985. Erythromycin 
was found to select significantly for resistance but no changes 
were recommended for this antibiotic (Harrison, Stross et al, 
1985
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4.2.3 Further techniques to reduce risk of bacteraemia
Prevention of IE may involve techniques which do not require only 
the administration of chemical aqents in those susceptible to its 
development. Guntheroth (1984) suggested that one of the most ef­
fective methods to complement the use of protective chemotherapy 
would be the practice of good oral and dental hygiene and an ag­
gressive dental management programme. In contrast, certain 
authors appear to cast doubt on accepted philosophies in this 
regard (Coulter et al, 1990)
The AHA recognises the risk of poor oral hygiene and periapical 
and peridontal infections on the development of bacteraemias in 
at-risk patients and an optimal standard of oral health is en­
couraged. Suitable oral rinses are recommended as an adjunct (van 
der Bijl, 1992)
4.3 Experimental models in animals
4.3.1 Animal trials
Investigators have used animal experimentation to support the ad­
visability of antibiotic chemoprophylaxis use. Bacterial species 
employed in trials are those against which patients would most 
likely require protection. Studies on the prevention of strep­
tococcal IE have been performed in rat and rabbit models (Bernard 
et al, 1981; Glauser et al, 1983; Malinverni et al, 1983; Fran- 
cioli et al, 1985; Moreillon et al, 1986; Pujudas et al, 1986; 
Berney and Francioli, 1990)
Valvular lesions are produced mechanically by intention (Drake 
and Sande, 1986) with the insertion of cardiac catheters into the
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heart chambers one or more days before initiation of trials. 
Defined amounts of antibiotics are then administered to the in­
jured animals at predetermined times (usually 30 minutes) prior 
to the introduction by injection of bacteria into the blood­
stream, the inoculum size of which can vary between researchers. 
Efficacy of specific antibiotics are tested when administered as 
single agents or in combination, as single or multiple doses and 
at varying time intervals. Success of prophylaxis is determined 
by animal sacrifice 24-72 hours after antibiotic administration 
(Drake and Sande, 1986). To determine the proportion of infected 
animals, valvular vegetations are excised and cultured
Whatever animal model is employed, all share common patho­
physiological features in the (i) production of endothelial cell 
denudation, (ii) exposure of underlying extracellular matrix, and 
(iii) local deposition of platelets and fibrin (Baddour, 1994)
Francioli et al, (1985) showed that amoxycillin is equally ef­
fective against a small bacterial inoculum when used alone or in 
combination with gentamicin. In another experiment on rats, a 
single dose of amoxycillin was used to prevent IE after bacterial 
challenge with organisms that were amoxycillin-tolerant (Berney 
and Francioli, 1990). Antibiotic prophylaxis was successful, 
however, only when the the size of experimental bacterial dose 
was smaller than the infective dose. Malinverni et al (1987) 
tested multiple-dose regimens of amoxycillin alone and in com­
bination with gentamicin against two viridans species (S. sanguis 
and S- intermedius) and two Enterococcus faecalis isolates in ex­
perimental streptococcal endocarditis. Amoxycillin as a single 
agent was effective only against the oral streptococci but not 
against the E. faecalis strains where only the combination proved 
successful
When bacteria are sensitive and rapidly killed by an antibiotic,
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Glauser and Francioli (1982) found single-dose prophylaxis 
successful irrespective of the number of organisms used to induce 
endocarditis
In contrast, tolerant viridans streptococci are only controlled 
effectively by beta-lactams and other cell-wall active and bac­
teriostatic antibiotic agents (erythromycin and clindamycin) when 
bacterial numbers are less than 90% of the infective dose 
(Glauser et al, 1983; Francioli et al, 1985; Moreillon et al, 
1986; Berney and Francioli, 1990)
Further properties of administered antibiotics, other than their 
bactericidal ability, may, however, play a role. In 1981, Bernard 
et al, found vancomycin prophylaxis in IE-susceptible rats ef­
fective against an injected vancomycin-tolerant S. sanguis strain 
and ascribed this phenomenon to a reduction of tissue adherence 
properties of the bacteria
4.3.2 Clinical relevance of animal trials
The relevance of data derived from the experimental development 
of IE in animal models and extrapolated to IE in humans has been 
queried (Malinverni et al, 1987). For example, the large quantity 
of bacteria injected into laboratory animals to produce IE far 
exceeds that detected in the blood-stream after dental and other 
procedures in humans. Animal experimentation and clinical situa­
tions are incomparable because of vastly unequal number of 
"seeding bacteria" introduced into the blood-stream (Petersdorf, 
1 978)
It ought to be borne in mind, however, that the injection of bac­
teria into the animals is, of necessity, a crude attempt at 
simulating the biological processes found in nature. Bernard and
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his co-workers (1981) indicate, in apparent defence of the 
laboratory method that, when circulating bacterial levels are 
determined in the animals shortly after IV injection, numbers 
soon decrease from the high levels present initially. In the rab­
bit model, Petersdorf noted that this animal provides a more 
stingent prophylaxis model than anticipated because of factors 
which appear to disadvantage the animal more than they apparently 
would humans: the disproportionally large number of bacteria 
necessary to induce endocarditis (see above); secondly, the use 
of indwelling cardiac catheters tends to reduce antibiotic effec- 
tivity (see below) and thirdly, the inherent very rapid rate of 
antibiotic excretion which the rabbit displays
Importantly, results of antibiotic trials for the therapy of IE 
in the animal models are consistent but experimental design and 
other variables require critical examination (Drake and Sande, 
1986). This latter comment is relevant when observations and con­
clusions are drawn from data. The authors mention specifically 
factors such as the effect which the presence or absence of 
intra-cardiac catheters may exert on antimicrobial agent activity 
(an aspect discussed by Petersdorf, 1978), the time of antibiotic 
administration relative to the time of bacterial infection, dose 
sizes and interdose intervals, and the species of infective bac­
terial agents used in the model
4.4 Summary
From the interpretation of experimental antmicrobial prophylaxis 
research data, results of its use in the clinical situation is 
often confusing and inconclusive. Effectiveness of IE prohylaxis 
regimens is not absolute (Friedlander and Yoshikawa, 1990) and 
medico-legal aspects generally dictate its employment whenever 
uncertainty arises on the issue (van der Bijl, 1992)
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Despite great strides made in the clinical and scientific fields 
of medicine, streptococcal IE is still frequently encountered in 
both the apparently healthy and diseased heart (Bayliss et al, 
1983). Prophylactic antibiotic regimens, although based on avail­
able clinical knowledge and experimental data, are still empiri­
cal in nature (MacFarlane et al, 1983) and no prophylactic 
regimen has been proven, beyond reasonable doubt, to be effective 
against the development of endocarditis after invasive procedures 
of a surgical nature. Only indirect evidence is available on the 
efficacy of prophylaxis used in humans because of very obvious 
ethical problems involved with the experimental testing of such 
regimens on human subjects. What evidence there may be is often, 
of necessity, anecdotal (Bayliss et al, 1983; Durack et al, 
1983). Because of the seriousness of IE development in a 
patient, routine measures are employed which are hoped would 
reduce the likelihood of post-operative complications occurring. 
The serious level of debate is illustrated by Bayer et al in 1990 
for instance, who found no controlled studies which, in their 
view, were able to confirm satisfactorily the benefits of 
prophylaxis in preventing endocarditis of native valves
A contentious issue which has been raised on many occasions in 
the medical and scientific literature involves the role which 
dental procedures may play in the causation of IE. Its importance 
has been questioned by some researchers (Guntheroth, 1984), while 
others believe there is a direct dental link (Durack et al, 1983)
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Chapter 5
ANTIMICROBIAL CANDIDATES FOR INFECTIVE ENDOCARDITIS PROPHYLAXIS
5.1 Introduction
Recommendations for the use of prophylactic chemotherapy are 
based mainly on susceptibility patterns of organisms most likely 
to produce IE in given clinical situations as well as the phar­
macokinetic properties of the candidate antibiotics. There is 
general agreement that the effect of the prophylactic an­
timicrobial agents on the target organisms should ideally be bac­
tericidal in nature (Coulter et al, 1990)
In an effort to determine possible clinical efficacy in humans, 
in vitro studies into the antimicrobial action of antibiotics 
against specific bacterial pathogens are performed initially in 
the laboratory and then tested on animal models. Animal testing 
is regarded as essential as laboratory models simulating given 
prophylactic regimens are seldom able to overcome the problems of 
control of the variable factors present in in vivo systems. Vari­
ables requiring attention in in vitro systems include inoculum 
size, incubation conditions (duration, temperature, humidity, and 
oxygen and carbon dioxide concentrations), nature of the culture- 
medium (solid, semi-solid, broth), pH of the medium and the ef­
fect on organisms of the presence of blood or serum. This may ac­
count for often widely varying sensitivity values in the litera­
ture for specific species against the same antibiotic
Neu and Labthavikul (1983) were able to show an apparent dif­
ference in antibiotic sensitivity by varying only one independent
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factor. They determined what effect human serum would have on the 
action of teichoplanin on bacterial isolates. By supplementing 
broth with the serum to a concentration of 50%, MBC values in­
creased by an average 8- to 16-times (the MBC remained unchanged 
in one case). MIC's, however, were reduced by a quarter or one 
half for 5 isolates and doubled in the other
Antibiotic effectivity may be influenced by factors not normally 
recognised to be important. In an in vivo study, Oikarinen and 
Malmstrom (1972) showed that in spite of high systemic blood con­
centrations of penicillin V, levels of this antibiotic in oral 
tissues were found to be markedly affected by vasoconstrictors 
incorporated into local anaesthetics used to infiltrate areas in 
the oral cavity. Fifty-six out-patients received one million 
units (600mg) of penicilllin-V by mouth. Concentrations of this 
antibiotic in cubital vein blood and in extraction sockets in the 
mandible and maxilla, with and without vasoconstrictor use 
respectively, were determined. Penicillin V blood concentrations 
were markedly higher in those maxillary extraction patients in 
whom local anaesthetic without vasoconstrictor was used than in 
those where the local anaesthetic contained vaso-active com­
pounds. In the former, extraction socket levels of penicillin V 
approached those found in venous blood of the cubital vein. When 
regional nerve blocks were administered in the mandible prior to 
extraction, there was no meaningful difference in socket and 
cubital vein blood penicillin V levels
Toxicity of an antibiotic preparation, if sufficiently severe, 
may preclude its use in the clinical situation however suitable 
it may prove to be in vitro. However, because of the short dura­
tion of IE prophylaxis required even a relatively toxic agent 
such as vancomicin may be a legitimate candidate for this purpose
To develop suitable antimicrobial prophylaxis regimes, suscep­
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tibility patterns of viridans streptococci are required. Oral 
streptococci are sensitive to virtually all the commonly 
prescribed beta-lactam antibiotics including penicillins-V and 
penicillin G, ampicillin and amoxycillin as well as several mac- 
rolides (erythromycin, roxithromycin, clarithromycin and 
azithromycin) and others (eg. clindamycin, vancomycin)
5.2 fi-lactam antibiotics: penicillin G, penicillin V, ampicillin 
and amoxycillin
5.2.1 Introduction
"8-Lactam antibiotics are bactericidal because they inhibit bac­
terial cell-wall synthesis" (Donowitz and Mandell, 1988a)
Penicillin G is the second oldest of the antibacterial agents in 
clinical use today after the sulphonamides (O'Brien et al, 1987). 
Observations published in the Lancet in 1940 noted in vitro an­
tibacterial action on a number of organisms, including an isolate 
of a "Str. viridans strain from a tooth", and the therapeutic ef­
fects on normal animals of a solution of an impure, brown, water- 
soluble penicillin preparation in powder form (Chain et al) 
(1940)
As early as 1942, before the use of penicillin G on a world-wide 
scale, Hobby et al showed this antibiotic to be highly bac­
tericidal on rapidly replicating bacteria but was only bacterios­
tatic on non-dividing bacterial cells
Penicillin G, penicillin V, ampicillin and amoxycillin are beta- 
lactam antibiotics in common use for the prevention and treat­
ment of infection by viridans streptococci susceptible to 
penicillin (Sprunt et al, 1968; Basker et al, 1977; Bougault et
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al, 1979; Dowson et al, 1990)
Sensitivity of Gram-positive bacteria to natural and semisyn­
thetic and synthetic penicillins differs. Strains inhibited by 
natural penicillins tend to be less susceptible to extended- 
spectrum compounds such as ampicillin and amoxycillin (Moenning 
et al, 1989). However, viridans streptococci are generally sus­
ceptible to penicillin with an average MIC of 0.2 mg/1 (Hall and 
Heimdahl, 1989)
Bourgault et al (1979) found viridans streptococci to be sensi­
tive to penicillin G in vitro. Susceptibility ranged from a very 
sensitive MIC of 0.06-4 mg/1 and an MBC of 0.06->8 mg/1 penicil­
lin G. Of 63 viridans strains examined, <_1 mg/l penicillin G 
killed 51 isolates. S. mitis and S. sanguis II were reported to 
be the most resistant strains in the study: five of the former 
and two of the latter were killed only by 2->8 mg/1 antibiotic. 
Ampicillin exhibited activity similar to penicillin G
Coulter et al (1990) found bacteraemic viridans isolates to 
possess an MIC range of <0.01-2.0 mg/1 and MBCs of between 0.01 
and 2 mg/1 penicillin G. Using broader spectrum amoxycillin, the 
same isolates had ranges of <0.01-4 mg/1 and 0.01-4.0 mg/1 for 
the MIC and MBC's respectively. Penicillin G was seen to be mar­
ginally more effective in vitro than amoxycillin
In 1978, Shanson et al compared penicillin V and amoxycillin ac­
tivity in both in vivo and in vitro tests. They showed pre­
operative prophylactic antibacterial action against viridans bac­
teria of 2 g penicillin V to be as efficient in clinical trials 
as 2 g of amoxycillin. When tested against 43 bacteraemic iso­
lates, all were sensitive to both antibiotics with MICs of _^0.12 
mg/1. MICs of both penicillin V and amoxycillin ranged between 
0.002 and 0.05 mg/1. For 7 viridans organisms, MBCs were equal to
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the MIC and _£0.12 mg/1 antibiotic. However, in spite of apparent 
antibiotic sensitivity of organisms, the authors were able to 
isolate bacteraemic streptococci from 12% (5 of 40) of the ex­
traction patients on penicillin V and 5% (2/40) on amoxycillin 
percentages significantly lower than the 40% (16/40) obtained in 
the control group. In an earlier study of Phillips et al (1976), 
most bacteraemic viridans isolates were very sensitive to 
penicillin V with MICs similar to figures determined by Shanson 
et al (1978): 0.12 mg/1. Sixteen percent (49/301) were more
resistant with an MIC of >_1 .0 mg/1 penicillin V. Because of the 
better and more consistent absorption of amoxycillin and its 
greater and more rapid bactericidal activity, this antibiotic is 
preferred to penicillin V
Amoxycillin is synthesised by modifying the structure of (semi­
synthetic) ampicillin to produce a compound with improved phar- 
mokinetic and other characteristics. Notwithstanding a very 
similar molecular structure, amoxycillin possesses intrinsic in 
vitro and in vivo antibacterial activity which differs marginally 
from that of ampicillin (Bodey and Nance, 1972; Neu, 1974; Brog- 
den et al, 1975). As noted in Chapter 3, amoxycillin is more 
rapidly bactericidal than ampicillin although they are equally 
inhibitory (Comber et al, 1975)
Sutherland et al (1972) found the antibacterial spectrum of 
amoxycillin to be almost identical to that of ampicillin and to 
show good activity against viridans streptococci. Similarly, in 
clinical trials Shanson et al (1978) found spectra of amoxycillin 
and penicillin V against viridans streptococci to be very similar 
when used to control post-extraction bacteria'emia in 120 healthy 
adults. In 1974, Neu reported viridans streptococci to be in­
hibited by 0.012 mg/1 amoxycillin and that it possessed an an­
tibacterial spectrum similar to that of ampicillin. After being 
taken by mouth, blood (and urine) levels were achieved that were
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almost twice those of ampicillin
5.2.2 Serum levels
The clinical advantage of amoxycillin over ampicillin is an im­
proved absorption from the gasto-intestinal tract after oral in­
take and high blood levels of the former (Sutherland et al 1972). 
Satisfactory blood levels are evident from experimental data. 
Cannon et al (1984) determined serum levels of oral amoxycillin 
after extractions under general anaesthesia in two groups of 
patients - one older than 12 years of age (24 volunteers) who 
took 3 g and the other younger group (17) who took half the dose 
of amoxycillin. The mean duration between amoxycillin administra­
tion and the induction of anaesthesia was 4 hours 25 minutes and 
blood was drawn immediately after completion of the extraction 
procedures. The average serum level for the older group was 9.08 
(+/- 5.59) mg/1 amoxycillin and younger 8.21 (+/- 4.7) mg/1. The 
average for both groups was 8.49 (+/- 5.07) mg/1. In another 
trial (Shanson et al, 1984), serum levels of amoxycillin reached 
an average of 16.1 mg/1 in 10 healthy adult males two hours after 
the oral administration of 3 g of the antibiotic in reconstituted 
powder (syrup) form. The difference in serum levels between the 
two trials is explained by the difference in time at which the 
bloods were drawn after administration; more than 4 hours for the 
first and two hours for the second (Shanson) trial
In an early trial conducted by Neu (1974), amoxycillin serum 
levels reached an average peak of 7.6 mg/1 (range: 4.5-14 mg/1) 
in eight fasting volunteers. Oral ampicillin in the same trial 
reached only 3.8 mg/1, range 2.75-8 mg/1. Non-fasting amoxycillin 
serum levels were found to reach 98% those in fasting subjects. 
The highest serum levels were reached after 2 hours and after 
250. 500, 1500 and 3000 mg doses, levels of 3.2, 7.7, 13.2 and
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25.5 mg/1 were found
5.2.3 Resistance to penicillin
It is generally accepted that antimicrobial agents select for 
resistant bacterial mutants. The appearance of resistance in 
populations of bacteria of clinical importance affects directly 
the choice of suitable candidate agents
Bacterial resistance to penicillin was recognised soon after it 
was taken into clinical use. Krumwiede (1949) reported the 
development in "rheumatic children" on daily doses of oral 
penicillin, as a "means to protect them from streptococcal 
pharyngitis", of resistant "alpha-haemolytic streptococcus" 
(which "was later successfully treated by massive doses of 
penicillin"). She reported that in strains isolated before and 
during its administration, penicillin susceptibilities from both 
the penicillin-treated and control (those not receiving 
antibiotic) groups of children were comparable (and sensitive), 
with the exception of four isolates from the controls which were 
notably more resistant. One child on 50 000 units of penicillin 
twice daily developed acute bacterial endocarditis (and the of­
fending alpha-haemolytic streptococcus was "not highly 
resistant"!). Krumwiede recognised that this antibiotic 
eliminated susceptible strains and selected for resistant clones 
in the population
Resistance develops as a result of a number of mechanisms. Three 
genetically controlled forms of penicillin-resistance are known: 
(i) production of beta-lactamase enzymes by bacteria which inac­
tivate certain members of this antibiotic group; (ii) changes in 
bacterial cell permeability to beta-lactams (only a problem in 
gram-negative bacteria) and (iii) structural alteration of
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membrane-bound target sites or receptors of beta-lactams, the 
penicillin-binding proteins (PBPs). Neu (1985) included a 
tolerance mechanism operating in Staphylococcus aureus and Strep­
tococcus pneumoniae which is dependent upon inhibition of 
autolytic enzymes required for cell wall formation. Viridans 
streptococci are not known to produce beta-lactamse enzymes
In 1983, Farber et al found that resistance to penicillin in 
viridans streptococci occurred with the alteration of PBPs to 
produce receptors with a lowered affinity for this antibiotic. 
Dowson et al (1990) investigated this phenomenon in clinical iso­
lates of resistant viridans strains in the United Kingdom and 
found that the transfer of genetic material which encoded for 
penicillin resistance via PBPs may occur between resistant S . 
pneumoniae and previously sensitive S . oralis isolates. They dis­
covered that the PBP2B-gene variant in penicillin-resistant 
strains of S. oralis was almost identical to that in the 
pneumococcus
The precise mechanism of killing of sensitive bacteria by 
penicillin is unknown. Tomasz, in 1986, wrote that "the quantita­
tive relationship between the MIC of a 6-lactam antibiotic and 
its reactivity with certain PBPs is not well understood" and 
"also poorly understood is the mechanism by which inhibition of 
PBP function causes triggering of suicidal autolytic activity" by 
certain of these agents. Osmotic lysis of bacteria whose cell 
walls have been damaged by 6-lactams has been postulated to play 
a role in the final killing of bacteria by these antibiotics but 
6-lactams such as imipenem are bactericidal but do not possess 
any lytic activity
Several studies have been performed to analyse the effect of an­
timicrobial agents on the sensitivity patterns of oral strep­
tococci. Since the publication of Krumwiede's 1949 article, the
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emergence of penicillin-resistance amongst bacteria has been com­
monly reported. Drucker and Jolly (1971), using antibiotic disks, 
isolated organisms with differing antibiotic sensitivities from 
different areas of the mouths of patients with no known prior ex­
posure to specific antimicrobial agents under examination. The 
investigators found that a large percentage of patients (29%) in 
the experimental groups carried resistant oral streptococci. The 
gingival crevice and free gingival margin together contained the 
highest number of penicillin-resistant oral streptococci (38%). 
Amongst streptococci in the gingival crevice resistance ranged 
between 12 and 22% and on the gingival margin between 18 and 30%. 
The authors did not identify isolates beyond the Streptococcus 
genus level and were unable to observe that certain species of 
viridans bacteria are more common in some areas of the mouth than 
others. As an explanation of the high levels of antibiotic resis­
tance without evidence of administration, the authors noted that 
some volunteers were medical and dental personnel who may have 
acquired antibiotic-resistant bacteria from their work environ­
ment. The importance of the gingival margin as a source of bac- 
teraemic streptococci in dental procedures, however, was stressed 
by Drucker and co-worker
Josefsson and Nord (1982) employed a modified version of American 
Heart Association (AHA) IE-prophylaxis recommendations to deter­
mine the susceptibility of oral bacteria after prolonged ex­
posure. Eight volunteers received a stat 2 g penicillin V oral 
loading dose in tablet form plus a single 800 mg dose one hour 
later and then every 8 hours thereafter for a total of eight 
doses. The authors sampled dental plaque after a week and again 
after eight days and identified viable aerobic and anaerobic or­
ganisms. A significant decrease in, amongst other bacteria, S. 
salivarius and S. sanguis numbers was found and indicated an ap­
parent sensitivity of these oral organisms to penicillin V in 
their study. However, the opposite was noted later by MacGregor
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and Hart (1986). Investigating amoxycillin resistance amongst 
viridans streptococci in volunteers after an oral 3g dose, they 
observed that subsequent to a noticable drop in all oral strep­
tococci directly afterwards, numbers of S. salivarius isolates 
increased to 41.8% of all viridans from an initial 29.3% - a 
relative increase of 12.5%. S. mutans numbers also increased 
slightly from 4.6% of all cultures to 7.3% after the amoxycillin 
was taken. There did not appear to be a marked increase in 
amoxycillin MICs but MacGregor and Hart did not comment on the 
possible (clinical) significance of their findings
Leviner and colleagues (1987) identified resistant oral viridans 
streptococci in volunteers after the taking of penicillin V at 
doses based on the recommendation of the AHA (Special Report, 
1984). Twenty-nine healthy volunteers took 2 g penicillin V, 
another 1 g 5-hours after the first plus an extra 1 g 10-hours 
again after the start of the investigation (total 4 g in that 
period). No further antibiotic was administered. Leviner et al 
detected resistant oral isolates six hours after the initial 
penicillin dose in a third (9 or 31%) of the subjects and still 
found resistant organisms in the mouths of volunteers at least 8 
days after the withdrawal of the penicillin. Unlike MacGregor and 
Hart (1986) (and BSAC, 1986) who saw no reason to limit penicil­
lin use again soon after its employment for prophylactic purposes 
(see later), Leviner suggested that caution should be exercised 
for at least 8-days thereafter as resistant strains may still be 
present in a patient's mouth
Even without evidence of prior antibiotic exposure, marked an­
tibiotic resistance is known to appear. Longman et al (1991) 
reported viridans amoxycillin-resistance to concentrations of >_6 
mg/1 (one quarter of the maximum blood-levels after 3g 
amoxycillin) in 7% of the 54 endocarditis-susceptable patients 
and 5% of the 65 healthy volunteers. S. sanguis biotypes I and
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II, S. mitis and S . salivarius (and one S. milleri) were iso­
lated. All were resistant to either amoxycillin or erythromycin. 
Neither patients nor volunteers had taken antibiotics in the 
three months prior to the investigation
In 1983, Southall et al performed a similar trial on volunteers 
after multiple oral doses of 3g amoxycillin as described by Shan- 
son et al, (1980). All participants, free of penicillin-resistant 
isolates prior to the start, developed resistant viridans strep­
tococci on completion of the study. Two 3 g amoxycillin doses, 
administered 8 hours apart, were taken by each of the 11 volun­
teers once weekly until the first resistant viridans streptococci 
were found. Specimens for resistance-screening were selected from 
saliva specimens and gingival sulcus material. By the fifth week, 
all volunteers had acquired streptococci resistant to 0.5 or 1.0 
mg/1 amoxycillin. The average time before the emergence of resis­
tance was 3.6 weeks although in one volunteer this occurred after 
the first of the two 3 g doses. All resistant isolates (17) were 
identified as S. sanguis and MICs of amoxycillin varied from 1.0 
to 16.0 mg/1 and MBCs from 2.0-16.0 mg/l. Resistance of viridans 
isolates to erythromycin varied, but isolates retained suscep­
tibility to clindamycin and vancomycin. MICs against these an­
tibiotics were not stated. After discontinuation of the an­
timicrobial therapy, resistant streptococci disappeared from the 
mouths of 8 of 9 volunteers after 7 weeks, and in all 9 volun­
teers finally after 13 weeks
To examine the development of beta-lactam resistance amongst oral 
streptococci, Woodman et al (1985) conducted a study using the 
prophylactic amoxycillin regimen proposed by the BSAC (1982). 
Amoxycillin was administered to two 10-member volunteer groups. 
One group (group "A") received a single 3g amoxycillin dose while 
the second (group "B") received three doses of the same size at 
weekly intervals. A third 4-member group ("P") was selected from
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volunteers of group A to take three doses of placebo, also at 3- 
weekly intervals, starting 3 months after their single 3g 
amoxycillin dose. To serve as a microbiological baseline control, 
specimens were collected from all volunteers in an attempt to 
partially identify and quantify resident salivary populations of 
amoxycillin-sensitive and -resistant bacteria before the inves­
tigation was initiated. All group "A" and "B" subjects harboured 
bacteria resistant to 2 mg/1 amoxycillin when tested before the 
culture medium was supplemented with the antibiotic, although not 
all strains from the same subjects (2) were always resistant. 
Specimens from 9 (of 20) subjects grew bacteria resistant to 40 
mg/1 amoxycillin. The authors calculated that the volunteers 
carried less than 1% of resistant oral flora in total - still a 
very large pool of resistant strains if one accepts that 1 g of 
wet plaque contains 22-179 thousand million bacteria (Gordon et 
al, 1971)
After the orally administered dose of amoxycillin, the strep­
tococcal count in group "A" (including those resistant to 2 mg/1 
antibiotic) returned to baseline counts after 3 weeks. However, 
streptococci resistant to 40 mg/1 amoxycillin fell in number to 
levels below those which existed prior to antibiotic administra­
tion. Total streptococcal (and anaerobic) counts in group "B" 
soon returned to baseline levels after the three doses but there 
was a statistically significant rise in amoxycillin resistance 
after the second and third doses. High counts of resistant strep­
tococci lasted on average for 28 and 21 days for the organisms 
resistant to 2 mg/1 and 40 mg/1 repectively. In two subjects, 
amoxycillin resistance returned to baseline levels only after 7 
weeks and it took 11 weeks for resistance to 40 mg/1 to disappear 
from the saliva of all subjects. Placebo group members showed no 
statistically significant change in anaerobe or streptococcal 
numbers although there were noticeable fluctuations in anaerobe 
numbers
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The time interval between induction of penicillin resistance and 
oral clearance of mutant penicillin-resistant organisms would 
have important clinical implications were compromised patients to 
require further antibiotic treatment within this period. Woodman 
et al (1985) suggested that either a single or double dose 3 g 
amoxycillin regimen (with a 7 day interval in the latter 
instance) would be acceptable for at-risk IE patients. If spaced, 
multiple dental procedures are required in a patient, either a 
suitable alternative antibacterial agent should be used or an ab­
solute minimum time interval of 4 weeks between treatments should 
be observed were the original antibiotic to be re-used. Woodman 
et al are supported by Southall et al (1983); others not sub­
scribing to this view are discussed below
Penicillin-resistant micro-organisms may be part of normal oral 
flora and writers state that it is possible to isolate resistant 
organisms in 7% or less of the general population and up to 100% 
in special groups (Drucker and Jolly, 1971; Sukchotiratana et 
al, 1975; Phillips et al, 1976; Elliot and Dunbar, 1977; Leviner 
et al, 1983; Leviner et al; 1984. Sukchotiratana et al (1975) 
suggested that the emergence of resistant streptococci so soon 
after taking the antibiotic (24 h in their study of dental 
crevicular flora) was as a result of resistant isolates already 
present in undectable numbers before the trial was initiated - a 
point supported later by Woodman et al (1985). Bacteria resistant 
to gingival fluid or salivary concentrations of penicillin V 
quickly increased in number after the elimination of sensitive 
elements by the antibiotic, and persisted for 8-weeks after its 
discontinuation
Several reports are contrary to often quoted studies on the ap­
pearance and development of penicillin-resistant strains. 
MacGregor and Hart (1986) found no significant increase in resis­
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tance amongst viridans streptococci to amoxycillin when taken as 
a single "prophylactic" dose. Further, they found there to be no 
contra-indication for the repeat administration, during the three 
weeks following the first dose, of another dose were this 
required. This is a position on prophylaxis use similar to that 
taken by the BSAC in the same year (BSAC, 1986) who recommended a 
shorter 2-week minimum period before a repeat dose. MacGregor and 
Hart used ten suitable participants who acted as their own con­
trols. They had no prior antibiotic exposure for four weeks prior 
to their inclusion in the study. Saliva specimens were collected 
and cultured for viridans streptococci at specified times begin­
ning 3 weeks before and ending three after the oral administra­
tion of 3g amoxycillin. Viridans numbers dropped off markedly im­
mediately (1 hr after swallowing this antibiotic) but, after 7- 
days, numbers had returned to levels which existed prior to the 
administration of the amoxycillin. During the 21-day control 
(pre-administration) phase of the investigation, one particpant 
had two salivary isolates (both S. mitis) with MICs of 1.0 mg/1 
amoxycillin but most other cultures were found to have lower MICs 
between <0.03 and 0.25 mg/1. After the amoxycillin, 3 isolates 
had MICs of 1.0 mg/1; two were S. mitis species and a single S . 
salivarius strain. The fact that participants in this study only 
received a single dose of antibiotic may account for the disap­
pearance of resistant mutants so soon after the administration of 
the stat dose
Penicillin V, proposed in older AHA prophylaxis regimens, was 
found to leave normal salivary, throat and faecal flora unaf­
fected in 10 subjects screened for 29-days after the start of a 
week's oral administration of 800 mg 12-hourly in capsule form 
(Heimdahl and Nord, 1979). Although serum penicillin V levels in 
blood drawn 1 hour after the first daily dose increased gradually 
from an initial 3.8 to 5.2 mg/1 during the trial, no antibiotic 
was detected in any salivary (or faecal) specimens. A small
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decrease in unspeciated salivary streptococcal numbers was noted 
and no resistant strains were isolated. The lack of any apparent 
disturbance in oral flora is ascribed by the authors to the use 
of the antibiotic in capsular and not tablet form. Clindamycin 
was tested in a similar manner (discussed later)
In a 1976 publication, Phillips et al speculated on whether the 
presence of resistant strains carried by an individual was as the 
result of (i) the acquisition from patients, with prior an­
tibiotic exposure, of such strains of oral streptococci, (ii) the 
overgrowth of certain intrinsically resistant species or (iii) 
the selection of resistant mutants from previously sensitive com­
mensal streptococci. The researchers isolated a greater number of 
resistant streptococci from patients with known prior penicillin 
exposure than from those without. Leviner et al (1984) found that 
hospital staff in contact with patients "who were consumers of 
high doses of penicillin" had greater numbers of resident 
penicillin-resistant oral viridans streptococci (48.08%) than 
"low-contact" staff groups (7.89%). Phillips et al (1976), 
Leviner et al (1984) and Drucker and Lolly (1971) shared the same 
views on the concept of carriers or reservoirs of resistant 
strains
Antibiotic resistance in oral streptococci may, theoretically, be 
used to advantage through their ability to compete for colonisa­
tion by more difficult-to-treat organisms such as gram-negative 
bacilli but this potentially beneficial effect would be difficult 
to apply in clinical situations on a routine basis. Studies were 
undertaken by Sprunt et al (1971) on the exertion of such an in­
terference phenomenon by certain antibiotic-resistant bacteria on 
others in compromised patients. They investigated whether over­
growth by pathogenic gram-negative bacteria in the oro-pharynx 
might be prevented by some bacteriological means in patients 
after cardiac surgery. A total of 29 patients who received IV
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penicillin plus 1g of streptomycin for 5-7 days post-operatively, 
were studied. Thirteen of 29 patients showed an overgrowth of en­
teric bacilli and all but one demonstrated a loss of alpha- 
haemolytic streptococci in the pharynx during the period of high 
antibiotic administration. However, during this period, in 15 of 
the 16 patients in whom no pharyngeal gram-negative overgrowth 
could be demonstrated, alpha-haemolytic streptococci were 
demonstrated in their pharynges instead. Alpha-haemolytic strep­
tococci were found to be susceptibile to <0.3-0.6 mg/1. Five 
patients, in whom resistant alpha-haemolytic strains were 
selected after receiving oral penicillin for 3-5 weeks prior to 
surgery, were all found to be free of enteric Gram-negative 
bacilli. The hypotheses which Sprunt et al postulated viz. that 
(i) the persistence of viridans streptococci after large doses of 
penicillin would result in the absence of Gram-negative enteric 
bacilli from the patients' pharynges and that (ii) the presence 
of interfering bacteria would be as a result of penicillin resis­
tance which would develop in the streptocooci, appear to be sup­
ported by their investigation. The resistant viridans strep­
tococci apparently served a useful, protective (bacillus 
repellent) role which may conceivably have contributed positively 
towards post-operative recuperation of patients in the study. 
The potentially beneficial result of microbial incompatibility 
(Ellen, 1982) may occur between resident penicillin-resistant 
alpha-haemolytic streptococci and enteric bacilli competing for 
colonisation of parts of the oro-pharynx of compromised patients 
in an area of the body not normally associated with their 
presence in the healthy host
5.3 Macrolides and related antibiotics: erythromycin, 
roxithromycin and clindamycin
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5.3.1 General properties of macrolides
Macrolides are a broadly homogenous group of antibiotics with 
four notable characteristics: they possess similar (i) macro- 
cyclic lactone rings, (ii) antibacterial spectra, (ii) mechanisms 
of action and bacterial resistance and (iii) pharmacokinetics. 
Additionally, they possess relatively high lipid solubility, a 
low degree of ionisation and wide tissue distribution. Macrolides 
exert their antibacterial activity by binding bacterial 50s- 
ribosomal subunits and interfering with normal protein synthesis 
by competitively inhibiting access of t-RNA-amino acid complexes 
to the m-RNA (Wilson and Cockerill, 1983), at the level of DNA 
translation (Molinari, 1983)
Macrolides in clinical use at present are erythromycin, roxith­
romycin, clarithromycin, azithromycin and dirythromycin. The lat­
ter four compounds share similar activities and spectra to eryth­
romycin but have markedly improved pharmacokinetics. Only roxith­
romycin of the newer macrolides was included in the experimental 
design of this study and will therefore be discussed in some 
detail even though other recently released agents of this group 
of antibiotics (which were not yet available in South Africa when 
this investigation was initiated) may be similarly useful for IE 
prohylaxis
5.3.2 Erythromycin
Erythromycin, one of the so-called 14-carbon lactonic ring class, 
was isolated originally from Streptomyces erythreus and is cur­
rently one of the most important of the macrolide antibiotics. 
Although serious adverse reactions are rare, gastro-intestinal 
(GI) intolerance is more common (Mandell, 1985) but is usually 
the consequence of large dose size (Maskell et al, 1988). Apart
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from GI intolerance, mild drug fever and hypersensitivity to one 
of the erythromycin forms may occur. It is regarded as being one 
of the safest antibiotics in common clinical use (Neu, 1988)
Erythromycin is available in erythromycin-estolate, -stearate and 
base (enteric-coated) preparations. The latter two are safer to 
use in patients with liver disease than the first which may also 
induce sensitivity reactions
5.3.2.1 Pharmacokinetics and activity spectrum of erythromycin
Unpredictable absorption of erythromycin is a prominent clinical 
failing of this agent (Maskell et al, 1988). Film-coated prepara­
tions produce significantly higher maximum peak serum levels than 
either the estolates or stearates. In a study by Josefsson, Ber- 
gan et al (1982), a 500 mg enteric-coated erythromycin-base dose 
produced a significantly higher serum level (a 3.5 mg/1 average) 
than the equivalent stearate form (2.5 mg/1). The maximum in­
dividual serum concentrations for the 250, 500 and 100 mg coated 
base doses were 1.9, 3.8 and 6.5 mg/1 respectively, and for the 
500 mg stearate equivalent, 2.9 mg/1. Absorption was erratic as 
indicated by late or bi-phasic serum peaks after oral intake
Erythromycin has a broad spectrum of activity against both Gram­
positive and Gram-negative bacteria and is often used as an al­
ternative to penicillin - to which it has a similar spectrum 
(Molinari, 1983), but is regarded as having fewer primary 
therapeutic indications (Steigbigel, 1985)
Erythromycin is highly active against viridans streptococci. When 
tested against unspeciated groups of viridans bacteria, Jones 
(1985) determined an MIC range of 0.1-0.8 mg/1 erythromycin for 
these bacteria
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A dose administered orally one hour prior to dental extraction 
reduced the incidence of post-operative streptococcal bacteraemia 
markedly. In a study by Shanson et al in 1985, viridans strep­
tococci were isolated from blood cultures in only 15% of patients 
(6 of 40) given 1.5 g oral erythromycin pre-operatively compared 
to three times that number (43%) of patient controls (18/42) who 
had not received pre-operative erythromycin. Species isolated 
from the six members of the group given erythromycin consisted of 
three isolates each of S. sanguis and S. mitis. Minimum in­
hibitory (and minimum bactericidal) concentrations were 0.03, 
0.03 and 0.01 (0.06, 0.12, 0.12) for the former and 0.06, 0.01 
and 0.01 (0.12, 0.06, 0.06) for the latter strain, respectively. 
Similar MICs were obtained for species isolated from patients who 
had not received prophylaxis (range 0.01-0.06 mg/1, mean 0.02 
mg/1). Their MBCs reached higher concentrations (0.06-1.0 mg/1, 
mean 0.19 mg/1). Shanson's team also found that amongst patients 
who had received erythromycin, those who were culture-negative 
had higher serum erythromycin levels (3.7 mg/1 erythromycin) than 
the small number (6) from whom blood-borne viridans streptococci 
were cultured (1.8 mg/1). Harrison, Stross et al (1985) measured 
serum concentrations which ranged from undetectable levels to 8.3 
mg/1 erythromycin 2 -3 hours after oral administration of a 
smaller 1 g dose
5.3.2.2 Erythromycin resistance
Resistant strains possessing biochemically altered erythromycin 
binding sites on ribosomal 50S sub-units (O'Brien et al, 1987) 
are selected after prolonged erythromycin exposure. Molinari 
(1983) stated that resistance to this antibiotic (as well as to 
clindamycin and chloramphenicol) develops as a result of bacteria 
becoming impermeable to the drug
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Researchers appear not to agree on the effect which prolonged 
erythromycin exposure to this antibiotic had on bacterial flora. 
Some detected only minor changes to resistance patterns while 
others found these to be marked and/or prolonged. Heimdahl and 
Nord (1982) studied what effect erythromycin exposure may exert 
on the resident oral, throat and faecal flora. They were able to 
detect what they termed "minor" changes after the ingestion of 
500 mg erythromycin (in stearate form) twice daily for 7-days. 
Ten volunteers, none of whom had received any antibacterial agent 
for 6 months prior to the start of the study, had saliva, throat 
and faecal specimens cultured for aerobic and anaerobic bacteria 
for 16 days after the first dose. Antibiotic levels were also 
determined in these specimens. Serum concentrations determined in 
finger-prick blood taken 1.5 hours after the first daily 500 mg 
erythromycin dose ranged from approximately 1.5-3.25 mg/1 over 
the test period. The authors were unable to detect erythromycin 
in certain blood specimens of two patients. Salivary levels 
ranged from 0-1.8 mg/1 and 4 of 10 volunteers showed pronounced 
drop in S. salivarius numbers. Changes in populations of other 
species was also noted (3 of 10 showed a drop in staphylococci). 
They saw that aerobe numbers in the saliva and throat appeared to 
be less affected, and were minor, although there was an increase 
in colonisation by enterobacteria and enterococci with MICs to 
erythromycin of >16 mg/1. Changes which occurred in the composi­
tion of bacterial populations after the long-term use of this 
macrolide were significant enough to affect aerobic and anaerobic 
faecal flora
Also in 1982, Josefsson and Nord detected a significant decrease 
in numbers of certain oral streptococci after erythromycin. They 
used an initial loading dose in eight volunteers of 500 mg eryth­
romycin (base) followed 2 hours later with a further 500 mg plus 
500 mg every 8 hours up to a total of 6 doses. A significant
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decrease in S. salivarius numbers (like Heimdahl and Nord 1982) 
and micrococci was detected although these authors also con­
sidered it to be "minor" (sensitivity changes which developed did 
so, they postulated, as a result of the appearance of eryth­
romycin in the saliva). They found neither an increase in resis­
tance to erythromycin (or to penicillin V) amongst the bacteria 
tested nor colonisation of oral areas by enterobacteria or en­
terococci
In 1983, Southall et al planned an experiment to detect and iden­
tify amoxycillin-resistant oral streptococci, if any, after a 
repeated two-dose regimen of this antibiotic and to test the 
resultant (resistant) isolates against erythromycin and two other 
antibiotics (clindamycin and vancomycin). They administered 3 g 
amoxycillin by mouth plus another 3 g eight hours thereafter to 
12 healthy volunteers (9 of whom were finally to complete the 
study) once weekly until oral streptococci resistant to 0.5 or 
1.0 mg/1 amoxycillin appeared. Oral secretions were sampled on 
the day following the intake of the antibiotic. All subjects were 
screened prior to the study and found to be free of resistant or­
ganisms but all carried strains after the fifth weekly "double 
dose". One subject developed resistant viridans after the first 
weekly doses and another after the second week. Subjects showed a 
marked decrease in numbers of sensitive species within 24-hours 
of the first doses and numbers of resistant organisms returned to 
undetectable levels within 13 weeks after the last dose in all 9 
volunteers. Seventeen resistant isolates were identified as S . 
sanguis (non-dextran-producing) by two methods of identification. 
The cultures showed an MIC range of 1.0-16.0 mg/1 amoxycillin and 
MBCs of 2.0-16.0 mg/l. However, when tested against erythromycin, 
3 of 11 volunteers carried amoxycillin-resistant strains sensi­
tive to this antibiotic (MIC £0.25 mg/1) and the other 8 had MICs 
which were resistant or moderately resistant to it (1-2 mg/1 
erythromycin). By disc testing, the 17 S. sanguis strains were
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sensitive to clindamycin and vancomycin
Other authors reported that long-term exposure of oral strep­
tococci to erythromycin induces noticeable bacterial resistance. 
Harrison, Stross, et al (1985) found that the repeated ad­
ministration to volunteers of erythromycin stearate selected for 
erythromycin resistance amongst oral streptococci after the 
second of 2 identical regimens after a 7-day interval. Each con­
sisted of 1 g erythromycin per os initially plus 500 mg 6 and 12 
hours thereafter. Whether the antibiotic was in a capsular form 
or not was not specified. Prior to the study, none of the 10 
volunteers carried streptococci with erythromycin MICs >_0.25 
mg/1. After the first three-dose regimen, the total number of 
plaque streptococci dropped off in all participants but had 
returned to normal levels after the second course of antibiotics 
when erythromycin resistance was detected. On withdrawal of the 
antibiotic, although erythromycin resistance showed a general 
decline, eight volunteers still harboured these strains after 23 
weeks and in at least 4 of them at 43 weeks. Two species (S . san­
guis and S. mitior) isolated from four volunteers were highly 
resistant to erythromycin having MICs from 16->256 and MBCs be­
tween 128->256 mg/1. The rest (six) yielded strains with MICs of 
between 1-4 mg/1 but of these isolates, a., number had MBCs >256 
mg/1 - so-called "tolerant" strains. More than one species was 
isolated from some participants and, in total, 9 highly resistant 
cultures were identified; five S. mitior and four S. sanguis 
species. Seven showed MICs >256 mg/1 and all had MBCs of this 
magnitude. Different isolates of these two species were found to 
show moderate resistance to erythromycin. All nine highly resis­
tant isolates were very sensitive to vancomycin and benzyl- 
penicillin. Harrison found no correlation between concentrations 
of erythromycin in saliva and the occurrence of highly resistant 
viridans streptococci, unlike Josefsson and Nord (1982)
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Multiple doses of erythromycin were also found by others to in­
duce resistance to this antibiotic. Herbert et al, (1988) 
screened plaque specimens isolated from the two volunteers in his 
study which, where possible, followed closely that of Harrison, 
Stross et al (1985). He used the erythromycin regimen proposed by 
the BSAC (1982) where erythromycin 1.5 g was administered to 
volunteers and followed by 500 mg 6 hours later. Herbert ad­
ministered the antibiotic regimen three times with 7-day inter­
vals and found after the second two-dose set that both subjects 
carried a significant proportion of the total streptococcal count 
resistant to erythromycin. After the third 1.5 g dose, eryth­
romycin resistance was found to consitute between 30-100% of all 
isolates. Minimum inhibitory concentrations of resistant isolates 
were, however, less than 8 mg/1 erythromycin while MBCs were ^32 
mg/1 in the very small two subject sample. From volunteer 2, Her­
bert et al identified 18 of 22 resistant isolates as S. mitior, 
three as S. sanguis and the remaining strain as a S. salivarius 
specimen. Volunteer 1 produced mostly S. mitior isolates with 
fewer S. sanguis and others also being cultured. A significant 
proportion of resistant streptococci appeared 3 hours after the 
second administration in both volunteers and maintained this high 
level until the third. Persistence of resistance was not measured
In a 7-day study, Heimdahl et al (1984) showed that, unlike 
penicillin V and doxycycline, erythromycin and clindamycin each 
suppressed S. salivarius numbers in the oral cavity to a degree 
that its continued use could result, the authors claimed, in an 
overgrowth of other oral bacteria such as Group A streptococci. 
This situation could, they speculated, compromise yet further the 
health of any patients already medically compromised when the 
normal inhibitory effect of bacteriocins produced by commensial 
S. salivarius populations against other (potentially harmful) 
oral bacteria was either reduced or absent. Contrary to the study 
of Heimdahl et al, Herbert et al, (1988) found an isolate of S.
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salivarius which was resistant to erythromycin. In 1982, Josefs- 
son and Nord identified the suppression of S. salivarius numbers 
by both erythromycin and penicillin V
Maskell et al (1990) conducted an investigation to determine mac- 
rolide resistance amongst salivary viridans streptococci in 
volunteers after and/or before the oral intake of two different 
macrolides. Either erythromycin (1.5 g stat plus a single 500 mg 
dose 6 hours thereafter) or another macrolide (josamycin) was ad­
ministered. Maskell et al showed substantially more resistant 
streptococci in the volunteers after macrolide therapy than 
before the time, when a small proportion was identified. Volun­
teers who took part in the experiment were 45 hospital staff mem­
bers who only supplied saliva specimens, and 2 groups of 8 dental 
students who each supplied both pre- and post-antibiotic 
specimens of saliva. Of 45 staff members, 44 (97.8%), 44 (97.8%), 
38 (84.4%) and 38 (84.4%) harboured streptococci with MICs of 
0.25 (an MIC indicating sensitivity), while resistant strains had 
MICs of 1, 4 and 64 mg/1 erythromycin respectively. Before taking 
the antibiotic, streptococci resistant to 1 mg/1 erythromycin 
were cultured from all 16 students (and 15 to 1 mg/1 josamycin). 
All were resistant to erythromycin at a concentration of 1 mg/1; 
87% (14 of 16 volunteers) to 4 mg/1; and 50 (8 of 16) to 64 mg/1. 
Additionally, the authors found that 13 of the 16 students (81%) 
harboured streptococci that were also resistant to 1 mg/1 
amoxycillin. After administration of erythromycin, 23%, 17% and 
6% of the total oral streptococci were found to be resistant 48 
hours after the 1.5 g dose to 1, 4 and 64 mg/1 of the antibiotic, 
respectively. Five days later only 7% of isolates showed low- 
level resistance (1 mg/1) and 0.5-1.5% were moderately (2.4 mg/1) 
to highly resistant (>_8 mg/1). One month thereafter erythromycin 
resistance amongst the bacteria declined to 2% and even lower 
after three months. Average erythromycin concentrations in saliva 
were 3.88 and 1.1 mg/1 at 90 minutes and 6-hours respectively
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However, in terms of volunteer numbers, highly resistant viridans 
streptococci (j^ 64 mg/1) were isolated from 7 of the 8 students 
who took erythromycin. Three individuals carried the organisms 
prior to dosing and these were still present in the mouth after 
90 days in at least two of the students (a third was not re­
tested). Three streptococcal species, S. sanguis, S. mitis and S . 
salivarius, were isolated from the three prior to dosing and S . 
sanguis (2 isolates) and S. mitis (4) were found in 7 students 
thereafter. In total, 17 highly resistant strains were identified 
in this study: S. mitis (9), S . sanguis (7) and S. salivarius 
(1). All isolates were sensitive to amoxycillin at MICs which 
varied from between 0.015-0.12 mg/1 but the majority were resis­
tant to 256 mg/1 of roxithromycin, clindamycin (and azith­
romycin, clarithromycin) but susceptible to pristinamycin (0.25 
mg/1)
A degree of bias was evident in the trial as volunteers who made 
up both experimental groups were not randomly selected from an 
"unaffected" population. Volunteers commenced the study with 
erythromycin-resistant viridans streptococci already present in 
their mouths and this could possibly have skewed results and con­
clusions. To clarify the situation, the authors state that as 
none of the participants had taken antibiotics in the three 
months prior to the study, the resistant strains appeared to have 
originated from the hospital environment or from foodstuffs. 
However, in its favour, this form of exposure to resistant 
strains may simulate in some measure, the selection which occurs 
amongst those taking daily penicillin V prophylaxis
Leviner et al (1984) identified hospital-borne antibiotic- 
resistant viridans isolates in hospital staff volunteers in a 
similar study
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Harrison, Stross et al (1985) supported the findings of Maskell 
et al (1990) on the general behaviour of oral streptococci with 
regard to erythromycin resistance. Both research teams found that 
resistant organisms persisted for long periods after exposure to 
erythromycin: 43 weeks in Harrison's and at least three months in 
Maskell1s study (and resistance to >64 mg/1 erythromycin was 
still identifiable in 4 of 6 volunteers). However, the latter 
authors did not speculate on whether any of the resistant iso­
lates identified in the staff and student groups during the 
screening period, subsequent to completion of the antibiotic 
course, had had a possible direct environmental origin or not
Furthermore, Maskel et al did not appear to recognise that saliva 
carries organisms flushed from populations of bacteria attached 
to the various exposed oral (especially the tongue; Hardie, 
1983) and dental structures. Bacteria which find their way into 
the blood-stream after trauma to bone and soft tissue of the jaws 
tend to be those attached, characteristically, to specific oral 
structures (Chow et al, 1978). When these structures are located 
directly within a surgical field, for example, bacteraemia arises 
from recognised populations of organisms specific to those areas 
and not necessarily from those suspended in saliva which, 
naturally, is sterile prior to its emptying into the mouth
In 1978, Hunt et al attempted culture of 74 clinical exudate 
specimens from soft tissue oral infections and 68 yielded bac­
teria for antibiotic susceptibility testing (six specimens failed 
to yield growth on culture). Of interest was the finding that 
streptococci were found in pure culture in 57% of cases in this 
study. A total of 31 viridans isolates were cultured and 20 were 
in pure culture. It is conceivable that surgery of the infected 
sites could have produced a viridans bacteraemia. Only 5 tested 
sensitive to erythromycin and 26 were resistant (no MICs were 
supplied). However, all 31 isolates were sensitive to ampicillin
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and 26 to penicillin V. Isolates were not identified to species 
level beyond the general viridans grouping. Important selection 
forces were absent in this investigation as none of the patients 
received prolonged antibiotic therapy that may have lead to the 
development and retention of antibiotic-resistant viridans 
strains
The serious conseguences of erythromycin resistance amongst oral 
streptococci was demonstrated by Eng et al (1982) in a patient 
after maxillo-facial surgery. IE developed in a penicillin- 
allergic, 44 year-old man after undergoing maxillary sinus sur­
gery in spite of his having received 4 g intravenous erythromycin 
lactobionate pre-operatively. After completion of the surgical 
procedure, he received oral preparations of erythromycin stearate 
(2 g) daily for 4 days and again for 3 days after day 10 when he 
complained of feeling unwell. Seven weeks after surgery he was 
diagnosed as having IE. All blood cultures were positive and 
yielded S. sanguis biotype I. MICs and MBCs were determined for 
penicillin (MIC:0.007; MBC:0.007 mg/1, respectively), vancomycin 
(0.5; 2.0 mg/1) and erythromycin (40; >_320 mg/1). The patient 
recovered uneventfully on vancomycin therapy
The inappropriateness of erythromycin use as IE treatment was il­
lustrated in an experimental rabbit model in 1975. Pelletier et 
al found that erythromycin at 15 mg/kg, in multiple doses, failed 
to protect heart catheter-damaged animals with IE against the 
causative organism, an erythromycin-sensitive S. sanguis II (MIC 
0.08 mg/1, MBC 0.15 mg/1 erythromycin). An S . sanguis II inoculum 
of 100 million cfu's was utilised to infect the animals and its 
large size may have rendered the treatment ineffective
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5 . 3 . 3 Roxithromycin
Roxithromycin is chemically related to erythromycin and has im­
proved pharmakinetic activity (Nilsen, 1987) in addition to use­
ful properties common to other macrolide-type antibiotics. These 
include lipid solubility, low degree of ionisation and wide 
tissue and body fluid distribution
Roxithromycin is well tolerated by patients after oral intake 
(Smith et al, 1989) and displays an excellent safety profile in 
both adults and children where a small number of between 3.1 and 
4.1% of approximately 3000 patients taking 150 mg roxithromycin 
twice daily experienced side-effects of nausea, gastro-intestinal 
pain or diarrhoea in equal proportions (Blanc et al, 1987; Neu,
1988). In another study on 211 subjects (Sasaki, 1987), 2.4% (5) 
had gastro-intestinal upsets and minor changes in liver function 
tests in 3 of 92 subjects (3.3%). Neu (1988) noted that there was 
no significant haematological or renal toxicity and less than 1% 
of patients had changes in liver function tests in his overview
5.3.3.1 Improved pharmacokinetic activity
5.3.3.1.1 Serum levels, half-life and saliva concentration
Roxithromycin has been shown to produce markedly higher serum 
concentrations than erythromycin at similar or higher oral doses. 
Dose-related serum concentrations were detected after ingestion 
of single 150 and 300 mg dose sizes. After the smaller dose, 
plasma concentrations were in the range of 6.61-7.9 mg/1 and for 
the larger 300 mg roxithromycin, 9.1-10.82 mg/1 (Nilsen, 1987; 
Puri and Lassman, 1987; Kees et al, 1988; Tremblay et al, 1988)
Six male subjects produced a mean peak serum level of 3.0 mg/1
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(range: 0.3-7.3 mg/l) one hour after receiving 300mg roxith­
romycin on three occasions after 7-day intervals in a trial con­
ducted by Smith et al (1989). Saliva and gingival fluid were 
found to be free of roxithromycin at concentrations ^0.2 mg/l
In the clinical trial of Kess et al (1988), roxithromycin 150 mg 
was found to have an elimination half-life of approximately 15.5 
hours, a time which was 9-times longer than that of 500 mg eryth­
romycin (1.7 hours). Investigators reported the half-life to 
range from between 10 to 16 hours with an average in the region 
of 12 hours (Neu, 1988). The half-life was not prolonged when the 
single-dose size was increased from 150mg to 300mg or 450mg 
(Tremblay et al, 1988). The values in the trial of Tremblay et al 
(1987), using the three dose sizes, ranged from 10.5 hours for 
150mg of roxithromycin to 11.91 and 13.84 hours for the higher 
300 and 450 mg doses respectively. Puri and Lassman (1987) deter­
mined the half-life for this antibiotic and their data did not 
differ substantially from those of either Kess et al (1988) or 
Tremblay et al (1988). The half-life values of Puri and Lassman 
were 10.5 and 10.3 hours for the 300 and 450 mg doses but 8.4 
hours for 150 mg - an half-life marginally less than the other 
authors using the same dose. The roxithromycin half-life for the 
150 mg and 300 mg doses for all the above authors, therefore, 
ranged from 8.4 to 15.5 hours. Nilsen (1987), too, reported the 
mean half-life for roxithromycin at different doses to be between 
8 and 14 hours and for erythromycin to be substantially shorter, 
ranging from 1.5 to 3 hours
In saliva, roxithromycin levels after a 300 mg loading dose fol­
lowed by six 150 mg doses at 12-hourly intervals were either un­
detected (Puri and Lassman, 1987) or showed very low concentra­
tions of <0.05 mg/l saliva (Acar et al, 1988)
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5 .3 .3 .1 .2 Macrophage activity
Polymorphonuclear neutrophils and other phagocytic cells form an 
important part of the body's immunological defence system against 
invading pathogens (Sohnle et al, 1991) and these antibiotic com­
pounds are actively concentrated in the cells. Roxithromycin was 
found to accumulate in polymorphonuclear neutrophils to levels 
which were 14-times the extracellular concentration 
(erythromycin, 8-times) and in alveolar macrophages from smokers 
to 190-times the concentration (non-smoker macrophages, 61- 
times). For erythromycin, levels in smoker and non-smoker macro­
phages were 46- and 38-times the extracellular concentration 
respectively (earlier et al, 1987)
Anderson et al (1987) investigated further the intracellular ac­
tivity of roxithromycin and erythromycin. His results showed that 
neutrophils concentrated both antibacterial agents (roxithromycin 
30- and erythromycin 10-fold) but, additionally, that intracel­
lular activity of the compounds was dependent upon normal, intact 
oxygen-dependent intrinsic phagocytic cellular antimicrobial sys­
tems
By employing human phagocytes in vitro, Yokota and Bhattacharyya 
(1988) were able to show that cells incubated with roxithromycin 
ingested more bacteria per cell (in this instance S. aureus in 
numbers larger than 30 bacteria per cell) than in the presence of 
either erythromycin or josamycin. Roxithromycin was bactericidal 
with lower MICs and lysozymal concentrations than either of the 
other two antibiotics. This phenomenon was noted by the authors 
to indicate synergy between this antibiotic and lysozyme ac­
tivity. The serum bactericidal activity of this antibiotic in 
whole blood was found to be no different to that of erythromycin
White blood cells were used in a similar investigation. In a
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preliminary in vitro study, Prieto-Prieto et al (1988) compared 
the effects which roxithromycin and three other macrolide an­
tibacterial agents exerted on certain polymorphonuclear 
neutrophil (PMN) functions at concentrations of 0.5, 5.0, and 50 
mg/1 antibiotic. PMN adhesion, spontaneous cell mobility, 
chemotaxis and phagocytosis were observed. Although the results 
were very similar, roxithromycin enhanced polymorphonuclear ad­
herence and chemotactic activity to a slightly greater degree 
than the others. No agent appeared to affect the phagocytic func­
tion of the white blood cells in this study. Spontaneous PMN 
mobility, however, was reduced by all compounds
5.3.3.2 Spectrum of activity
Roxithromycin, like erythromycin and other macrolides, produces 
its antibacterial effect by the intracellular inhibition of 
protein synthesis
The in vitro antibacterial spectrum of roxithromycin is similar 
to that of erythromycin (Barlem and Neu, 1984; Young et al,
1989). Streptococcal strains involved in endocarditis such as S . 
mutans, S. sanguis, S. mitior and other viridans streptococci, 
are inhibited by <_1 mg/1 roxithromycin (Neu, 1988)
Barlam and Neu (1984) compared the activity of roxithromycin (RU 
28965) with that of erythromycin. Several different aerobic and 
anaerobic species were tested. Thirteen unspeciated viridans 
streptococci were equally sensitive with identical ranges (<0.1- 
>100 mg/1) and MIC 50 and MIC 90 values (both 0.8 mg/1). Against 
four S . mutans, roxithromycin was markedly more effective with 
the range of the former £0.1-0.4 while the latter was £0.1->200; 
MIC 50s were identical at 0.1 mg/1 but MIC 90s were 0.4 and >200 
mg/1 antibiotic, respectively. Against eight S. mitis strains,
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MIC 50 (0.1) and MIC 90 values (0.4 mg/1) were identical but only 
the MIC upper range limits differed marginally: roxithromycin 
range was _£0.1->200 mg/1 and erythromycin's, _£0.1->300 mg/1
This antibiotic was tested by Sasaki (1987) against bacteria iso­
lated from oro-facial infections (pericoronal and periodontal in­
fections and osteitis). Of 144 mixed aerobic (60) and anaerobic 
(84) clinical isolates from 73 of 193 patients, 85.4% were sensi­
tive to roxithromycin (MIC _^3.1 3 mg/1). A 1 44 isolate total in­
cluded 36 unidentified alpha-haemolytic streptococci where 12 
isolates were inhibited by 0.20 mg/1, 9 by 0.39 mg/1 and 1 by 
0.78 mg/1 of this antibiotic. However, 14 were not inhibited by 
concentrations >100 mg/1 roxithromycin. The latter highly resis­
tant viridans isolates comprised 66.6% (14 of 21) of all clinical 
strains recovered from patients in the trial
5.3.3.2.1 Effect of roxithromycin on normal flora
The consumption over 10 days of either roxithromycin or eryth­
romycin in drinking water produced only minor changes in the fae­
cal flora of experimental animals (mice) in the trial of Koopman 
et al (1988). The authors postulated that gut flora would remain 
generally unaffected after single doses or very short prophylaxis 
regimens
In human trials, no effect on the colonisation resistance of the 
oropharynx to bacteria resident in the area could be demonstrated 
after oral roxithromycin (or erythromycin) during a shorter 7-day 
trial (Vollaard et al (1987). Gut flora was also examined and, 
contrary to Koopman's et al (1988) work on mice, the authors 
noted a detectable effect on the composition of normal bowel 
flora. Secondary colonisation of the bowel by Enterobacteriaceae 
after both macrolides and amoxycillin occurred. However, roxith­
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romycin and erythromycin, unlike amoxycillin, did not appear to 
affect gut counts of enterobacteria unduly - numbers were not 
raised to levels which were higher than the original pre-dose 
counts. With less disturbance of normal flora, roxithromycin may 
produce fewer microbe-related gastro-intestinal side-effects than 
amoxycillin
5.3.3.3 Resistance to roxithromycin
Following the administration of roxithromycin to two volunteers, 
Smith et al (1989) observed an increase in resistance to roxith­
romycin amongst streptococci isolated from smooth surface dental 
plague. Three resistant (but unidentified) isolates from the 2 
volunteers were detected prior to its start: two from one volun­
teer which were resistant to 2 and 8 mg/1, respectively, and a 
third resistant to 2 mg/1 roxithromycin from the other. After 
completion of the study - after the third weekly single 300 mg 
oral stat dose - all isolates had become resistant to roxith­
romycin at the same two concentrations. Five of 7 distinguishable 
strains, identified as four S. mitior and a single S. sanguis 
strain, were resistant to >64 mg/1 roxithrmycin, erythromycin and 
clindamycin but susceptible to penicillin G. From the results of 
this study, prolonged administration of roxithromycin to patients 
would appear to induce the development of resistance to macro- 
lides and the prophylactic use of erythromycin or clindamycin in 
IE-susceptible patients shortly after roxithromycin therapy would 
appear to be unwise. Roxithromycin in concentrations greater than 
0.2 mg/1 was not detected in the saliva or gingival fluid
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5.3.4 Clindamycin
5.3.4.1 General properties
Clindamycin is a chlorine derivative of lincomycin isolated from 
Streptomyces lincolnensis and belongs to the lincosamide class of 
antibiotics. They have a completely different chemical composi­
tion compared to macrolides but its mode of action and spectrum 
is very similar to that of the macrolides
The drug is well absorbed from the GIT where food has little ef­
fect on absorption and penetrates most body tissues (Wilson and 
Cockerill, 1983). It attains levels in bone which are very 
favourable when compared to those in serum: expressed as ratio of 
bone/serum concentration (serum concentrations in brackets), it 
produced values in rats of 1.11 (5.8); 0.83 (4.8); 0.90 (2.5);
0.78 (2.3) and 1.30 (1.3) respectively when measured at 30
minutes and 1,2, 3 and 4 hours after administration of 15 mg/kg
IV clindamycin (Summersgill at al, 1982)
5.3.4.2 Mode of action
The lincosamides and macrolides, two otherwise unrelated groups 
of antibiotics, exert their anti-bacterial effect by the
biochemical modification of the 50s subunit in bacterial 
ribosomes (O'Brien et al, 1987). Clindamycin and macrolide an­
tibiotics show cross-resistance amongst viridans streptococci. 
Sprunt (1970) reported erythromycin-resistance amongst viridans 
streptococci resistant to lincomycin. Similar cross-resistance 
between clindamycin and erythromycin is found in pneumococci and 
staphylococci (Barber and Waterworth, 1964)
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5.3.4.3 Effect of clindamycin on normal flora and 
pharmacokinetics
During an investigation into the effects of penicillin V on nor­
mal resident viridans streptococci, Heimdahl and Nord (1979) also 
ran a test on the effects which clindamycin might have on the 
flora in saliva, the throat and faeces of 10 other subjects. One 
hundred and fifty milligrammes of clindamycin was taken six- 
hourly in capsule form by mouth. Serum and salivary concentra­
tions varied and showed values of 1.8-2.3 mg/1 in the former and 
0-1.7mg/l clindamycin in the latter during the administration 
period. Like penicillin V, only a slight change in salivary 
streptococcal numbers was observed. However, a great reduction in 
anaerobe numbers was detected in the mouth, throat and gut. 
Clindamycin-resistant flora spread into and proliferated in these 
areas after sensitive populations of bacteria were eliminated 
after the multiple-dose, week-long antibiotic regimen. The use of 
clindamycin, as is the case with several other antibiotics has 
been linked to antibiotic-associated colitis caused by 
Clostridium difficile (George et al, 1980)
5.4 Vancomycin
5.4.1 General properties
Vancomycin, identified originally in Amycolatopsis orientalis 
(previously Streptomyces orientalis) (Nagarajan, 1991), contains 
a central hepta-peptide core common to all members of the 
glycopeptide group of antibacterial agents. It is poorly absorbed 
from the intestinal tract. The antibiotic inhibits the cell-wall 
peptidoglycan synthesis process in sensitive organisms and its 
action is largely bactericidal (Hermans and Wilhelm, 1987). In 
addition to inhibition of peptidoglycan polymerase by steric
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hindrance, binding of glycopeptides to the D-alanine terminus of 
the subunit effectively blocks the vital transpeptidation reac­
tion that links the growing peptidoglycan chain to the mature 
cell wall (Reynolds, 1989). Vancomycin may also alter the per­
meability of the cell membrane and selective inhibition of RNA 
synthesis is possible (Watanakunakorn, 1984). The antimicrobial 
spectrum is narrow and is used traditionally to treat serious in­
fections caused by Gram-positive organisms (S . aureus and others) 
resistant to alternative therapeutic compounds. This agent is in­
dicated only when penicillins and other more conventional com­
pounds cannot be used (penicillin allergies) (Molinari, 1983)
5.4.2 Spectrum and resistance
Leuconostoc species are intrinsically resistant (Dutka-Malen et 
al (1990) and Gram-negative bacteria are resistant to vancomycin 
(Nagarajan, 1991; Hermans and Wilhelm, 1987). Almost all Gram­
positive bacteria are susceptible to this antibiotic (Dutka-Malen 
et al, 1990; Watanakunakorn, 1984). Southall et al (1983) found 
all 17 S. sanguis strains with varying degrees of penicillin- 
resistance in their study, to be sensitive to vancomycin. Shanson 
et al (1987) found oral streptococci, isolated after extraction 
from patients who received prophylactic pre-extraction doses of 
different antibiotics, to be sensitive to this antibiotic at MIC 
ranges of between 1-2 mg/1 (mean 1.2 mg/1 vancomycin)
The vast majority of viridans streptococci are susceptible. 
Bayer et al, 1990 considered viridans streptococci to be 
"universally" susceptible, but already in 1984 Watanakunakorn 
listed resistant strains which had been reported in the litera­
ture
Vancomycin is used as a reserve antibiotic for IE-prophylaxis in
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high-risk patients (Hermans and Wilhelm, 1987). It was wholly ef­
fective as treatment of an IE patient who carried an 
erythromycin-resistant strain of S. sanguis biotype I with MIC 
and MBC values of 40 and 2.320mg/l, respectively (Eng et al, 
1982). Vancomycin MIC and MBC values for the isolate were 0.5 and 
2.0 mg/1, respectively
High resistance to vancomycin by a viridans strain was reported 
by Shlaes et al (1984) after complications arose in a patient 
after resection of a malignant tumour of the mandible. S, sanguis 
II was isolated with a MIC and MBCs >128 mg/1 vancomycin. Addi­
tionally, it was found to be tolerant to penicillin (MIC=0.5; MBC 
>16 mg/1) and to cephalothin (MIC=2; MBC >16) and cefoxitin 
(MIC=256; MBC >256), and a third generation cephalosporin, 
cefotaxime (MIC=2; MBC >64)
Tolerance of bacteria to vancomycin is known to occur (Shanson 
and Tadayon, 1986), and is common amongst enterococci
Tuomanen (1986) found vancomycin (and other compounds such as 
imipenem) to be effective in killing non-growing, amino acid 
deprived E. coli and S . pneumoniae bacteria
5.4.3 Side-effects
Systemic toxic reactions, like the so-called "red neck" or "red 
man" syndrome, have been described in patients receiving van­
comycin who exhibit pruritis, a maculopapular rash of the face, 
neck and upper torso and possibly also hypotension. This reaction 
has been ascribed to a massive release of histamine and mast cell 
degranulation after the rapid intravenous infusion of vancomycin 
(Hermans and Wilhelm, 1987). It has, however, been noted that 
this syndrome may also develop rarely after a slow infusion
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(Bayer et al, 1990). Harmful side-effects include thromboph­
lebitis, oto- and nephrotoxicity and allergenic reactions 
(Molinari, 1984) 226]. Ototoxicity may develop when serum levels 
exceed 30 mg/1 vancomycin (Hermans and Wilhelm, 1987)
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Chapter 6
TOLERANCE TO B-LACTAM ANTIBIOTICS
6.1 Description of the phenomenon
Certain bacteria are known to exhibit unusual growth behaviour in 
the presence of particular antibiotic agents
6.1.1 Genetically determined (genotypic) tolerance
Shockman et al (1979) and Tomasz (1979) noticed in their studies 
that some strains of susceptible organisms appeared only to un­
dergo growth inhibition rather than succoumb to the normally bac­
tericidal action of penicillins when exposed to these agents. 
This unusual reaction was observed when penicillin G and other 
beta-lactams inhibited synthesis of the bacterial cell wall and 
did not to lead, eventually, to cell rupture and death. These B- 
lactams normally disrupt critical stages in the biosynthesis or 
assembly of the bacterial cell wall which results in lysis and 
death of the cells (Tomasz et al, 1970)
Strains which survived in the presence of antibiotics tradi­
tionally active against the cell-wall biosynthesis, were sub­
sequently shown to be deficient in certain essential, naturally- 
occurring enzymes necessary for penicillin and other beta-lactams 
to exert a lytic effect on micro-organisms. These mediators of 
lysis-associated bacterial killing, present after exposure of the 
organisms to beta-lactam agents, were discovered to be endogenous 
peptidoglycan hydrolases or autolysins (Handwerger and Tomasz,
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1985)
The function of autolysins in the bacterial cell is to produce 
enzymatic breaks in the mesh-work of cell-wall polymers to permit 
the insertion, in specific areas, of newly synthesised wall 
material required during cell growth. Thus, any process which 
only inhibits the production of new cell wall material without 
also inhibiting the action of cellular autolysins, would lead to 
disintergration of the cell wall (Tomasz et al, 1970)
Toumanen, Durack and Tomasz (1986) note that antibiotic tolerance 
differs fundamentally from all other resistance mechanisms in 
that a change in the drug MIC is not involved - bacteria evade 
only the killing action of the antibiotic (as reflected by the 
MBC values)
The phenomenon where bacterial growth only was inhibited at low 
concentrations and the cells not lysed or killed by the normally 
bactericidal beta-lactam antibiotics at higher concentrations of 
the antibiotic (a bacteriostatic effect), became known as an­
tibiotic "tolerance" - a term originally proposed by Tomasz et al 
in 1970
Certain bacterial substances appear able to reduce the antibac­
terial effect of antibiotics. Raynor et al (1979) suggested that 
tolerance could result from the enhanced secretion by certain or­
ganisms (S . aureus in his study) of an autolysin inhibitor such 
as lipoteichoic acid (LTA). Shockman et al (1979) supported this 
finding when they found that in the presence of LTA, normally 
lethal concentrations of penicillin G produced only sub-lethal 
effects in a wide variety of Gram-positive bacteria able to gen­
erate and release this substance
Subsequently, four mechanisms of improved survival amongst clini-
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cal isolates have been described and collectively referred to as 
"survivor mutations" by Toumanen et al (1986). These authors 
noted that all isolates exhibited susceptible levels of drug sus­
ceptibility in terms of MICs but possessed some secondary 
mechanisms which involved changes in cidal and lytic effects. All 
four mechinisms contributed to what the authors termed "superior" 
survival during exposure to cell wall inhibitory antibiotics: (i) 
this is a strain-specific phenomenon (which also affects viridans 
streptococci) and appears independent of antibiotic concentration 
(Goessens et al, 1984). Survivors appear to die at a slower rate 
than other cells in the culture which have lower degrees of sur­
vival. This mechanism is found amongst so-called persister 
mutants and may be dependent upon the sensitivity to antibiotics 
of the organism during particular stages of the cell cycle (Moyed 
and Bertrand, 1983). (ii) The paradoxical effect is exhibited by 
several bacterial pathogens (including viridans stretococci) in 
which bactericidal activity fails to occur above certain con­
centrations of antibiotic (Handwerger and Tomasz, 1985). (iii) A 
third form is drug specific and resembles that which occurs 
amongst LYT(+) TOL(+) laboratory mutant pneumococci not deficient 
in autolytic activity (Williamson and Tomasz, 1980). (iv) The 
final mechanism described by Tuomanen et al (1989) is exhibited 
by several bacterial species which have autolytic defects similar 
to those of lysis-defective (tolerant) laboratory mutuants of 
pneumonococci
In studies by Voorn et al (1994), non-tolerant variants of S . 
aureus were induced by repeated subculture of a tolerant clinical 
isolate on an antibiotic-free medium. The parent strain exhibited 
a paradoxical response to cloxacillin both in vivo and in vitro. 
The authors showed that continuous administration of this an­
tibiotic in the treatment of endocarditis in rats caused by the 
tolerant strain failed to kill the organisms because of sustained 
high concentrations of cloxacillin in the blood. The same authors
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showed that after repeated cycles of exposure to 25 mg/1 
cloxacillin or 10 mg/1 vancomycin alternating with growth in 
antibiotic-free medium, they could induce tolerance in non- 
tolerant S . aureus strains. Conversely, tolerant strains lost 
their tolerance after repeated subculture in antibiotic-free 
medium at 37 degrees Celcius for 50 days (Voorn et al, 1994). In 
similar studies, Moore et al (1994) generated an isogenic pair of 
fi-lactam tolerant and non-tolerant strains of S . aureus by 
selecting tolerant variants from a non-tolerant strain. They sug­
gested that there may well be a relationship between tolerance 
and the paradoxical effect as both phenomena can be induced in 
the same strain (Voorn et al, 1994). Voorn et al (1994) specu­
lated on whether (uncommon) altered responses to the bactericidal 
activity of 8-lactam agents exhibited by strains may be elicited 
as a direct result of exposure to those agents; ie. sampled 
specimens already exposed to the agents during therapy of the in­
fection
6.1.2 Phenotypic tolerance
Tuomanen (1986) distinguished between genotypic tolerance to 
beta-lactam antibiotics - where a mutant, non-functional 
autolytic enzyme is produced by an organism - and the phenomenon 
which non-growing (and for that reason beta-lactam insensitive) 
bacteria exhibit in the presence of most of these antibiotics. 
She suggested that the latter be referred to as phenotypic 
tolerance. This term will be used in this dissertation to distin­
guish the phenotypically tolerant or refractory state exhibited 
when susceptible bacteria with low MICs and MBCs in vitro survive 
the bactericidal activity of antibiotics, from the traditional 
use of the term tolerance, based on the difference between MICs 
and MBCs of bacteria
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Evidence of phenotypic tolerance has been observed to occur both
in vitro and in vivo
6.1.2.1 Phenotypic tolerance in vitro
Chain suggested in 1945 that it was not bacterial cell division 
which was essential for effective killing by penicillin, but 
rather active bacterial metabolism. Jawetz et al in 1951 ex­
panded upon the studies of Chain and concluded that active syn­
thesis of specific proteins within the cell (and which can be in­
hibited by chloramphenicol) was critical for penicillin activity. 
Derangement of synthesis was noted to occur with the deprivation 
of a wide variety of essential nutritional requirements which in­
cluded usable carbon and nitrogen sources, vitamins and minerals. 
With the experimental removal of these substances from the bac­
terial environment, arrest of the logarithmetic increase in cell 
numbers occurred within minutes and there was a marked and coor­
dinated reduction in all macromolecule synthesis rates (Goodell 
and Tomasz, 1980). All changes which ensure the survival of an 
organism and which occur in situations of deprivation are said to 
be under the control of the rel A genetic locus - the so-called 
"stringent response" (Ramey and Ishiguro, 1978) - a mechanism not 
well understood (Tuomanen, 1986)
The use of the chemostat, however, has shown that there is a cor­
relation between killing and cell lysis amongst bacteria grown in 
the absence of essential nutrients and is a direct function of 
the generation time of the bacterium (Tuomanen et al, 1986)
Slow rates of growth or actual cessation of growth are com­
monplace at numerous sites of bacterial infection in vivo 
(Tuomanen, 1986)
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6 . 1 . 2 . 2 Phenotypic tolerance in vivo
6.1.2.2.1 Experimental in vivo phenotypic tolerance
Toumanen et al (1985) used a rabbit model of experimental 
pneumococcal meningitis to examine bacterial growth in the sub­
arachnoid space. Two important observations relevant to the 
tolerance phenomenon were made: (i) a long lag period was evident 
between inoculation of test organisms into the cerebrospinal 
fluid and the initiation of growth and (ii) maximal growth rate 
of bacteria in the space was significantly lower than levels 
achieved in vitro. Retarded growth characteristics in the space 
may be linked to lower concentrations of buffer (a third of op­
timum level) and concentrations _>100-fold deficient in leucine, 
isoleucine, cysteine, glycine, valine, serine and the minerals 
magnesium and manganese in cerebrospinal fluid (CSF) compared 
with a minimal chemically defined medium. This type of growth be­
haviour was also noted in vitro in bacteria in nutrient-deficient 
growth media
Phenotypic tolerance was further investigated by these authors in 
an ex vivo animal experiment using heat-treated serum or 
leukocyte-free CSF removed from healthy rabbits. Pneumococci in­
oculated into these fluids behaved in a manner observed in vivo - 
they displayed retarded and slower growth patterns similar to 
those strains inoculated into the subarachnoid space of rabbits 
discussed above
6. 1  . 2 . 2 . 2 In vivo phenotypic tolerance associated with 
bacteraemia
Hall et al (1993) unknowingly observed the phenomenon of
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phenotypic tolerance in humans in vivo. It was noted that 
viridans streptococci survived in the blood of individuals who, 
following dental extraction procedures and the administration of 
penicillin V or amoxycillin, survived killing despite the fact 
that isolates were subsequently shown to have MICs and MBCs well 
below the respective 6-lactam blood concentrations
As already noted, the precise nature of events which produces 
phenotypic tolerance to antimicrobial agents remains unclear but 
the response is observed to occur under a number of different 
conditions: (i) amongst bacteria which exhibit reduced growth 
rates in altered micro-environments (for example, where there is 
an increased concentration of various enzymes and metabolic 
products), (ii) after nutrient deprivation or depletion of es­
sential substances and substrates such as carbon and nitrogen 
sources, dissolved gases, vitamins and minerals (iron) or (iii) 
in bacteria buried in adherent microbial biofilms through which 
either nutrients and antibiotic compounds have difficulty in 
passing (Holmes and Evans, 1989; Cozens et al, 1986; Brown et al, 
1988). Bacteriological conditions similar to any one or more of 
the above exist within bacterial films coating urinary catheters 
(Nickel et al, 1985) and may exist within endocarditis vegeta­
tions, on vascular or similar prostheses and other devices, as 
well as in dental plaque
6.2 Tolerance amongst viridans streptococci
In this study the term "tolerance", when not specifically 
qualified, will refer to genotypic tolerance and the adjective 
"phenotypic" will precede this term when the phenomenon of 
phenotypic tolerance is referred to
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6 . 2 . 1 Tolerance to 6-lactam antibiotics
Species of viridans streptococci are reported to exhibit 
tolerance to penicillin G (Holloway et al, 1980; Dankert and 
Hess, 1982). S. sanguis was the first such oral streptococcus 
that was studied in detail by Horne and Tomasz in 1977. Penicil­
lin G halted bacterial growth of this strain at an extremely low 
MIC of 0.013 mg/1, and produced reversible, non-lethal mor­
phological changes at 10x MIC where 63% of cells survived. It 
also displayed tolerance to oxacillin, cephalexin and 
cephaloridine. Against the latter antibiotics the strain had a 
survival rate of 67%, 100% and 79%, respectively. The tolerant 
response of this strain to penicillin and other cell-wall in­
hibitors mimicked typical features of "autolysin-defective 
bacteria" (Horne and Tomasz, 1977)
Penicillin tolerance is not limited only to S. sanguis (19%), 
however, and was noted by Holloway et al, (1980) to occur in all 
viridans species tested except S. salivarius. The phenomenon was 
common in strains of S . mutans (27%), S. mitior (20%) and S . san­
guis (19%). Two hundred and fourteen gingival sulcus, dental and 
bacteraemic isolates were screened for penicillin sensitivity in 
their study and 151 (71%) had MICs <0.8 U/ml (equivalent to 0.48 
mg/1) penicillin. Eighty-three of 151 (55%) had MBCs lower than 
this value and 68 (45%) higher. Tolerance (MBC = >_1 Ox MIC) was 
noted in 29 (19%) of the 151 "sensitive" strains (MIC <0.48 mg/1) 
and in 14 (22%) "resistant" strains (MIC 2.0-48 mg/1). A high 
average MBC/MIC ratio of 153 was found amongst the 43 tolerant 
strains and for two isolates it was approximately 1000-fold. The 
authors suggested that the former, where the MIC's are in the 
normal range but MBCs are high, be termed "endurant" streptococci 
to distinguish them from those which also exhibited high 
(resistant) MICs
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Viridans streptococci were screened for tolerance by Powley et al 
in 1989. Sputum specimens (of no particular clinical 
significance) were collected and viridans cultures identified. Of 
these, 13 of 40 strains (32.5%) were found to be tolerant to 
penicillin G: 3 of 5 S .sanguis I biovar 2 isolates (60%), 6 of 20 
S. sanguis II (30%) and 4 of 9 S. mitis (44%) isolates. No iso­
lates of either S. sanguis biovar 1 or S. mitis exhibited 
tolerance to this antibiotic in the small sample tested
Hess et al (1983) stated that the the presence of tolerant 
viridans species in vivo may increase the risk of IE development 
in spite of prophylaxis with penicillin G alone after experimen­
tal development of this infection in the rabbit model. Using 
strains of S. sanguis II isolated from the gingival sulci of 
children (three strains) and one from a patient with endocar­
ditis, the IE infection rate in compromised rabbits who received 
penicillin G prophylaxis ranged from 9-80% (average 47%) depend­
ing upon which isolate was introduced to produce the infection
In a case report (Denning et al, 1984), an indigent patient died 
after the extraction of 24 teeth in spite of his receiving 3 g 
amoxycillin stat 2 hours pre-operatively. S. milleri was isolated 
from the blood and found to be tolerant to amoxycillin with an 
MIC of 0.025 mg/1 and MBC >10 mg/1
In a publication in which the involvement in IE of S. mutans was 
reputedly first identified (Harder et al, 1974), manipulation of 
penicillin G susceptibility data showed that in all cases (9 in 
total) MBC:MIC ratios fulfilled the lower reguirements for 
tolerance (see Section 6.2.2) and were >J 0. Of these, seven 
strains had ratios >_125, two were >_625 and one had an extremely 
high MBC:MIC ratio of >J000. Four and two of the six isolates 
tested against vancomycin had MICs of 5 and 1 mg/1 antibiotic, 
respectively
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6 . 2 . 2 Tolerance to vancomycin
Amongst 13 penicillin-tolerant viridans cultures (penicillin 
MBC:MIC ratio £20) from patients with endocarditis - all col­
lected prior to their receving antibiotic, vancomycin MICs ranged 
between 2-4 mg/1 (Shanson and Tadayon, 1986). Sixteen mg/1 van­
comycin failed to produce a 99.9% viable count reduction after 
overnight culture. MBC values were variable. Four strains 
possessed MBCs of £32 mg/1 vancomycin and for 3 strains it was 
£16 mg/1. Of the organisms with MBCs £32 mg/1, three were S . 
mitior and one a S. sanguis I. Two isolates with MBCs greater £16 
mg/1 were both S. mitior
Bourgault et al (1979) tested more than 63 clinical viridans 
isolates against 12 different antibiotics. At a concentration of 
1 mg/1, vancomycin was bactericidal to only 25.7% of strains (19 
of total of 73). Seventy-three percent (54 of 73) were only in­
hibited by this concentration. Eleven isolates, including four S . 
mitis and three S. sanguis II species, required concentrations of 
>8 mg/1 vancomycin for killing. Seven strains required vancomycin 
MBCs of >8mg/l. In 1984, Watanakunakorn reported vancomycin MIC 
values for viridans streptococci to range between <0.312 and 8.0 
mg/1
Tolerance was common amongst clinical isolates from IE patients 
in a study by Meylan et al (1986) where susceptibility of 25 oral 
streptococci against amoxycillin and vancomycin was determined. 
Ten S. mitis, 7 S. sanguis and 2 S. salivarius strains were iden­
tified. Five were unspeciated. All had amoxycillin MICs of £0.25 
mg/1 and MBCs which were either low (<0.5 mg/1) in 6 non-tolerant 
strains (25%) or high (>128 mg/1) in 18 (75%) tolerant strains. 
The MIC of vancomycin against all 24 strains was £1.0 mg/1 while
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the MBC was <1mg/l in 3 (12.5%) non-tolerant isolates and >128 
mg/1 in 21 (87.5%) displaying tolerance
In another study, two unspeciated vitamin B-6 dependent IE 
viridans isolates were found to be tolerant to vancomycin with 
MBCs of >_32 mg/l and individual vancomycin MICs of 0.05 mg/1 and 
1 mg/1 (Feder et al, 1980). Several other examples of nutri­
tionally variant streptococci that are tolerant have been 
reported in the literature (Gephart and Washington, 1982; Hol­
loway and Dankert, 1982)
There is a noticable variation in the literature as to what 
MBC:MIC ratio constitutes tolerance to antibiotics. Ratios of >_1 0 
(Holloway et al, 1980), >_20 (Shanson and Tadayon, 1986) and >32 
(Dankert, Holloway et al, 1982; Powley et al, 1989) have been 
employed by various researchers
6.2.3 "Tolerance" to antibiotics not acting directly on
bacterial cell wall formation
A number of viridans strains collected in the study of Harrison, 
Stross, et al (1985) exhibited MICs in the range 1-4 mg/1 of 
erythromycin but had MBCs >256 mg/1. These concentrations clearly 
fit the parameters of tolerance described previously. However, 
the term tolerance is normally reserved for agents acting upon 
cell walls of Gram-positive bacteria. Several antibiotics such as 
macrolides and tetracyclines which act on protein synthesis are 
described as being mainly bacteriostatic. However, at high con­
centrations, which are unachievable in tissues, they may be bac­
tericidal. This situation is not normally described as tolerance. 
For the purposes of this study, it is proposed, however, to apply 
this term to the macrolides and clindamycin in the case of strep­
tococci where these antibiotics are normally bactericidal at
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relatively low concentrations which are achievable at sites of 
infection
6.3 Clinical implications of tolerance in viridans streptococci
Clinical implications of bacterial antibiotic tolerance to 
penicillin, for example, are uncertain, but were it of any sig­
nificance, "it is likely to be in those conditions in which the 
use of bactericidal agents is essential for therapeutic success" 
(Powley et al, 1988). This is clearly the case in the treatment 
of IE
Serum bactericidal activity against the causative organisms in IE 
is often used to predict the outcome of therapy. A serum bac­
tericidal level required for efficient use against tolerant 
pathogens may be very useful but unachievable in some cases in 
clinical situations, eg endocarditis chemotherapy. Such levels 
are especially important for prognostic purposes when drug com­
binations are used for the treatment of IE
Serum bactericidal levels believed to be essential for effective 
therapy against particular pathogens may be unachievable in 
clinical situations (endocarditis chemotherapy). Metlan et al 
(1986), using data from the separate exposure of isolates to van­
comycin and amoxycillin, proposed that for (all) tolerant strep­
tococci, the "reduction in viability" (time-kill kinetics) was a 
more accurate indication than the MBC alone of successful clini­
cal outcome which depends on bactericidal antibiotic activity. It 
has also been suggested that the ability of antibiotics to kill 
bacteria affects the efficacy of prophylaxis (Glauser, Bernard et 
al, 1983)
1 0 1
Chapter 7
CLASSIFICATION OF VIRIDANS STREPTOCOCCI
7.1 Problems associated with the classification of viridans 
streptococci
The classification of oral streptococci has proved to be par­
ticularly difficult: "viridans-type streptococci encountered in 
oral cavities and pharynges have been curiously refractory to 
satisfactory classification" (Kilian et al, 1989). Their defini­
tion is surprisingly poor in spite of their "dominant role in 
early dental plaque and caries" (Nyvad and Kilian, 1990) and 
other diseases
Considerable problems have been encountered by researchers study­
ing post-operative streptococcal bacteraemias and these have been 
compounded by inconsistencies relating to the taxonomy of oral 
streptococci. The diversity of this group of bacteria severely 
hampered efforts to determine the identity, distribution and num­
bers of micro-organisms which colonise and inhabit the oral 
cavity. Difficulties were encountered during sampling, culture 
and isolation of such organisms (Hardie, 1983)
The most abundant streptococci in the mouth are undoubtedly the 
viridans group of streptococci. These bacteria are gram­
positive, spherical or ovoid, facultatively anaerobic, non-spore 
forming, non-motile organisms which most commonly produce alpha- 
haemolysis when cultured on blood agar. Streptococci occur 
singly, in pairs, in short or longer chains of 8 to 10 cocci when 
grown on suitable media (Hardie, 1983; Schuster, 1983)
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Non-haemolytic streptococci are those whose colonies are neither 
alpha-haemolytic nor do they produce clear haemolytic zones on 
blood agar after the complete destruction of erythrocytes (beta- 
haemolysis) incorporated into the medium. In contrast, alpha- 
haemolysis, the haemolysis form exhibited by most viridans strep­
tococci, is characterised by a greenish zone of discolouration 
which develops around colonies after partial digestion of the 
haemoglobin (Coykendall, 1989)
Several methods of classification have been proposed but agree­
ment on this matter has yet to be obtained internationally. The 
inabilty of investigators to reach consensus on the choice of 
phenotypic traits of viridans streptococci which would distribute 
these bacteria into clusters that could serve as easily identify- 
able species has contributed to the confusion. Organisms giving 
identical biochemical reactions have often been allocated dif­
ferent identities in different schemes
Viridans streptococci belong to the genus Streptocococcus. The 
taxonomic position of the genus as well as several other Gram­
positive cocci with similar physiological properties has not been 
finalised (Bergey's Manual, 1986). Characteristics of chain or 
coccal pair formation, the lack of cytochromes and catalase 
negativity typify the Streptococcus genome (Facklam and Smith, 
1976). Sherman (1937) distinguishes viridans streptococci from 
enterococci by the former's inability to tolerate extreme tem­
peratures, lack of growth in the presence of bile, high salt con­
centrations and alkali, and by their weak reducing powers
Major differences are apparent in British and American taxonomic 
schemes (Facklam, 1984; Hardie, 1983). In Facklam's editorial 
(Facklam, 1984) mention is made of the more convenient and infor­
mative Lancefield antigen grouping system used for identifying
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beta-haemolytic streptococci. But it is unsuitable for use on 
"non-beta-haemolytic" streptococci which often fail to react to 
Lancefield grouping sera
7.2 Different systems of classification
A plethora of schemes for the identification of the oral viridans 
streptococci have been proposed in the last two to three decades 
and include those of Carlsson (1968), Colman and Williams (1972), 
Colman (1976), Cowan and Steel (1974), Deibel and Seeley (1974), 
Hardie and Bowden (1976), Parker and Ball (1976), Facklam (1977), 
Jones (1978) and Parker (1983). Later schemes include Colman and 
Ball (1984), French et al 1989, Coykendall (1989) and Kilian et 
al (1989) and others
7.3 Classification of Kilian et al (1989)
The method of Kilian et al (1989) was used in this investigation 
and was complemented in part by proposals of Coykendal (1989) to 
identify S, vestibularis colonies. An extensive list of biochemi­
cal and physiological characteristics is used by Kilian to dif­
ferentiate between the various viridans species and include dif­
ferences in biochemical activity, antigenic cell-wall components, 
fimbriation, coaggregation properties, affinity for salivary 
glycoproteins and others. In his study (Kilian et al, 1989), 151
isolates were subjected to categorisation based on nine colony 
morphological types, five inhibition tests, 28 biochemical tests, 
26 enzymatic tests and 16 antiserum reactions. The authors noted 
that many cultures were not stable, and even after at least five 
serial subcultures continued to show a mixture of colony types
A total of 7 species and a number of biovariants were recognised,
namely: S. sanguis (4 biovars), S. qordonii (3 biovars), S . 
oralis, S. mitis (2 biovars), S. salivarius, S. anqinosus and S . 
mutans
Usefully, most strains gathered for the Kilian et al study had 
previously been subjected to genetic analyses. This information 
proved especially valuable where "difficult" decisions on 
taxonomy had to be made
The classification proposed by Kilian et al correlates reasonably 
well with Facklam's. Although full recognition has not been 
awarded to all species proposed by Killian et al (1989), their 
classification has received considerable support and identifica­
tion schemes based on this classification are freely employed 
(Douglas et al, 1993; Whiley and Beighton, 1991)
Although, by way of DNA hybridisation and cellular polypeptide 
electrophoresis, Coykendall (1989) found S. vestibularis to be 
related most closely to S. salivarius, he considered it suffi­
ciently distinct to warrant assignment to a separate species. 
This proposal was incorporated into the present study
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Chapter 8
EXPERIMENTAL DESIGN AND METHODOLOGY
8.1 Introduction
The in vitro experiments described in this dissertation were 
designed to assess the potential efficacy of antimicrobial agents 
which are candidates for the prophylaxis of infective endocar­
ditis (IE) following dental procedures. The effect of in vitro 
exposure of dental plaque streptococci from different groups of 
individuals to a representative 8-lactam agent (penicillin G) 
formed an essential part of the studies and the susceptibility of 
survivors to candidate prophylactic agents was used to compare 
the potential usefulness of candidate prophylactic agents
8.2 Informed consent
Informed consent was obtained from all participants prior to 
their inclusion in the study. The project was approved by the Re­
search and Ethics Committee of the Medical University of Southern 
Africa, Medunsa, and The University of the Wi’twatersrand, Johan­
nesburg
8.3 Subjects
8.3.1 Subjects exposed to 6—lactam antibiotics
Two subgroups of patients who received prior antibiotics were
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used. The first consisted of 41 volunteers who received daily 
doses of penicillin V for rheumatic fever prophylaxis (the RF 
subgroup) and a second smaller group of nine patients who 
received high therapeutic doses of ampicillin at Ga-Rankuwa 
Hospital for at least one week and not longer than 8 weeks (A- 
subgroup). The two subgroups were considered together as 6-lactam 
"exposed" individuals (E-group) or, where appropriate, indepen­
dently
8.3.2 Subjects not exposed to fi—lactam antibiotics
Sixty-seven volunteers about to undergo dental extraction formed 
a separate group of individuals who have not recently been ex­
posed to antibiotics. None of these volunteers had received an­
tibiotics for a minimum period of three months prior to plaque 
sampling. They were labelled the "unexposed" group (UE-group)
8.4 Specimen collection
Dental plaque was removed from adjacent interproximal supra- and 
subgingival surfaces of the first and second upper molars using 
sterile Gracy currettes (Ash Instruments). In persons without 
maxillary molars, plaque specimens were removed from comparable 
anatomical sites on mandibular molars
8.5 In vitro selection in broth: a model
Dental plaque material was inoculated into 10 ml 
broth (Oxoid, Basingstoke, UK) containing 0.125 mg/1 
(Hoechst Pharmaceuticals), 0.125 mg/1 penicillin G 
tamicin (Eli Lilly) and 1.0 mg/1 penicillin G. The
Todd-Hewitt 
penicillin G 
plus 5% gen- 
gentamicin-
containing broth cultures were used not only to simulate regimens 
recommended for IE therapy due to viridans streptococci with MICs 
>_0.5 mg/1 and enterococci (Tanner and Durack, 1990), assuming 
that the combination may deal more effectively with the strep­
tococci than penicillin G alone: but also, and more importantly, 
because a combination of penicillin plus an aminoglycoside has 
been suggested for IE prophylaxis following studies demonstrating 
survival of viridans streptococci in the blood - despite parental 
penicillin G prophylaxis used singly (Hess et al, 1983. Blood 
agar plates inoculated with gentamicin-containing broth cultures 
showed better separation of streptococcal colonies from those of 
non-streptococcal species compared with plates inoculated with 
broth cultures containing penicillin G alone
Following overnight incubation at 37 degrees Celcius, a loop-full 
from each of the three suspensions was transferred onto one 
antibiotic-free blood-agar plate (Oxoid, Columbia agar plus 5% 
horse blood) and incubated for a further 24 hours. Alpha- 
haemolytic colonies with differing morphological characteristics 
were selected for speciation and susceptibility testing from one 
or more of the plates
Cultures of isolates were labelled according to their sources and 
selection procedure and stored at -20 degrees Celcius until fur­
ther studied
8.6 Species identification
Strain identification was performed according to the taxonomic 
approach of Kilian, Mikkelsen and Hendrichsen (1989). Mannitol, 
melibiose and maltose fermentation tests were performed, as were 
tests based upon growth in the presence of 4% and 6.5% NaCl and 
in aesulin-bile, hydolysis of aesulin, arginine and urea, suscep­
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tibility to sulphamethoxazole and vancomycin (using disc 
diffusion) and production of dextran, laevan and alkaline phos­
phatase. In addition, the Vogues-Proskauer reaction (VP) of iso­
lates was determined, and indicator plates which allowed for the 
selection of strains producing hydrogen peroxide (Muller, 1984) 
were included in the series of biochemical tests. Coykendall's 
method (1989) was used to classify S. vestibularis, while the 
identification of S. anqinosus, which includes S . intermedius and 
S. constellatus as well as S. milleri, was based on recommenda­
tions of Coykendall (1989) and Kilian et al (1989). The iden­
tification of the various Streptococcus species and biovars was 
based on the following flow chart
8.7 Susceptibility testing
8.7.1 MIC and MBC determinations
MICs and MBCs were determined by a micro-titre broth dilution 
technique performed according to NCCLS recommendations (NCCLS 
Document, 1990). Antibiotic concentrations were prepared within 
the ranges of 0.003-256 mg/1 for penicillin V (Sigma, Missouri), 
0.003-4 mg/l for amoxycillin (Beecham Pharmaceuticals), eryth­
romycin (Abbott Laboratories), roxithromycin (Roussel 
Laboratories) and clindamycin (Upjohn), and 0.03-32 mg/l for van­
comycin (Eli Lilly). The inoculum was prepared according to NCCLS 
methodology to give a final concentration of 100-500 thousand 
CFU/ml in each well. Staphylococcus aureus ATCC 29213 served as 
control
The MIC was defined as the lowest concentration of the antibiotic 
that inhibited growth as assessed by the naked eye, while the MBC 
denoted the lowest concentration that produced a 2,99.9% kill as 
demonstrated on blood agar plates (5% horse blood) where <0.11%
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LABORATORY PROCEDURES FOR THE IDENTIFICATION OF VIRIDANS 
STREPTOCOCCI FOLLOWING THE METHODS OF KILIAN et al AND COYKENDALL
Parti: Preliminary steps
cell morphology cocci +
cocco-bacillary +
rods +
cell arrangement chains +
pairs +
clusters
gas production in presence of glucose
vancomycin susceptibility yes
streptococcal typing variable (v)
growth in aesculin bile v
pyrase v
growth: in 6.5 % NaCI
at 45 Celcius v
atlOCelcius
Part II: Species identification
Step 1.
Growth in the presence of:
Hydrolysis of:
6.5 % NaCI 
aecsulin bile
hydrogen perox. +
aesculin
arginine
aesculin +
arginine +
growth in 4 % NaCI
dextran prod.
melibiose 
(acid prod.) 
4 % NaCI 
starch
v
+
+
S. mitis biovar 1
detran prod, 
melibiose (acid prod) +
NaCI -(100% )
starch hydrolysis +
S. oralis
alkaline phosphatase 
production
S.qordonii S. sanguis
melibiose 
(acid prod)
>y
melibiose 
(acid prod)
biovar 1 biovar 2/3 biovar 4
acid phosphate growth in 4 % 
prod.
biovar 1
biovar 3
Step 2.
Growth in the presence of:
6.5 % NaCI
aesculin bile 
hydrogen peroxide
(Coykendall)
+
sulphamethoxazole 
(inhibition by ~)
starch hydrolysis: 
dextran production:
Step 3.
arginine hydrolysis 
aesculin hydrolysis +
mannitol (acid prod.) +/-
S. mutans
aesulin hydrolysis +
arginine hydrolysis 
mannitol (acid prod) 
laevan +
S. salivarius
VP reaction + 
urea hydrolysis + (71 %)
6.5 % NaCI 
aesculin bile 
hydrogen peroxide
V aesculin hydrolysis +/-arginine hydrolysis +/-mannitol (acid prod)
alkaline phos. prod +/-S. nainosus
(Coykendall)
of the original inoculum for MIC testing survived as CFUs from 
wells showing no growth after overnight incubation during the 
first step (MIC determination) of the MBC technique
For penicillin V and amoxycillin, isolates were regarded as sus­
ceptible when their MICs were <^ 0.12 mg/1, intermediately resis­
tant when their MICs ranged from 0.25-2 mg/1 and resistant when 
MICs were >_4 mg/1. For comparative purposes, it should be noted 
that penicillin G is more active against streptococci than 
penicillin V, the former being roughly up to two-fold more active 
(Garrod, 1960a; Garrod, 1960b). Penicillin G is also slightly 
more active against non-enterococcal streptococci than amoxycil­
lin (Coulter et al, 1990). MIC levels of penicillin V and 
amoxycillin are for many strains the same as for penicillin G but 
a minority of strains have MICs twice those of penicillin G 
(Garrod, 1960a; Garrod, 1960b; Coulter et al, 1990)
8.7.2 Definitions relating to survivors of in vitro selection
process
8.7.2.1 Phenotypic tolerance
Isolates of viridans streptococci which had MBCs of penicillin V 
and amoxycillin less than the selection concentrations of 
penicillin G (0.125 mg/1 and 1.0 mg/1) were regarded as being 
phenotypically tolerant. This assumption was based upon the 
premise that penicillin V and amoxycillin are equivalent to or 
slightly less active against viridans streptococci than penicil­
lin G. Strains with low MBCs of penicillin V and amoxycillin 
should therefore, under favourable conditions, be killed by an 
equivalent concentration of penicillin G
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8 .7 .2.2 R e s i s t a n c e  i n  t h e  c o n t e x t  o f  t h e  s e l e c t i o n  p r o c e s s
Based on the same reasoning as above, survivors with penicillin V 
and amoxycillin MBCs greater than the equivalent penicillin G 
selection concentrations, were regarded as intrinsically resis­
tant at the relevant concentrations. It should be noted that the 
levels of resistance in the context of the in vitro selection 
model are not exactly the same as those based on internationally 
regarded breakpoint concentrations denoting resistance or degrees 
of resistance
8.7.3 Recording of tolerant strains
Degrees of tolerance (genotypic) were recorded as MBC:MIC ratios. 
Although it is accepted that most authorities regard ratios of 
>^ 32:1 to denote tolerance by definition, differences in excess of 
2:1 ratios between MBCs and MICs were also noted
8.7.4 Definition and recording of persisters
The presence of persisters was based on the survival of up to 
0.1% of bacterial cells in the original inoculum at the MBC, 
demonstrated as CFUs in the second step of the MBC technique (see 
8.7.1) by subculture on blood agar plates. When persisters were 
present at concentrations higher than the MBC (but with _< 0.1 % 
survivors of the original inoculum), these concentrations were 
also recorded
8 . 8  S t a t i s t i c a l  a n a l y s i s :
The design of the study did not allow for the accurate standard­
isation of the amount of dental plaque material removed from the 
teeth for investigation. Also, the number of colonies selected 
per broth selection procedure varied as described earlier. These 
factors may have affected, to some extent, the accuracy or 
validity of our statistical analyses which were, none-the-less, 
applied when considered appropriate. For analysis of categorical 
variables, the Fisher exact and Chi-squared tests were used and 
the U-test of Mann-Whitney for continous variables
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Chapter 9
IDENTITY AND SUSCEPTIBILITY OF ORAL STREPTOCOCCI TO CANDIDATE
ANTIBIOTICS
9.1 Introduction
Extensive in vitro studies have been conducted to evaluate can­
didate drugs used in the prophylaxis of infective endocarditis 
(IE). Most of these studies based their assessment on the effect 
of these antibiotics on the drug susceptibility of oral flora, 
including their potential to select for resistant viridans 
strains, and in a few studies, their propensity to give rise to 
colonisation by other bacteria. Further investigations dealt with 
susceptibility profiles of oral streptococcal species within the 
oral cavity, and in others, the effect of prophylactic 6-lactam 
antibiotics on bacteraemic isolates. These latter studies 
demonstrated that both resistant and susceptible organisms may 
survive in the blood despite serum concentrations higher than the 
MBCs of the isolates (Hall et al, 1993)
In this chapter, streptococci from dental plaque which survived 
exposure to penicillin G alone and penicillin G plus gentamicin, 
were subjected to MIC and MBC determinations against six can­
didate antibiotics and the possible effect of previous exposure 
to 6-lactam antibiotics on the susceptibility of these strep­
tococci to a battery of antibiotics analysed
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9 . 2  M ethodology and d e f i n i t i o n s
The methods employed in this chapter of the study have been re­
corded in detail in Chapter 8. Briefly, Streptococcus species 
were identified according to the classification of Kilian et al 
(1989) with a number of modifications, as described in that chap­
ter. MICs and MBCs were performed in microtitre trays as 
specified in the NCCLS guidelines (NCCLS Document, 1990)
9.3 Results
9.3.1 Identity of viridans streptococci after in vitro
selection in penicillin G
The identity of viridans streptococci following selection in 
penicillin G is given in Table 9.1 and is recorded into groups 
according to their previous exposure to /3-lactam antibiotics (E- 
group) or lack of recent exposure (UE-group)
Seventy-nine viridans streptococcal isolates collected from the 
plaque of 67 UE-group volunteers were classified into eight 
species according to Kilian et al (1989) and Coykendall (1989) 
(Table 9.1): S. oralis (31 isolates), S. mitis biovar 1 (22), S . 
mitis biovar 2 (18), S. sanguis biovar 4 (2), S. vestibularis 
(2), S. sanguis biovar 1 or 3 (1), S. qordonii biovar 2 or 3 (2) 
and S. sanguis biovar 2 (1). Seventy-four isolates from the 50 
member E-group comprised 49 S. oralis, 5 S. mitis biovar 1, 12 S . 
mitis biovar 2, 2 S. sanguis biovar 4, 2 S. vestibularis and 4
S. qordonii biovar 2 or 3. With the exception of S. sanguis 
biovar 1 or 3 and S . sanguis biovar 2 which were not recovered 
from the E-group, all the abovementioned species were isolated 
from both UE- and E-groups. Coykendall's classification was 
utilised to identify S. vestibularis strains not recognised by
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Table 9.1 Number and identity of viridans streptococcus isolates speciated according to Kilian et al (1989) in different p-lactam exposure 
groups following selection in penicillin G only and penicillin G plus gentamicin
Species according to antibiotic exposure
Unexposed, 
speciation only 
(n = 67)*
Unexposed,
also susceptibility tested 
(n = 54)
Exposed to rheumatic 
fever prophylaxis 
(n = 41)
Exposed to ampicillin 
treatment 
(n = 9)
Streptococcus oralis 31 26 40 9
S. mitis biovar 1 22 15 5 0
S. mitis biovar 2 18 18 9 3
S. sanguis biovar 4 2 2 2 0
S. vestibularis (Covkendall) 2 2 2 0
S. sanauis biovar 1 or 3 t 1 1 0 0
S. aordonii biovar 2 or 3 t 2 1 4 0
S. sanauis biovar 2 1 1 0 0
Total 79 66 62 t 12 X
* n = number of subjects in each group
t  Range of identification tests used did not allow for differentiation between biovars 1 and 3 of S. sanguis or biovars 2 and 3 of S. qordonii
respectively
$ The respective subgroups together form the E-group: 62 + 12 = 74 isolates
NOTE: This table is identical to Table 11.2(a)
Kilian et al (1989)
S. oralis was significantly more plentiful (49 out of 74; 66%) in 
the E-group than in the UE-group (31 of 79; 39%) (chi squared 
test, Yates modification; p<0.001) while S. mitis biovar 1 was 
more frequently found in the UE-group than the other group 
(Fisher exact test; p<0.001). S. mitis biovar 2 (12/74; 16%) was, 
like S. oralis, common in the 8-lactam-exposed group but more so 
in those not exposed to these antibiotics: 18 out of 79 (23%) 
(Table 9.1)
S. salivarius attaches preferentially to the tongue (Hardie, 
1983). None was isolated from the plaque samples in this study. 
No other important oral streptococcal species such as S . mutans 
(Hall and Heimdahl, 1989; Franklin, 1992; Bayliss et al, 1983; 
Baddour, 1994) or S. milleri (Sussman et al, 1986) were recovered
9.3.2 Susceptibility patterns in the different 8—lactam
antibiotic exposure groups
All 74 identified viridans isolates from E-group volunteers were 
tested for susceptibility to a panel of 6 antibiotics but 13 iso­
lates from 13 UE-group subjects were not available for further 
investigation and only underwent speciation. The remainder (66 of 
79) were tested (Table 9.1)
9.3.2.1 Susceptibility to candidate antibiotics within the 
UE—group and the E—groups as a whole
Susceptibility profiles of isolates from the two exposure groups 
are presented in Table 9.2 for comparative purposes. The MICs 50 
denote concentrations at which 50% of strains, ranked according
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t o  t h e i r  MICs, a r e  i n h i b i t e d
Table 9.2 Minimum inhibitory concentrations (in mg/1 antibiotic)
The following abbreviations are used in this table and elsewhere: 
pen V = penicillin V; amoxy = amoxycillin; ery = erythromycin; 
rox = roxithromycin; clinda = clindamycin; vanco = vancomycin
a ) UE-group
MIC range MIC 50 MBC 50 MBC range
pen V 0.015-2 0.12 0.25 0.015-2
amoxy £0.007-2 0.03 0.03 £0.007-2
ery £0.007-0.25 £0.007 0.007 £0.007-1
rox £0.007-4 0.015 0.03 £0.007-4
clin £0.007-0.06 0.007 0.015 £0.007-4
vanco 0.25 -1 1 1 0.25-2
b) E--group
MIC range MIC 50 MBC 50 MBC range
pen V 0.003-8 0.25 0.5 0.003-1 6
amoxy 0.007-16 0.25 0.25 0.007-32
ery £0.003-> 64 0.015 0.03 £0.007-> 64
rox £0.007-> 64 0.06 0.12 £0.007-> 64
clinda £0.007-> 64 0.015 0.03 £0.007-> 64
vanco 0.25 -1 0.5 0.5 0.25-2
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There are notable differences between the UE-group and E-group 
when the upper limits of both the MIC and MBC ranges for all an­
tibiotics in the study are considered, except for vancomycin to 
which organisms were consistently susceptible. The differences 
between the two exposure groups were especially pronounced for 
the macrolides and clindamycin. Similar but less marked dif­
ferences were observed when MIC 50 values in the two antibiotic 
exposure groups were compared. It is obvious from these observa­
tions that exposure to high doses of ampicillin and prolonged ex­
posure to penicillin V may result in viridans bacteria that are 
not only more resistant to 6-lactam agents, but also to macro­
lides and to clindamycin
With regard to comparative susceptibilities between the various 
antimicrobial agents, erythromycin and clindamycin showed the 
greater activity with the lowest MICs in both the UE- and E- 
groups. Roxithromycin was only slightly less active
9.3.2.2 Susceptibility within E-subgroups
As indicated in Chapter 8, the E-group consisted of two 
subgroups: one (subgroup A) receiving high doses of therapeutic
ampicillin (the 9 member, 12 isolate so-called "high-exposure" 
subgroup) and the other (RF-subgroup) who were on rheumatic fever 
prophylaxis (62 isolates from 41 individuals). Susceptibility 
ranges and MICs 50 and MBCs 50, as well as MICs 90 and MBCs 90, 
were calculated for these isolates:
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T a b l e  9 . 3  MIC and MBC p r o f i l e s  o f  12 i s o l a t e s  o f  t h e  A-
( a m p i c i l l i n )  subgroup ( i n  mg/1 a n t i b i o t i c )
MIC range MIC 50 MIC 90
pen V 0.12-4 1 4
amoxy 0.06-16 0.5 8
ery <0.007->64 0.03 4
rox 0.015-> 64 0.12 8
clinda 0.007— > 64 0.03 4
vanco 0.5-1 0.5 1
MBC range MBC 50 MBC 90
pen V 0.12-4 2 4
amoxy 0.6-32 1 1 6
ery _£0.007-> 64 0.06 4
rox 0.015-> 64 0.12 16
clinda 0.007->64 0.03 >64
vanco 0.5-1 0.5 1
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T a b l e  9 . 4  MIC and MBC p r o f i l e s  o f  62 i s o l a t e s  i n  RF- (rheumatic
f e v e r )  subgroup ( i n  mg/1 a n t i b i o t i c )
MIC range MIC 50 MIC 90
pen V 0.003-8 0.5 4
amoxy 0.007-8 0.25 4
ery 0.003-8 0.015 2
rox 0.007-> 64 0.06 4
clinda 0.003-> 64 0.015 0.06
vanco 0.25-1 0.5 1
MBC range MBC 50 MBC 90
pen V 0.003-16 0.5 4
amoxy 0.007-16 0.25 4
ery 0.003-16 0.015 4
rox 0.007-32 0.06 8
clinda 0.007-> 64 0.03 0.06
vanco 0.25-2 0.5 1
Listed below in Table 9.5 are, for comparative purposes, suscep­
tibility ranges of candidate antibiotics using MIC values and 
then MBC values, for the E-group as a whole, the A- and RF- 
subgroups as well as the UE-group
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T a b l e  9 . 5  Comparison o f  MIC and MBC r a n g e s  ( i n  mg/1 a n t i b i o t i c )
between i s o l a t e s  from t h e  d i f f e r e n t  a n t i b i o t i c  e x p o s u r e  groups
MIC ranges:
E-group A-subgroup RF-subgroup UE-group
pen V 0.003-8 0.12-4 0.003-8 0.015-2
amoxy 0.007-16 0.06-16 0.007-8 £0.007-2
ery £0.003->64 £0.007->64 0.003-8 £0.007-0.25
rox £0.007-> 64 0.015-> 64 0.007-> 64 £0.007-4
clinda £0.007->64 0.007-> 64 0.006-> 64 £0.007-0.06
vanco 0.25-1 0.5-1 0.25-1 0.25-1
MBC ranges:
E-group A-subgroup RF-subgroup UE-group
pen V 0.003-16 0.12-4 0.003-16 0.003-2
amoxy 0.007-32 0.6-32 0.007-16 0.007-2
ery 0.003-> 64 £0.007-> 64 0.003-16 £0.007-1
rox £0.007-> 64 0.015-> 64 0.007-32 £0.007-4
clinda £0.007-> 64 0.007-> 64 0.007-> 64 £0.007-4
vanco 0.25-2 0.5-1 0.25-2 0.25-2
In order to determine the possible effects of previous 6-lactam 
antibiotic exposure, the following lists of MICs 50 and MBCs 50 
for the E-group, A-subgroup, RF-subgroup and the UE-group are 
provided
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T a b l e  9 . 6  Comparison o f  MICs 50 and MBCs 50 between i s o l a t e s
from t h e  d i f f e r e n t  a n t i b i o t i c  e x p o s u r e  groups ( i n  mg/1)
E-group A-subgroup RF-subgroup UE-group
MIC 50 (R)* MIC 50 (R) MIC 50 (R)
pen V 0.5 (4.2) 1 (8.3) 0.5 (4.2) 0.12
amoxy 0.25 (8.2) 0.5 (16.7) 0.25 (8.3) 0.03
ery 0.015 (12) 0.03 (14.3) 0.015 (12) 10.007
rox 0.06 (4) 0.12 (8) 0.06 (4) 0.015
clinda 0.015 (12) 0.03 (14.3) 0.015 (12) 10.007
vanco 0.5 (0.5) 0.5 (0.5) 0.5 (0.5) 1
E-group A-subgroup RF-subgroup UE-group
MBC 50 (R) MBC 50 (R) MBC 50 (R)
pen V 0.5 (2) 2 (8) 0.5 (2) 0.25
amoxy 0.25 (8.3) 1 (33.3) 0.25 (8.3) 0.03
ery 0.03 (14.2) 0.06 (1 8.6) 0.015 (12) £0.007
rox 0.12 (4) 0.12 (4) 0.06 (2) 0.03
clinda 0.03 (2) 0.03 (2) 0.03 (2) 0.015
vanco 0.5 (0.5) 0.5 (0.5) 0.5 (0.5) 1
* (R) is ratio betweeni the respective: exposure group and
the UE-group
When the MBCs 50 and MBCs 50 of the two group E-subgroups are 
compared with those of the UE-group (where differences are 
expressed in ratios for convenience) it is clear that the MICs 
and MBCs of both the A-subgroup and the RF-subgroup are consis­
tently higher than in the UE-group. This applies to all an-
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timicrobial agents except for vancomycin. Furthermore, the MICs 
50 and MBCs 50 were, for most agents, approximately twice to four 
times higher in the A-subgroup compared with the RF-subgroup. 
Noticably, there appears only to be marginal differences between 
erythromycin, roxithromycin and clindamycin activity. MIC values 
and ratios for these agents are either almost identical or differ 
only by a factor of approximately two
9.3.2.3 Antimicrobial susceptibility of individual species 
according to exposure group
Only S- oralis, S. mitis biovar 1, and S. mitis biovar 2 strains 
were present in sufficiently large numbers to permit the meaning­
ful comparison of susceptibility data relating to E- and UE- 
groups (shown hereunder). The following lists indicate MIC and 
MBC data (in mg/1 antibiotic) per streptococcal species in the 
form of ranges, MICs 50 and MBCs 50 as well as respective MIC 50 
ratios and MBC 50 ratios of E-groups to UE-groups
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T a b l e  9 . 7  Comparison o f  MICs 50 and MBCs 50 o f  S .  o r a l i s
(a) Minimum inhibitory concentrations:
A) UE-group (26 isolates)
MIC range MIC 50 E-/UE-group
pen V 0.03-1 0.06
amoxy £0.007-0.25 0.03
ery £0.007-0.015 0.007 (see below)
rox £0.007-0.06 0.015
clinda £0.007-0.06 0.007
vanco 0.25-1 1
B) E--group (49 isolates):
pen V 0.003-8 0.5 m00
amoxy 0.007-16 0.25 8.3
ery £0.007-> 64 0.015 2
rox £0.007-> 64 0.06 4
clinda £0.007-> 64 0.015 2
vanco 0.5-2 0.5 0.5
(b )  Minimum b a c t e r i c i d a l  c o n c e n t r a t i o n s
A) UE-group (26):
MBC range MBC 50
pen V 0.03-1 0.12
amoxy £0.007-0.5 0.03
ery £0.007-0.06 £0.007
rox <0.007-0.06 0.015
clinda £0.007-0.06 0.015
vanco 0.25-1 1
E/UE-group 
MBC Ratios
(see below)
B) E-group (49):
pen V 0.003-16 1 8
amoxy £0.007-32 0.5 16.7
ery £0.007-> 64 0.03 4.3
rox £0.007-> 64 0.12 8
clinda £0.007-> 64 0.03 2
vanco 0.5-2 1 1
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Table 9.8 Comparison of MICs 50 and MBCs 50 of S. mitis biovar 1 
(in mg/1 antibiotic)
(a) Minimum inhibitory concentrations
A) UE--group (15):
MIC range MIC 50 E/UE MIC 50
ratios
pen V 0.03-2 0.12
amoxy £0.007-2 0.03
ery £0.007-0.25 £0.007 (see below)
rox £0.007-2 0.03
clinda £0.007-0.06 £0.007
vanco 0.25-1 0.5
B) E--group (5):
pen V 0.5-1 1 8.3
amoxy 0.25-2 1 33.3
ery 0.007-2 0.03 >4.3
rox 0.03-4 0.12 4
clina 0.015-0.6 0.015 >2
vanco 0.5-1 0.5 1
1 2 5
(b )  Minimum b a c t e r i c i d a l  c o n c e n t r a t i o n s
A) UE-group (15):
MBC range MBC 50 Ratios
pen V 0.06-2 0.25
amoxy 0.015-2 0.03
ery _<_0.007—0.25 _£0.007 (see below)
rox ^0.007—2 0.03
clinda _<_0.007—0.25 0.015
vanco 0.25-2 0.5
B ) E-group (5):
pen V 1-2 1 4
amoxy 0.25-2 1 33.3
ery 0.007-4 0.03 4.3
rox 0.03-8 0.25 8.3
clinda 0.015-0.06 0.03 2
vanco 0.5-1 0.5 1
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T a b l e  9 . 9  Comparison o f  MICs 50 and MBCs 50 o f  S .  m i t i s  b i o v a r  2
a) Minimum inhibitory concentrations
A) UE-group (18):
MIC range MIC 50 E/UE MIC 50
ratios
pen V 0.015-0.5 0.12
amoxy £0.007-0.5 0.06
ery £0.007-0.12 £0.007 (see below)
rox £0.007-4 0.015
clinda £0.007-0.06 £0.007
vanco 0 cn 1 0.5
B) E-group■ (12):
pen V 0.003-8 0.12 1
amoxy 0.03-4 0.12 2
ery £0.003-2 0.03 >4.3
rox 0.015-4 0.06 4
clinda £0.007-0.03 0.015 >2
vanco 0.25-1 0.5 1
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b)  Minimum b a c t e r i c i d a l  c o n c e n t r a t i o n s
A) UE-group (18):
MBC range MBC 50 Ratios
pen V 0.015-1 0.25
amoxy 0.015-1 0.12
ery £0.007-1 £0.007 (see below)
rox £0.007-4 0.03
clinda £0.007-4 0.015
vanco 0.5-1 1
B ) E-group (12):
pen V 0.003-16 0.12 2
amoxy 0.03-4 0.25 2
ery £0.007-2 0.03 4.3
rox 0.015-8 0.06 2
clinda £0.007-0.06 0.015 1
vanco 0.25-1 0.5 2
Of all strains in this study, S. oralis was the only species to 
to exhibit MICs and MBCs in excess of 64 mg/1 for any particular 
antibiotic. Isolate number C5 was especially resistant to eryth­
romycin, roxithromycin and clindamycin: all MICs and MBCs were 
>64 mg/1
S. mitis biovar 1 displayed the greatest differences in suscep­
tibility to the various antibiotics when E- and UE-groups were 
compared. This was particularly noticable in the case of the 8-
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lactam agents where a 33.3x difference in MIC 50 values occurred 
with amoxycillin. Of the two agents, the S. mitis biovar 2 
species showed the smallest difference in sensitivity to penicil­
lin V between the two exposure groups. MIC 50 values of this an­
tibiotic for S. mitis biovar 2 were the same at 0.12 mg/1 in both 
E- and UE-groups. MIC ratios were _>4 for all streptococcal 
species against roxithromycin and, with the exception of S . 
oralis (a ratio of 2), against erythromycin. All isolates 
remained susceptible to vancomycin
9.4 Discussion
Of all species in this study, S. oralis was significantly more 
common in the E-group (49 out of 74) compared with the UE-group 
(31 out of 79; p=0.001) and S. mitis biovar 1 in the UE-group (22 
out of 79; p=0.001) than the E-group (5 of 74; p=0.0001). S . 
mitis biovar 2 was common in the UE-group (18 of 79 isolates) but 
somewhat less so in the E-group (12 of 74 isolates)
Except for vancomycin, MICs 50 and MBCs 50 were consistently 
higher in the E-group than the UE-group. Similarly, MICs/MBCs 50 
MICs/MBCs 90 figures for all antibiotics, except vancomycin, were 
slightly (but consistently with one or two exceptions) higher in 
the A-subgroup than the RF-group. MIC or MBC indices were identi­
cal in the case of penicillin V (MICs 90 and MBCs 90) and clin­
damycin (MBC 50). Compared with the UE-group, the A-subgroup had
4.3 to 16.7-fold higher MICs 50 and a 2 to 33.3-times higher MBCs 
50. MICs 50 and MBCs 50 were also somewhat higher in the RF- 
subgroup compared with the UE-group: both MICs 50 and MBCs were 
from 0.5 to 8.3-fold higher in the former subgroup
The reasons for the selection of resistance to antibiotics other 
than 13-lactams in dental plaque for which no record of prior ex­
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posure to the non-B-lactam antibiotics are available, are not 
clear. It is possible that some of the patients in the A- and RF- 
subgroups were previously exposed to non-B-lactam antibiotics. It 
also possible that the in vivo and in vitro selection pressures 
of the model used in the present studies may have selected for 
genetic material coding for multiple drug resistance such as 
plasmids or transposons. Examples of transposons (Tn 917 and Tn 
1545) carrying the erythromycin resistance gene erm AM in strep­
tococci, including S. sanguis, which also code for clindamycin 
resistance, are well described in the literature and have been 
recently reviewed by LeClercq and Courvalin (1991)
In this study, strains with increased MICs and MBCs to the macro- 
lides and clindamycin tended also to be intermediately or fully 
resistant to penicillin and amoxycillin
Penicillin susceptibility findings in this study approximate 
those in the literature. Isolates in the study of Neu (1974) were 
sensitive to 0.012 mg/1 amoxycillin. The MICs of isolates against 
both penicillin V and amoxycillin ranged from 0.002-0.05 mg/1 
with MICs 50 <_0.12 mg/1 (Shanson et al, 1976) while Phillips et 
al, in the same year, found MICs of approximately 0.12 mg/1 and 
MBCs >J .0 mg/1 penicillin V. Against amoxycillin, MacGregor and 
Hart (1986) determined a MIC range of <0.003-0.25 mg/1 for their 
viridans isolates and Hall and Heimdahl (1989) found isolates to 
be susceptible to 0.2 mg/1 penicillin. Coulter et al (1990) 
tested isolates against both penicillin V and amoxycillin. MIC 
and MBC ranges for penicillin V were <0.01-2 mg/1 and 0.01-2 
mg/1, respectively, and for amoxycillin, <0.01-4 mg/1 and 0.01-4 
mg/1. Against penicillin G, oral streptococcal MIC ranges were 
0.06-4 mg/1 and MBC ranges 0.06-8 mg/1 (Bourgault et al, 1990). 
The latter authors found that isolates of two species, S. mitis 
and S. sanguis II were killed only by levels >2-8 mg/1 antibiotic
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Other researchers identified strains of oral streptococci with 
far higher levels of resistance to /3-lactam agents. Isolates in 
the study of Southall et al (1983) showed MICs of 1-16 mg/1 and 
MBCs of 2-16 mg/1 to amoxycillin. Yet higher levels of resistance 
resistance to amoxycillin were identified in the study of Woodman 
et al (1985) who illustrated what effect prior exposure to an an­
tibiotic may have on the development of resistance. These authors 
screened salivary oral flora for susceptibility to this agent 
(Group A: after a single dose or, Group B; after three doses of 3 
g amoxycillin at weekly intervals) and found that all subjects in 
their study carried streptococcal strains resistant to 2 mg/1 an­
tibiotic (median count of 5700 cfu/ml saliva) prior to any 
receiving the agent, while 9 of 20 had isolates resistant to 40 
mg/1 (116 cfu/ml saliva). In those who received 3 g amoxycillin 
in multiple doses, the number of streptococci resistant to 2 mg/1 
and 40 mg/1 of this antibiotic agent increased markedly after the 
second and third doses (p<0.001) and remained at elevated levels 
for 28 and 21 days respectively. But, to put their findings in 
perspective, the researchers calculated that resistance occurred 
in substantially less than 1% of the total count - still a sub­
stantial proportion of all isolates, however. Their results sup­
port the trend of increased antibiotic resistance which was iden­
tified in this study amongst isolates from the E-group (Tables 
9.2-9.9)
As noted earlier in this chapter (Section 9.3.2.2), activity of 
the two macrolides and clindamycin were broadly similar against 
the UE-group isolates and against the E-group isolates
The significance of the susceptibility of the viridans strep­
tococcal isolates of the present study to the macrolides eryth­
romycin and roxithromycin and clindamycin, particularly in rela­
tion to their suitability as candidates for IE prophylaxis, is 
discussed in Chapter 10. This will permit the inclusion of con-
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s i d e r a t i o n s  o f  t o l e r a n c e  and t h e  p e r s i s t e r  phenomenon
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C h a p te r  10
GENOTYPIC TOLERANCE AND PERSISTERS IN VIRIDANS STREPTOCOCCI 
FOLLOWING SELECTION IN AN IN VITRO MODEL
10.1 Introduction
Examples of mechanisms of genotypic tolerance have been given in 
Chapter 8. Tolerance based upon MBC/MIC ratios, as is the prac­
tice in clinical laboratories, is likely to have a genetic basis 
provided the test media are nutritionally adequate and the in- 
ocula used in the first step of the experiments (MIC 
determination) are in the logarithmic growth phase. The term 
"genotypic tolerance" will be used to describe this type of 
tolerance in order to distinguish it from phenotypic tolerance 
which is used in this dissertation to denote susceptible sur­
vivors of selection in penicillin G and penicillin G plus gen­
tamicin broth cultures
The genetic basis and mechanism of persisters are not fully un­
derstood but are probably similar to those operating in genotypic 
tolerance. Persisters represent a small proportion of the in­
oculum (^0.1%) that survive longer than the 24 h exposure period 
used in MIC determinations and are therefore probably examples of 
genotypic tolerance based upon a slow rate of killing of the 
strain concerned. In this chapter, the presence of genotypic 
tolerance and persisters (as defined above) amongst the survivors 
of plaque streptococci following in vitro selection in penicillin 
G containing broth will be recorded
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10.2 Methods and definitions
10.2.1 Definition of genotypic tolerance
Definitions of genotypic tolerance to an antibiotic have been 
variously reported as ratios of the MBC to MIC greater than 10:1, 
20:1 or 32:1 (see earlier). A ratio of 32:1 is now generally ac­
cepted as the preferred definition by clinical microbiologists. 
Tolerance ratios were determined in this study for all the an­
tibiotics evaluated, including the macrolides and clindamycin, 
even though tolerance to the latter agents (which do not act 
directly on the bacterial cell wall and which are not generally 
regarded as primarily bactericidal) is not usually recorded in 
the literature
10.2.2 Persisters
A small proportion of bacterial cells still produce colony form­
ing units at MBCs of some isolates. This was demonstrated when a 
percentage of the original inoculum in the broth wells grew as 
colonies on the blood agar subcultures. The MBC endpoint by 
definition was achieved when >_99.9% of the bacteria in the 
original inoculum were killed. The remainder of viable bacteria 
(_<_0.1 % of the original inoculum) produced 1 to 50 colonies from 
the 10 microlitre volumes of broth transferred to the blood agar 
plates. These surviving colonies were recorded as persisters. 
Concentrations at which persisters were identified are listed 
hereunder per Streptococcus strain and exposure group
Persister colonies, as described above, were recorded at con­
centrations greater than MBCs, including the highest concentra­
tions at which they occurred
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10.2.2.1 Refractoriness of persisters to killing
The figures obtained when the lowest concentrations of an­
tibiotics at which persisters were completely eliminated are 
divided by the MBCs of the strains involved, relate to the rela­
tive refractoriness of the persisters to killing. The ratios ob­
tained in this manner are expressed as persister refractory in­
dices (PRIs)
10.2.3 Endurance indices
10.2.3.1 Endurance indices in relation to tolerant strains
The term endurance in relation to viridans streptococci has been 
proposed by Holloway et al (1980) to denote streptococci with 
penicillin G MICs less than the standard "breakpoints for 
resistance" but with MBCs appreciably greater than the MICs (see 
later). The term, as proposed, defined the penicillin G break­
point required for a bactericidal action in IE cases as 0.8 
units/ml (equivalent to 0.5 mg/1) and included strains with
MBC/MIC ratios of <10. In this dissertation, the British (British 
Society for Antimicrobial Chemotherapy's: A guide to sensitivity 
testing, J Antimicrob Chemother 1991, 27 Suppl D:1-47) and NCCLS 
breakpoint of >_0.25 mg/1 for both penicillin V and amoxycillin 
was used to measure endurance, and the term endurance index (El)
is proposed for the purpose in this study. This index was deter­
mined by dividing the MBCs of the relevant strains by their MBC 
breakpoint of 0.25 mg/1 in the case of both penicillin V and 
amoxycillin. Endurance to vancomycin using a breakpoint con­
centration of 8 mg/1 did not occur and endurance indices for the 
macrolides and clindamycin (MBC breakpoints have not been 
proposed in the literature) were not calculated
1 3 5
When the minimal antimicrobial concentrations required to 
eliminate persisters are divided by the resistance breakpoints of 
the antibiotics concerned (according to NCCLS criteria but based 
upon MBCs), the figure obtained is expressed as a persister en­
durance index (PEI). This index relates to concentrations that 
are achievable in the blood and indices of >1 would suggest that 
such persister strains may be difficult to eradicate by the an­
tibiotic concerned
10.3 Results
10.3.1 Genotypically tolerant strains and MBC:MIC ratios
The identity of isolates with MBC/MIC ratios of 4 or greater, 
their actual MICs and MBCs, adjusted ratios and the antibiotic 
agent against which the specific isolate was tested are shown in 
Table 10.1. Endurance indices in the case of cell wall-active an­
tibiotics are also recorded. Table 10.2 summarises the genotypic 
tolerance data and MBC/MIC ratios in the UE- and E-groups
Amongst isolates from UE-group volunteers, all had MBC/MIC ratios 
of 1 or 2 (data not shown) except for nine isolates including an 
isolate (isolate H61 I) with a marginally elevated MBC/MIC ratio 
of 4 against vancomycin (but with the MBC still within achievable 
blood levels) (see Table 10.1). The majority of isolates in the 
E-group, like those in the UE-group, displayed no tolerance as 
defined above. Many strains strains had marginally elevated 
ratios of 4 and higher; some against more than one antibiotic 
(four isolates). Amongst S. oralis, S. mitis biovar 1 and
10.2.3.2 Endurance indices in relation to persisters
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mitis biovar 2, four strains had ratios >10 (see Table 10.1). Two 
isolates in the E-group approached the 10:1 ratio against 
amoxycillin (8:1) and penicillin V (8.3:1). Another two isolates 
exhibited ratios of 10:1 against erythromycin (16.6:1) and clin­
damycin (16.6:1), while a further two exceeded the higher 32:1 
requirement for tolerance with ratios of 66.6:1 and 33.3:1 - both 
against erythromycin. All four of the latter isolates were 
strains of S. oralis and belonged to the E-group. One of the iso­
lates (C4) which was by definition potentially tolerant to clin­
damycin with a ratio >16, originated from the high-exposure 8- 
lactam A-subgroup
MBC/MIC ratios were clearly higher in the E-group compared with 
the UE-group, including classical tolerance to erythromycin as 
mentioned earlier (see Table 10.1 and Table 10.2)
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Table 10.1 MBC/MIC ratios of 2.4 amongst streptococcal species
Isolate Species MIC MBC Adjusted Endurance Anti-
number MIC/MBC index (El) biotic
ratio *
UE-group (9 out of 66 isolates, 13.6%)
H1 S. oralis 0.03 0.12 4:1 0.5 pen V
H7 I S. mitis 2 0.25 1 4 na ** rox
H1 2 s. mitis 2 £0.007 0.03 2.4.3 na ery
s. mitis 2 0.03 0.25 8.3 na clinda
H1 3 s. mitis 2 0.12 1 8.3 na ery
H53 III s. sanguis 1/3 £0.007 0.03 2.4.3 na clinda
H53 IV s. oralis £0.007 0.06 2.8.6 na ery
H55 II s. mitis 2 0.03 0.12 4 na ery
H61 I s. oralis 0.25 1 4 0.125 vanco
E-group (20 out of 74 isolates, 27.0%)
C1 # s. oralis 0.015 0.06 4 na clinda
C5 s. mitis 2 0.25 1 4 na ery
C4 # s. oralis 4 1 6 4 na rox
s. oralis 4 £64 >16 na clinda
C9 s. mitis 2 0.06 0.5 8.3 2 pen V
s. mitis 2 <0.003 0.015 >5 na ery
C10 I s. oralis 4 32 8 na rox
C10 II s. mitis 2 4 16 4 na ery
C19 I s. oralis 0.03 0.12 4 na rox
C19 II s. oralis 0.015 0.06 4 na clinda
C21 II s. oralis 1 4 4 na ery
C24 I s. oralis 2 1 6 8 64 amoxy
s. oralis 0.03 2 66.6 na ery
C24 II s. qordonii 2/3
4 1 6 4 na rox
C31 I s. oralis 0.015 0.25 16.6 na ery
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C32 # S. oralis 0.03 0.12 4 na clinda
C1 6 II s. oralis 0.03 0.12 4 0.5 amoxy
s. oralis 0.03 1 33.3 na ery
C39 s. oralis 0.06 0.25 4.2 na ery
s. oralis 0.06 0.25 4.2 na clinda
* = MIC:MBC ratio iadjusted to unity (ie. x: 1 )
** = not applicable (na) to non-13-lactam agents
# = isolates which originated from the high exposure ampicillin
A-subgroup of the E-group
Table 10.2 Genotypic tolerance: comparative MBC/MIC ratios in the 
E- and UE-groups
—  UE—group -------  -------  E—group  
MBC/MIC ratios MBC/MIC ratios
2.4 2.1 0 >_32 2.4 2.1 0 2.32
Pen V 1 0 0 1 0 0
Amoxy 0 0 0 2 0 0
Ery 4 0 0 8 3 2
Rox 1 0 0 4 0 0
Clinda 2 0 0 5 1 0
Vanco 1 0 0 0 0 0
Total 9 0 0 20 4 2
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1 0 . 3 . 2 Endurant strains
Only four isolates exhibited endurance with tolerance in the face 
of MICs below the proposed breakpoints to penicillin V and 
amoxycillin (Table 10.1). Of these four strains, two had en­
durance indices (El) of >1 (C9, S. mitis 2 with El = 2 and C24, 
S. oralis 2 with El = 64). Both of these isolates had MBC:MIC 
ratios of approximately 8. (Endurance indices = strain MBC 
divided by MBC breakpoint, see Section 10.2.3.1)
10.3.3 Persisters
10.3.3.1 Persisters at and above MBC levels in different species
MBCs of strains exhibiting persisters on plates are listed in 
Table 10.3. When strains showing persisters at a given MBC were 
also refractory to concentrations higher than their MBCs, the 
highest concentrations at which persisters were still present are 
given and are underlined to distinguish them from persisters at 
isolate MBCs only. The numbers of strains showing persisters 
against the different antibiotics are given in parentheses in the 
right hand column
MBCs
Table 10.3 Strains exhibiting persisters and their respective
a) UE-group
Nos of strains 
with persisters
S. oralis (26 isolates tested) ;
pen V 0.25 (1 )
amoxy 1; o .06; 0. 03 ; o. 03; 0. 03; 0. 03; 0.015 (7)
ery 0.12 ; o. 03; 0 .03; 0. 03; 0. 03; 0. 015 (6)
rox 0.03 ; 0. 12; 0 .12; 0. 03; 0. 03; 0. 06; 0.06 (7)
clinda 0.06 ; o. 06; 0 .015 ; 0 .03 ; o .03 ; o .015; 0.015 (7)
vanco (0)
S. mitis biovar 1 (15):
pen V (0)
amoxy 0.5; 0.06 (2)
ery 2; 0.25; 0.12; 0.03; 0.03; 0.03; 0.015 (7)
rox 4; 0.5; 0.25; 0.12; 0.06; 0.03; (6)
clinda 4; 0.25; 0.12; 0.015 (4)
vanco (0)
S. mitis biovar 2 (18):
pen V 4; 4 (2)
amoxy 4; 0.5; 1 ; 1 (4)
ery 8; 2; 1; 0.06; 0.03; 0.03; 0.015 (7)
rox 8; 8; 0.12; 0.06; 0.06; 0.06; 0.06; 0.03; 0.03;
0 . 03; 0.015 (11 )
clinda 8; 0.06; 0.06; 0.06; 0.03; 0.03; 0.03
0 . 03; 0.03; 0.03; 0.015; 0.015; 0.015 (13)
vanco (0)
S. sanguis biovar 4 (2):
pen V 1; 0.25 (2)
amoxy 0.5 (1 )
ery (0)
rox 0.06 (1 )
clinda 0.06; 0.06 (2)
vanco (0)
S . sanguis biovar 1 or 3 (1):
pen V 1 (1 )
amoxy (0)
ery (0)
rox (0)
clinda (0)
vanco (0)
S. vestibularis (2):
pen V (0)
amoxy 0.015 (1 )
ery 0.03 (1 )
rox 0.06; (1 )
clinda 0.06; 0.03 (1 )
vanco (0)
NB: No persisters were recorded in one isolate each of S. sanguis 
biovar 2 and S. qordonii
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Nos of strains 
with persisters
S. oralis (49):
b ) E—group
pen V 16; 8; 16; 4 (C8 III); 8; 8; 8; CO 4; 2; 1;
0.12; 0.12; 0.12; 0.12; (16)
amoxy 2; 2; 2 • 1 • Z.f l, (4)
ery 4; 4; 8; 8; _2; 0.12; 0.12; 0.06; 0.06; 0.06;
0.06; 0.03; 0.03; 0.015; 0.015 (15)
rox 8; 8; 2; 0.5; 0.25; 0.25; 0.25; 0.12; 0.12;
0.06; 0.03 (11 )
clinda 4; 2; 1; 0.5; 0.25; 0.25; 0.12; 0.12; 0.12; 0.12;
0.06; 0.06; 0.06 (13)
vanco (0)
S. mitis biovar 1 (5):
pen V (0)
amoxy 0.5 (1 )
ery 0.015 (1 )
rox 0.06 (1 )
clinda 0.06 (1 )
vanco (0)
S. mitis biovar 2 (12)
pen V 8; 4; 0.5; 0.12 (4)
amoxy 1; 0.25; 0.25 (3)
ery 0.25; 0.12; 0.12; 0.06 (4)
rox 2; 0.5; 0.25 0.12; 0.12 (5)
clinda 1; 0.25; 0.25 (3)
vanco 4 (1 )
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S. sanguis biovar 4 (2):
pen V 2 (1 )
amoxy (0)
ery 0.06 (1 )
rox 0.25 (1 )
clinda 0.25 (1 )
vanco (0)
S . qordoni i biovar 2 or 3 (4):
pen V 256; 16; 8 (3)
amoxy 1_6 (1 )
ery 8; 0.12 (2)
rox 1 (1 )
clinda 0.25 (1 )
vanco (0)
S. vestibularis (2):
pen V 2; 0.5 (2)
amoxy 2; 1 (2)
ery 0.06 (1 )
rox 0.12 (1 )
clinda (0)
vanco 2 (isolate no. C49 I) (1 )
144
10.3.3.2 Refractoriness of persisters to killing
Refractoriness to killing amongst persisters and persister en­
durance indices are shown in Tables 10.4-10.9 (according to 
species and antibiotic) in both the UE- and E-groups
Table 10.4 Persister refractory (PRI) and endurance indices 
(PEI) in streptococcal species according to principal B-lactam 
exposure groups (the PEI is based upon resistance breakpoint, 
RBP, concentrations)
a ) UE-group
Persister Persister Persister
Isolate Species MBC/strain refractory endurance
MBC ratio index (PRI) index (PEI)
Penicillin V : persisters in 6 strains , RBP 2.0.25 mg/1
H7 II S sanguis 4 1:0.25 4
H1 8 S. mitis 2 4:0.5 8
H22 S. mitis 2 4:2 2
H52 II S. sanguis 4 0.25:0.12 2
H64 II S. oralis 0.25:0.06 4
H53 III S. sanguis 1/3 1:0.5 2
Amoxycillin: persisters in 15 strains , RBP 2.0.25 mg/1
H4 S. mitis 1 0.5:0.12 4
H7 I S. mitis 2 1:0.06 17 4
H1 3 S. mitis 2 1:0.25 4
H1 9 S. mitis 2 1:0.5 2
H20 S. oralis 2:0.03 67 8
H43 S. mitis 1 0.06:0.03 2
1 45
H48 S. oralis 0.03;0.015 2
H52 II S. sanquis 4 0.5:0.25 2
H53 II s. oralis 0.03:0.015 2
H55 I s. oralis 0.03:0.015 2
H55 II s. mitis 2 4:0.5 8
H59 s. vestib. 0.015:0.007 2
H60 s. oralis 0.06:0.03 2
H63 II s. oralis 0.015:^0.007 >2
H64 II s. oralis 0.03:0.007 4
Erythromycin : persisters in 21 strains, RBP >_1 mg/1
H6 s. mitis 2 0.03:10.007 >4
H7 I s. mitis 2 1:0.12 8
H1 2 s. mitis 1 0.25:0.003 8
H1 3 s. mitis 2 2:1 2
H20 s. mitis 1 4:<0.007 >571
H21 s. mitis 1 0.03:10.007 >4
H26 s. mitis 1 0.03:10.007 >4
H40 s. mitis 1 0.03:10.007 > 4
H43 s. mitis 1 0.015:10.007 >2
H44 I s. oralis 0.12:0.015 8
H46 s. mitis 1 0.12:0.015 8
H49 s. oralis 0.03:10.007 >4
H50 I s. mitis 2 0.06:10.007 >9
H51 I s. mitis 2 0.03:10.007 >4
H52 I s. mitis 2 0.015:10.007 >2
H55 II s. mitis 2 8:0.12 7
H58 II s. oralis 0.03:0.015 2
H59 s. vestib. 0.03:10.007 >4
H61 I s. oralis 0.015:0.007 2
H61 II s. oralis 0.03:10.007 >4
H64 II s. oralis 0.03:0.015 2
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Roxi thromycin: persisters in 26 strains , RBP
H1 s. mitis 1 1 : 0.01 5 67
H4 s. mitis 2 0.015:0.007 2
H6 s. mitis 2 0.06:0.015 4
H9 s. oralis 0.03:^0.007 >4
H1 2 s. mitis 1 0.03:0.015 2
H1 3 s. mitis 2 8:4 2
H1 6 s. mitis 2 0.03:0.015 2
H20 s. mitis 1 8:0.06 133
H26 s. mitis 1 0.12:0.03 4
H43 s. mitis 1 0.06:0.03 2
H46 s. mitis 1 0.5:0.03 1 7
H48 s. oralis 0.12:0.03 4
H50 I s. mitis 2 0.06:0.03 2
H50 II s. mitis 2 0.03:0.015 2
H51 I s. mitis 2 0.06: <.0.007 >9
H52 I s. mitis 2 0.12:0.03 4
H52 II s. sanquis 4 0.06:0.015 4
H53 I s. mitis 2 0.03:0.015 2
H53 IV s. oralis 0.06:0.015 4
H54 II s. oralis 0.12:0.015 8
H55 I s. oralis 0.03:0.015 2
H55 II s. mitis 2 16:0.12 133
H56 I s. vestib. 0.06:0.03 2
H58 I s. oralis 0.03:0.015 2
H63 II s. oralis 0.06:0.015 4
H67 I s. mitis 2 0.06:0.015 4
Clindamycin: persisters in 28 strains, RBP 2.
H1 s. mitis 1 0.5:0.007 71
H6 s. mitis 2 0.03: <.0.007 >4
H7 II s. sanquis 4 0.6:0.015 4
H9 s. oralis 0.015:<0.007 >2
H1 3 s. mitis 2 0.03:<0.007 >2
1 47
4
0.25
8
0.5
H1 5 s. mitis 2 0.015: <.0.007 >2
H1 6 s. mitis 2 0.03:0.015 2
H1 8 s. mitis 2 0.03:0.015 2
H1 9 s. mitis 2 0.015:<0.007 >2
H20 s. mitis 1 8:0.03 266 8
H26 s. mitis 1 0.01 5: <.0.007 >2
H40 s. mitis 2 0.03:0.015 2
H44 II s. mitis 2 0.015:^0.007 >2
H46 s. mitis 1 0.12:0.015 8
H48 s. oralis 0.06:0.015 8
H51 I s. mitis 2 0.06:0.015 4
H52 I s. mitis 2 0.12:<^0.007 >17 0.12
H52 II s. sanquis 4 0.12:<0.007 >17 0.12
H53 IV s. oralis 0.015:^0.007 2
H55 I s. oralis 0.015:0.007 2
H55 II s. mitis 2 16:0.6 267 1 6
H56 I s. vestib. 0.03:0.015 2
H57 I s. oralis 0.03:0.015 2
H58 I s. oralis 0.06:0.03 2
H58 III s. oralis 0.03:0.015 2
H59 s. vestib. 0.06:0.015 2
H64 I s. mitis 2 0.03:0.015 2
H67 I s. mitis 2 0.06:0.03 2
* PEIs are only recorded when respective PRIs are >_1 0
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b ) E—group
Isolate Species
Persister 
MBC/strain 
MBC ratio
Persister 
refractory 
index (PRI)
Persister 
endurance 
index (PEI) *
Penicillin V : persisters in 26 strains, RBP 2.0.25 mg/1
C7 S. mitis 2 0.5:0.25 2
C8 I s. mitis 2 0.12:0.03 4
C8 III s. oralis 8:0.007 2667 32
C1 1 II s. oralis 32:0.5 64 1 28
C1 2 II s. mitis 2 16:0.03 533 64
C15 II s. qord. 2/3 2.256:2 2.1 28 >1024
C17 I s. oralis 0.12:0.3 4
C18 I s. gord. 2/3 16:0.12 133 64
C21 I s. oralis 16:2 8
C21 II s. oralis 8:0.5 1 6 32
C23 s. oralis 8:4 2
C24 II s. gord. 2/3 32:0.5 64 1 28
C25 II s. oralis 16:8 2
C27 I s. mitis 2 4:2 2
C30 S- oralis 4:2 2
C31 I s. oralis 0.12:0.06 2
C32 s. oralis 8:4 2
C34 s. oralis 8:2 4
C35 s. oralis 0.12:0.06 2
C43 s. oralis 1:0.5 2
C45 s. oralis 0.12:0.06 2
C46 I s. sanquis 4 2:1 2
C47 I s. oralis 4:2 2
C49 I s. vestib. 2:0.4 4
C49 II s. vestib. 0.5:0.25 2
C50 s. oralis 2:1 2
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Amoxycillin: persisters in 11 strains, RBP >.0.25 mg/1
C3 S. oralis 2:1 2
C7 s. mitis 2 1:0.5 2
C15 I s. mitis 2 0.5:0.03 1 7 2
C18 I s. qord. 2/3 >.16:0.12 2.133 64
C21 I s. oralis 2:1 2
C26 s. mitis 1 0.5:0.25 2
C27 II s. mitis 2 0.25:0.12 2
C43 s. oralis 2:1 2
C47 I s. oralis 1:0.5 2
C49 I s. vestib. 2:0.5 4
C49 II s. vestib. 1:0.12 8
Erythromycin : persisters in 24 strains, RBP 2.1 mg/1
C7 s. mitis 2 0.25:0.03 8
C8 I s. mitis 2 0.12:0.015 8
C8 III s. oralis 0.12:0.03 4
C9 s. mitis 2 0.06:0.015 4
C10 I s. oralis 8:4 2
C1 1 II s. sanquis 4 0.12:0.003 40 0.12
C12 III s. oralis 0.06:0.03 2
C13 I s. mitis 1 0.015:0.007 2
C16 II s. oralis 4:<0.007 2.571 4
C17 I s. oralis 0.12:0.03 4
C18 I s. qord. 2/3 0.25:0.007 36 0.25
C19 I s. oralis 0.03:0.015 2
C19 II s. oralis 8:0.03 267 8
C20 s. mitis 2 0.12:0.03 4
C21 I s. oralis 8:4 2
C24 II s. qord. 2/3 8:4 2
C32 s. oralis 2.8:2 2.4
C29 I s. oralis 0.06: <.0.007 2.9
C41 s. oralis 0.015: <.0.007 2.2
C44 s. oralis 0.03:^0.007 4
150
C47 I S. oralis 0.015:10.007 2
C48 II s. oralis 0.06:10.007 l9
C49 I s. vestib. 0.12:0.007 17 0.1
C50 s. oralis 0.06:10.007 2.9
Roxithromycin: persisters in 20 strains , RBP >2 mg/1
C2 s. mitis 2 2:0.03 67 1
C7 s. mitis 2 0.5:0.06 8
H00a s. mitis 2 0.12:0.015 8
C8 III s. oralis 0.25:0.06 4
C9 s. mitis 2 0.12:0.015 8
C1 1 I s. sanquis 4 0.25:0.03 8
C13 I s. mitis 1 0.06:0.03 2
C16 II s. oralis 4:0.015 266 2
C1 7 II s. oralis 0.5:0.06 8
C18 I s. qord. 2/3 1:0.12 8
C19 II s. oralis 1 8:0.12 2.67 4
C20 s. mitis 2 0.25:0.06 4
C21 I s. oralis 8:4 2
C29 I s. oralis 0.12:0.015 8
C31 II s. oralis 0.25:0.12 2
C38 s. oralis 0.03:0.015 2
C44 s. oralis 0.12:0.015 8
C47 I s. oralis 0.06:0.03 2
C49 II s. vestib. 0.12:0.03 4
C50 s. oralis 0.25:0.03 8
Clindamycin: persisters in 19 strains, RBP 2.1 mg/1
C6 s. oralis 2:0.03 67 2
C7 s. mitis 2 2:0.03 67 2
C8 I s. mitis 2 0.25:0.03 8
C8 II s. oralis 0.25:0.06 4
C8 III s. oralis 1:0.03 33 1
C9 s. mitis 2 0.5:0.015 33 0.5
151
0.5C1 1 I S. sanquis 4 0.5:0.03 17
C1 1 II s. oralis 0.25:0.06 4
C1 4 s. mitis 1 0.06:0.015 4
C1 6 II s. oralis 4:^0.007 2.57
C1 7 II s. oralis 0.12:0.03 4
C18 I s. qord. 2/3 0.25:0.06 4
C1 8 II s. oralis 0.12:0.06 2
C1 9 II s. oralis 8:0.06 133
C23 s. oralis 0.12:0.03 4
C29 I s. oralis 0.06:0.007 9
C41 s. oralis 0.06:0.03 2
C44 s. oralis 0.06:0.03 2
C50 s. oralis 0.12:0.015 8
Vancomycin: persisters in 2 strains, RBP 2.8
C7 s. mitis 2 4:0.5 8
C49 I s. vestib. 2:1 2
* PEIs are only recorded when PRIs are >J 0
[Reminder: PRI and PEI ratios:-
PRI = lowest concentration at which persisters are eliminated 
divided by strain MBC (a measure of refractoriness, see 
Section 10.2.2.1)
PEI = persister MBC divided by NCCLS resistance breakpoints 
(relates to achievable antibiotic blood levels, see 
Section 10.2.3.2)]
Refractoriness was common amongst persisters and the majority 
fell in the range of PRI values of 2-9 in both the UE-group and 
E-group (see above). In some strains, PRIs were found to be very 
high. Levels in the region of 500-times the MBCs of 4 strains
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were required to eliminate persisters completely within the 
prescribed period of 24 h (one of which originated from isolate 
H20, the only one in the UE-group) and in one organism (isolate 
C8 III), a concentration of more than 2500 times its MBC was 
required. In this particular strain, and most others, the 
original MBCs were low and the PEIs were therefore also con­
siderably lower. This trend applied to all persisters in the UE- 
group where values of corresponding PEIs (which ranged from 0.12- 
16) dropped substantially from their PRI values of 17-267 (Table 
10.3a). However, this did not apply to all persisters in the E- 
group (Table 10.3b). Examples of high PRIs and PEIs are strains 
C8 III and C15 II which had PRIs and PEI values of 2337 (PRI) and 
32 (PEI), and >_T28 (PRI) and >1 024 (PEI), respectively, against 
penicillin V (see Table 10.4 above)
Of the total number of times strains exhibiting persisters to one 
or more of the six antibiotics tested (198), refractoriness was 
observed 36 times (18.2%; see Table 10.7 and Table 10.8). The 
frequency of refractoriness was 24 out of 103; 23.5% in the E- 
group and 12 out of 96; 12.5% in the UE-group (Table 10.8 and 
Table 10.9)
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Table 10.5 Prevalence of persisters and refractory persisters 
(with PRIs 2.4 and PRIs 2.1 0) by species in the UE- and E-groups
UE-group 
No. %
E—group
No. %
S. oralis 26
Potential
maximum no. 1 56
persisters
Persisters 28 17.9%
Refractory
persisters
a) PRI l 4 1 2 7.7% (42.8%)
b) PRI >10 1 0.6% (3.6%)
49
294
59 20%
31 10.5% (52.5%)
11 3.7% (18.6%)
S. mitis 1 15
Potential
maximum no. 90
persisters
Persisters 19
Refractory
persisters
a) PRI 2.4 1 4
b) PRI 2.1 0 6
2 1 .1%
15.5% (73.7%) 
6.7% (31.6%)
5
30
4 13.3%
1 3.3% (25%)
1 3.3% (25%)
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UE--group E--group
NO. % NO. g ,o
S. mitis 2 18 12
Potential
maximum no. 108 72
persisters
Persisters 37 34.3% 20 27.8%
Refractory
persisters
a) PRI l4 17 15.7% (45.9%) 16 22.2% (80%)
b) PRI >_10 4 3.7% (10.8%) 4 5.6% (20%)
S. sanguis 4
Potential
2 2
maximum no. 1 2 12
persisters
Persisters 6 50% 4 33.3%
Refractory
persisters
a) PRI >_4 4 33.3% (66.7%) 3 25% (75%)
b) PRI >_10 1 8.3% (16.7%) 2 16.7% (50%)
S. vestibularis 2 2
Potential
maximum no. 12 1 2
persisters
Persisters 5 41 . 7% 7 58.3%
Refractory
persisters
a) PRI 2.4 1 8.3% (20%) 4 33.3% (57.1%)
b) PRI >10 0 0 0 1 8.3% (14.3%)
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UE—group
No. %
E—group
No. %
S. sanguis 1/3 
Potential 
maximum no. 
persisters 
Persisters 
Refractory 
persisters
a) PRI 2.4
b) PRI >10
0
0
16.7%
0
0
0 0%
0
0
S. qordonii 2/3 1
Potential
maximum no. 6
persisters 
Persisters 0
Refractory 
persisters
a) PRI >4 0
b) PRI >10 0
4
24
8 33.3%
6 25% (75%)
5 20.8% (62.8%)
S. mitis biovar 2 had the highest number of persisters in both 
UE- and E-groups (Table 10.5). With UE- and E-groups combined, 
the highest proportion of persisters were refractory amongst S , 
mitis biovar 1 strains (15 out of 23; 65%). S. mitis biovar 2 and 
S. oralis followed with 59% (33 of 56) and 49% (43 of 87) respec­
tively
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Table 10.6 Refractoriness of persisters with PRIs >10 exhibited 
against different antibiotics
Total
Species Pen V Amoxy Ery Rox Clinda PRIs >10 Total
UE E UE E UE E UE E UE E UE E pers's (%*)
So # 0 3 1 0 0 2 0 2 0 4 1 1 1 87 (14)
Sm 1 0 0 0 1 1 0 3 0 2 0 6 1 23 (30)
Sm 2 0 1 1 0 0 0 1 1 2 2 4 4 57 (14)
Ss 4 0 0 0 0 0 1 0 0 1 1 1 2 1 0 (30)
Sv 0 0 0 0 0 1 0 0 0 0 0 1 1 2 (8.3)
Ss 1/3 1 0 0 0 0 0 0 0 0 0 1 0 1 (0)
Sg 2/3 0 3 0 1 0 1 0 0 0 0 0 5 8 (63)
0 7 2 2 1 5 4 3 5 7 1 2 24 198
* Total no. of persisters (pers's) with PRIs >10 as % of no . of
pers's per species (eg. for So: [1 + 11] divided by 87 = 14%)
# So = S . oralis, Sm 1 = s . mitis biovar 1 , Sm 2 = S. mitis
biovar 2, Ss 4 = S. sanguis biovar 4, Sv = S. vestibularis, 
Ss 1/3 = S- sanguis biovar 1 or 3 and Sg 2/3 = S. qordonii 
biovar 2 or 3
Although numbers were small, a high proportion of S. qordonii 
strains (5 of 8; 63%) showed refractory persisters while figures 
for the more common species varied from 14-30%. The only persist­
ers to show a persister endurance index (PEI) greater than the 
PRI value (Table 10.4) were two S. qordonii biovar 2 or 3 strains 
(isolates C 15 II and C 24 II) and a single S oralis isolate (C 
11 II). All three showed higher PEIs than PRIs to penicillin V 
and could be more difficult to control (kill) with usual blood 
concentrations of antibiotic (see explanation of terms after 
Table 10.4)
High index refractoriness was demonstrated 24 times against the 
six antibiotics tested in the E-group - double the number from 
the UE-group (Tables 10.6, 10.7 and 10.8). The high frequency of 
PRIs >_10 in the E group was particularly pronounced in S. oralis 
and S. qordonii while a reverse trend was seen in S. mitis I 
strains (Table 10.9). Of agents to which Streptococcus species 
showed this phenomenon in the former group, fewest were refrac­
tory to amoxycillin (2) and roxithromycin (3) while five were 
refracory to erythromycin and seven each to clindamycin and 
penicillin V. The latter antibiotic also elicited the highest 
refractoriness (PRI of 2667) amongst the oral streptococci tested 
and was of a persister in S. oralis in the E-group. After clin­
damycin (observed 5 times), roxithromycin had the second highest 
refractoriness develop against it in the UE-group (4 times) 
(Table 10.6 and Table 10.7). Amoxycillin, the second lowest after 
vancomycin, had two refractory persisters (PRIs >10) and eryth­
romycin only one in contrast to the E-group, where erythromycin 
was second highest (5 times) only to penicillin V (7) and clin­
damycin (7). As noted elsewhere above, certain persisters of iso­
lates exhibited refractoriness to more than one agent
Sixty-six strains have the potential of producing the persister 
phenomenon in a total of 396 instances against the six an­
tibiotics in the UE-group. In this group, persisters were found 
in 12 isolate-antibiotic interactions giving a percentage value 
of 3.0. The corresponding figures in the E-group were: 74 strains 
yielding 24 out of a potential 444 positive tests to give a per­
centage of 5.4 (Table 10.8)
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UE-group (66 strains) E-group (74 strains)
Table 10.7 Persisters and persister refractory indices (PRIs)
related to antibiotics
Persisters PRI 2.10 (%) Persisters PRI 2.1 0
pen V 6 (9%) 0 (0%) 26 (35%) 7 (9%)
amoxy 1 5 (23%) 2 (3%) 11 (15%) 2 (3%)
ery 21 (32%) 1 (2%) 25 (34%) 5 (7%)
rox 26 (39%) 4 (6%) 20 (27%) 3 (4%)
clinda 28 (42%) 5 (8%) 19 (26%) 7 (9%)
vanco 0 (0%) 0 (0%) 1 (1%) 0 (0%)
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Table 10.8 Prevalence of persisters and refractory persisters
(with PRIs 2JO) in UE- and E-groups against 6 antibiotics
Strains
Potential maxi­
mum number of 
persisters
Persisters
Refractory 
persisters 
(PRIs >10)
UE—group 
No. (%)
66
396
96 (2 4 .2 )
12 (3 .0 )* (1 2 .5 )#
E-group
No. (%)
74
444
102 (2 2 .9 )
24 (5 .4 )* (2 3 .5 )#
* Percentage of the potential maximum number of persisters in 
66 and 74 strains in the UE- and E-groups respectively which 
show refractory persisters
# Percentage of persisters to show refractoriness
1 6 0
Table 10.9 Contribution of different Streptococcus species to 
produce persisters
UE--group E-group
Species No. % * NO % *
S. oralis 28 7.1 59 13.3
S. mitis 1 19 00 4 0.9
S. mitis 2 37 9.3 20 4.5
S. sanquis 4 6 1 .5 4 0.9
S. vestibularis 5 1 .3 7 1 .6
S. sanquis 1/3 1 0.2 0 0
S. qordonii 2/3 0 0 8 1 .8
S . sanquis 2 0 0 0 0
Totals 96 24.2% 1 02 23.0%
Potential 396 444
maximum no. 
of persisters
Percentage of antibiotic-isolate interactions that produced 
persisters out of the potential maximum number of persisters
S. oralis produced the greatest proportion of persisters in the 
E-group (59 of 444; 13.3%) compared with 7% in the UE-group. The 
two S. mitis biovars produced the greatest proportion in the UE- 
group with 4.8% and 9.1%, respectively
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10.4 Discussion
10.4.1 Genotypic tolerance and persisters in UE— and E-groups
Genotypic tolerance, according to one of the less stringent 
definitions (MBC/MIC ratios >10), was not identified amongst iso­
lates from the UE-group. This applied equally to all isolates in 
the E-group, except for four S. oralis strains whose tolerance 
ratios ranged from >16-66.6 (Table 10.1)
S. oralis was also the commonest species amongst which persisters 
developed (87 out of 226; 38%) (Tables 10.4-6 and 10.9) and in 
which persisters were refractory (43 out of 87; 49.4%) (Table 
10.5). However for this species, the highly refractory (PRI >10) 
proportion of all persisters (12 of 87; 14%) was smaller than 
those of S. mitis biovars 1 and 2 (both 30%), as well and S . qor— 
donii biovar 2 or 3 (63%) (Table 10.4 and Table 10.6)
The occasions when viridans streptococci in the UE-group produced 
persisters to the six antibiotics tested were very similar in 
frequency (96 out of 396; 24.2%) to those in the E-group (102 of 
444; 22.9%). However, refractoriness with PRI >10 in persisters 
in the UE-group (12 of 96; 12.5%) was statistically lower than in 
the E-group (24 of 102; 23.5%) (p<0.05, chi-squared test with 
Yates modification). These findings suggest that prior exposure 
to 8-lactam antibiotics may select for refractoriness in persist­
ers with PRIs >10. Why previous administration of 8-lactam an­
tibiotic should select for persister refractoriness against non- 
6-lactam antibiotics is, however, not clear. Not surprisingly, 
PEIs show very similar trends to those of PRIs >10
As noted, there are isolates in the study with a high degree of 
tolerance to antibiotics. The ability of antibiotic agents to 
alone routinely contain, control and cure IE in a patient without
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the participation of the host's own intact defence system, would 
appear unlikely. But this particular property to kill target bac­
teria is still regarded as being essential (Glauser et al, 1983; 
Coulter et al, 1990) and critical for therapeutic success (Powley 
et al, 1989). However, whether the need to kill persisters is 
required in the clinical situation has not been addressed in the 
literature and few routine diagnostic laboratories report on the 
presence of persisters, even in patients with IE
Some isolates which display tolerance appear to be what Holloway 
et al (1980) termed "endurant" (ie. with MICs in the susceptible 
and not resistant ranges). In this dissertation, the term en­
durance index (El) was coined to describe endurant strains with 
MBCs of penicillin V and amoxycillin >_2.5 mg/1. Strains with Els 
appreciably greater than 1 would theoretically be more difficult 
to eradicate during therapy than non-tolerant strains or endurant 
strains with MBCs below the MBC breakpoint of 2.5 mg/1. Only two 
isolates had Els to penicillin V or amoxycillin of >1 (Table 
10.1). Both these isolates were in the E-group and had Els of 2 
(S. mitis 2) and 64 (S. oralis) while one of the two isolates 
with Els of 0.5 was in the UE-group and the other in the E-group 
(both were S. oralis strains). The clinical relevance of Els is, 
at present, not known
Endurance amongst persisters with PEIs of >1 in strains with PRIs 
of >10 (Table 10.4) occurred 7 out of a potential maximum of 396 
antibiotic-strain interactions (from 12 strains) in the UE-group 
(1.8%) as opposed to 16 out of 444 antibiotic-strain interactions 
(3.6%) from 21 strains in the E-group. The PEIs in the E-group 
were considerably higher with a range of 0.12->1024 and a mean of 
74.9, compared with a range of 0.12-16 and a mean of 4.5 in the 
UE-group
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10.4.2 B-Lactam candidates for IE prophylaxis based upon 
susceptibility, tolerance and the frequency of 
persisters
With regard to the choice of agents for IE prohylaxis following 
dental procedures, it appears that when the presence of persist­
ers is considered as a criterion on its own, penicillin V would 
be more appropriate than amoxycillin in individuals not exposed 
to antibiotics during the previous three months, while amoxycil­
lin would be the preferred agent in individuals exposed to B- 
lactam agents (Table 10.7). No clear trend emerged, however, when 
genotypic tolerance was considered as a criterion for chosing be­
tween penicillin V and amoxycillin as candidates for prophylaxis 
(Table 10.1)
Genotypic tolerance was uncommmon in the present study and was 
less frequently found than in some other studies (Harder et al, 
1974; Pulliam et al, 1979 and Holloway et al, 1980). Many ex­
amples of tolerance in strains causing endocarditis involve S . 
mutans isolates (Harder et al, 1974), or nutritionally defective 
viridans streptococcal isolates which do not feature in the 
present study. It should also be noted that in some of these 
studies (Roberts et al, 1979) a definition of tolerance involved
a 10:1 MBC:MIC ratio rather than a 32:1 ratio (Pulliam et al, 
1979; Holloway, Dankert and Hess, 1980). Tolerant strains have 
also been isolated from the blood of patients following dental 
procedures involving the gingival sulcus (Pulliam et al, 1979)
It is noteworthy that there was poor correlation between strains 
which were phenotypically tolerant during the selection process 
and those that were subsequently found to be genotypically 
tolerant (data not shown)
10.4.3 Activity of candidate non—6—lactam agents of IE 
prophylaxis based on genotypic tolerance and the 
presence of persisters
It is interesting to examine the comparative activities of the 
various agents using MIC 50 and MBC 50 data independently (B- 
lactam and vancomycin data are included here for comparative 
purposes). The ranking order of MIC 50 values of UE-group volun­
teers from most to least active using dosage size (mg/1) had 
clindamycin and erythromycin as the most active candidates, fol­
lowed by roxithromycin, amoxycillin, penicillin V and vancomycin. 
For E-group isolates, the most active were erythromycin, clin­
damycin, roxithromycin, penicillin V together with amoxycillin, 
and lastly vancomycin. However, the picture altered slightly 
using UE-group MBC 50 values: here erythromycin headed the list 
followed by clindamycin, roxithromycin paired with amoxycillin, 
then penicillin V and finally vancomycin. Clindamycin and eryth­
romycin tie as the apparently most effective according to MBC 50s 
for the E-group, then follow roxithromycin, amoxycillin and 
penicillin V and vancomycin to take up the lowest rankings yet 
again
In Table 10.2, numbers of strains with MBC/MIC ratios 2.4, 2.10 or 
2_32 (degrees of genotypic tolerance) are presented for each can­
didate agent. The UE-group produced the smallest number and all 
were of the lowest magnitude (MBC/MIC ratio 2.4): most were 
genotypically tolerant to erythromycin (4 strains), none to 
amoxycillin and only one each to roxithromycin, penicillin V and 
vancomycin. Genotypic tolerance amongst E-group strains was 
markedly more pronounced and occurred at all three possible 
MBC/MIC ratios. Again, genotypic tolerance against erythromycin 
was most common (8 of 26 strains, 30.7%) but none was detected in 
the study against vancomycin. Of the macrolide and clindamycin 
trio, genetic tolerance was least common against roxithromycin (4
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of a 26 strain total, 15.4%) and all were at the lower MBC/MIC 
genetic tolerance ratio
As noted previously, all strains were exposed to each antibiotic 
agent and the appearance of persisters was noted and their MBCs 
determined (Tables 10.3 and 10.4). The non-B-lactam agent to 
produce the greatest number of persisters amongst UE-group 
strains was clindamycin (a total of 28 of all strains and 37% of 
75 persisters) and the least erythromycin (21, ie. 28%). (No per­
sisters developed against vancomycin). Ranks were almost 
reversed in the E-group. Clindamycin had the least (19, 29%) and 
erythromycin the most (24, 37%) persisters. (It is noteworthy 
that vancomycin had 2 persisters, or 3%, develop against it from 
E-group strains)
In all four of the initial rankings above, the macrolides and 
clindamycin nominally appear to give the best results. On the 
other hand, with regards to persisters, the two 8-lactam agents 
and vancomycin would appear to be superior (the exception being 
penicillin V with 26 persisters amongst E-group strains)
Although there appeared to be a variation between the ability of 
erythromycin, roxithromycin and clindamycin to produce persisters 
when the exposure groups were dealt with separately (a total of 
75 occurrences in the UE-group and 65 in the E-group), there was 
little difference between these agents when data from both ex­
posure groups was combined. The frequency of persister develop­
ment for erythromycin was 32.1% (45 of 140), roxithromycin 32.8% 
(46 of 140) and clindamycin 34% (47 of 140)
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10.4.3.1 Relative candidatures of roxithromycin and vancomycin 
as agents of IE prophylaxis
As noted elsewhere, roxithromycin has superior pharmacokinetics, 
comparable antibacterial activity to erythromycin, the smallest 
number of strains to show genetic tolerance and a similar general 
overall propensity to erythromycin and clindamycin to produce 
persisters. It appears to be marginally better than erythromycin 
in the latter regard in those with prior 6-lactam exposure. It 
deserves further attention as a candidate for routine IE 
prophylaxis
When all available criteria are assessed, vancomycin emerges as a 
very strong (the best) IE prophylaxis candidate because of the 
relatively few persisters which develop and the markedly rare ap­
pearance of tolerance to this agent. Although the MBCs of van­
comycin are higher than is the case with other antibiotics, blood 
levels are easily obtainable
More information is required on vancomycin concentrations ob­
tainable within the oral and plaque environments, and whether 
"free" salivary vancomycin would increase the development of 
resistance amongst oral streptococci - as it appeared to do in 
the case of unencapsulated penicillin V (dosage form) in a study 
of Heimdahl and Nord (1979) - is open to speculation. The use of 
this agent simply for prophylaxis purposes is not justified in 
the light of its possible toxic side-effects and its status as a 
"reserve" antibiotic in chemotherapy
1 6 7
C h a p te r  11
EFFECT OF PENICILLIN G SELECTION ON ORAL STREPTOCOCCI FROM 
ANTIBIOTIC EXPOSED AND NON-EXPOSED INDIVIDUALS IN AN
IN VITRO MODEL
11.1 Introduction
As discussed in earlier chapters, viridans streptococci are in­
digenous to the oral cavity and important aetiological agents of 
infective endocarditis (IE) (Roberts et al, 1979; AHA Report, 
1981; Cotran et al, 1989; Hall and Heimdahl, 1989). It was also 
indicated in Chapter 5 that oral streptococci are generally 
regarded as being susceptible to penicillin (Hall and Heimdahl,
1989) , but resistant strains have been isolated from both the 
oral cavity (Longman et al, 1991) and blood (Hess et al, 1983) of 
IE-susceptible patients
Antibiotic use is known to select for bacterial resistance in 
oral streptococci (Southall et al, 1983; Harrison, Stross et al, 
1985; Herbert et al, 1988; Smith et al, 1989; Maskell et al,
1990) . Antibiotic-resistant strains emerge readily in individuals 
with either recent or frequent exposure (Southall et al, 1983; 
Harrison, Rubin et al, 1985; Woodman et al, 1985). As discussed 
in Chapter 5, resistance may be detected in populations of oral 
bacteria shortly after administration of antibiotics to patients 
previously unexposed to such compounds (Leviner et al, 1987). Ac­
quisition of resistant strains may, however, occur without direct 
antibiotic exposure especially in hospital settings (Leviner et 
al, 1984), and persons without a history of exposure to an­
tibiotic are known to carry small numbers fo antibiotic-resistant
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bacteria as part of their normal oral flora (Longman et al, 1991; 
Woodman et al, 1985). It has also been shown that bacteraemia 
with penicillin-resistant oral streptococci - and IE - may follow 
amoxycillin prophylaxis in a rabbit model (Longman et al, 1992)
Recently Hall et al (1993) demonstrated that penicillin V- and 
amoxycillin-sensitive viridans streptococci and anaerobic bac­
teria survive in the blood circulation following prophylaxis with 
those antibiotics. The present study was designed to determine 
the identity and penicillin V and amoxycillin susceptibility, as 
well as susceptibility to other candidate antibiotics, of 
viridans streptococci from dental plaque which survive the 
presence of penicillin at levels which would exert /3-lactam ac­
tivity equivalent to those likely to be obtained in blood during 
IE-prophylaxis. As described in Chapter 8, the source of strep­
tococci in this in vitro model was dental plaque from individuals 
who had had or without prior antibiotic exposure. Penicillin G 
was used for the in vitro selection process not only as a com­
promise candidate to simulate the effect of penicillin V and 
amoxycillin prophylaxis, but also as this antibiotic is most of­
ten the single agent of choice in IE therapy. In an extention of 
the study, gentamicin which is known to act synergistically with 
/3-lactam agents, was used to determine whether this combination 
will modify the effect of penicillin G alone on the survival of 
oral streptococci
11.2 Design of an in vitro model of IE prophylaxis with 13-lactam 
antibiotics
The in vitro model described in this dissertation was designed to 
mimic IE prophylaxis using /3-lactam antibiotics and the selection 
pressure prophylaxis may exert on oral streptococci. Because of 
cost considerations, penicillin G was used as a surrogate 8-
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lactam agent to obviate a study using both amoxycillin and 
penicillin V (see last paragraph above)
This model was described in full in Chapter 8 but, briefly, it 
entails the sampling of plaque material from the teeth of two 
groups of individuals. One group represented persons recently ex­
posed to 8-lactam antibiotics and the second group comprised in­
dividuals who had not received such agents during the preceeding 
three months. Plaque specimens were inoculated into broth media 
containing 0.1 and 1.0 mg/1 penicillin G, as well as into broth 
containing 0.125 mg/1 penicillin G plus 5 mg/1 gentamicin. After 
overnight incubation, these selection broth cultures were subcul­
tured onto blood agar plates for single colonies. Representative 
colonies on the plates were selected for susceptibility evalua­
tion against penicillin V and amoxycillin and the four other an­
tibiotics covered in Chapter 9. Susceptibility assessment in­
cluded MIC and MBC determinations and the demonstration of 
tolerant strains and strains yielding persisters
11.3 Results
11.3.1 Patterns observed following different penicillin G 
selection procedures
The distribution of viridans streptococci isolated from dental 
plaque of individuals who were either receiving 8-lactam an­
tibiotics (E-group) or who were not recently exposed to these 
agents (UE-group), and their penicillin V and amoxycillin MICs 
and MBCs following in vitro selection by penicillin G or penicil­
lin G plus gentamicin, are shown in Table 11.1. It is clear that 
in vitro exposure to the two concentrations of penicillin not 
only permitted the survival of strains with penicillin V and 
amoxycillin MBCs greater than the equivalent concentrations of
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penicillin G in broth as expected (phenotypic tolerance) (66 of 
144; 47% and 88 of 140; 63% respectively), but also failed to 
destroy plaque bacteria that were refractory to killing at 
penicillin concentrations appreciably higher than their MICs and 
MBCs (genetically-based resistance)
11.3.2 Effect of gentamicin in penicillin G selection broth
Survival of strains of viridans streptococci with penicillin V 
and amoxycillin MICs and MBCs both higher and lower than the 
equivalent selection concentration of penicillin G also occurred 
in the presence of gentamicin (Table 11.1)
The addition of gentamicin to 0.125 mg/1 penicillin G did not ap­
pear to affect, to any great extent, the selection of isolates 
with MICs greater than the selection concentration of penicillin 
G in the case of penicillin V, ie. the selection of strains 
resistant to this antibiotic with MICs H).125 mg/1 (12 out of 19; 
63% for selection in penicillin G only, as opposed to 29 of 54; 
54% with p=0.66, chi-squared test with Yates modification). 
However, in the case of amoxycillin, the addition of gentamicin 
appeared to have made a significant difference in the survival of 
resistant streptococci (MICs _>0.25 mg/1) (11 of 19; 58% vs. 10 of 
54; 19%, p=0.003; chi-squared test, Yates modification)
The corresponding figures with regard to MBCs are 14 of 19 (74%) 
and 36 of 54 (67%) for penicillin V at the penicillin G-only 
0.125 mg/1 selection concentration, and at the same selection 
concentration plus gentamicin, respectively. The difference is 
not statistically significant. With regard to amoxycillin, 
however, the proportions of resistant to susceptibile 
(phenotypically tolerant) isolates according to MBCs at the 0.125 
mg/1 penicillin G-only selection concentrations are 12 of 19
1 71
(63%) vs 10 of 54 (19%) (p<0.001; chi-squared test, Yates
modification)
An interesting observation is that the effect of penicillin G at 
the concentration 0.125 mg/1 plus gentamicin compared with that 
of penicillin G only at 1.0 mg/1 on amoxycillin MBC patterns was 
very similar in both the E-group and UE-group. The proportion of 
resistant to phenotypically tolerant strains in the UE-group was 
6 out of 45 (13.3%) vs 2 out of 12 (16.7%), and 4 of 9 (44.4%) vs
23 of 55 (41.8%) respectively in the E-group. The differences 
were clearly not significant. However, as mentioned previously, 
there were statistically significant differences between both the 
amoxycillin MICs and MBCs when selection by the antibiotic com­
bination was compared with penicillin G alone at the 0.125 mg/1 
level. These differences were, however, comfined to the UE-group
With regard to penicillin V, the patterns after selection at 
penicillin G 0.125 mg/1 plus gentamicin and with penicillin G 
alone (0.125 mg/1) are similar, as indicated earlier. It is in­
teresting that in the E-group the penicillin V patterns were 
similar when selection at 1.0 mg/1 penicillin G was compared with 
selection in penicillin 0.125 mg/1 plus gentamicin. This was, 
however, not the case when the corresponding penicillin V pat­
terns in the UE-group were compared (p=0.003; chi-squared, Yates 
modification)
In summary, these comparisons suggest a modifying effect on sur­
vivors of penicillin G plus gentamicin selection with regard to 
amoxycillin susceptibility which was only convincingly shown in 
the UE-group. But a similar effect based upon penicillin V sus­
ceptibility was not demonstrated, not even in the UE-group (MICs:
24 out of 45; 53% vs 5 out of 9; 56% and MBCs: 31 out of 45; 69%
vs 7 of 9; 78%)
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11.3.3 Comparison of MIC and MBC activities of penicillin V 
and amoxycillin
When the MIC and MBC findings in Table 11.1 are studied it is 
clear that amoxycillin exhibited greater activity against 
viridans streptococci than penicillin V. For example, at the MIC 
level of <0.125 mg/1, 73 out of 140 strains (52%) were inhibited 
by amoxycillin compared with 46 of 140 (33%) by penicillin V 
(p<0.002, chi-squared test, Yates modification) while the cor­
responding figures for MBC values were 70 of 140 (50%) for 
amoxycillin as opposed to 34 of 140 (24%) for penicillin V 
(p<0.00002). Furthermore, when the E- and UE-groups were con- 
pared, a larger number of isolates had MBCs >_0.125 mg/1 in the E- 
group compared with the UE-group (58 of 74; 78% and 48 of 66; 
73%, respectively, in the case of penicillin V while the 
amoxycillin figures were 51 of 74; 69% vs 19 of 66; 29%). It is, 
none-the-less, clear that the difference in the bactericidal ac­
tivity between penicillin V and amoxycillin was much more evident 
in the UE-group (48 of 66; 73% vs 19 of 66; 29% and p=0.000001; 
chi-squared, Yates correction). As expected, very similar trends 
were shown when breakpoints were used (see Tables 11.4a and 
11.4c). Interestingly, the difference in bacteriostatic activity 
between penicillin V and amoxycillin following selection in 
penicillin G only (Table 11.4b) was not as marked as was the case 
when gentamicin was added to penicillin G in the selection proce­
dure (Table 11.4c)
Amoxycillin also appeared to be more active than penicillin V, 
especially in the UE-group, when the individual species (S . 
oralis, S. mitis I, and S. mitis II) were compared (Tables 11.3a, 
11.3c, 11.4a, 11.4c). An interesting observation is demonstrated 
in Tables 11.5a and 11.5b where amoxycillin was shown to be more 
active than penicillin V at the MIC 50/MBC 50 levels but the
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trend was reversed at the MIC 90/MBC 90 levels
Not only was amoxycillin more active than penicillin V overall, 
but when the penicillin V and amoxycillin MICs of individual 
strains were compared, a good correlation was obtained 
(correlation co-efficient, 0.87). The few deviations from this 
excellent correlation occurred mainly in the strains with higher 
MICs/MBCs (see Tables 11.5a and 11.5b)
11.3.4 Exposure to two penicillin G concentrations in broth
After the 24 hour exposure at 37 degrees Celcius to the higher 
concentration of penicillin G in broth, 27 strains out of 67 
(40%) had penicillin V MBCs >_1 .0 mg/l while the remaining 40 
strains (60%) survived selection despite having MBCs of <_1 .0 mg/l 
penicillin V (Table 11.1). The amoxycillin figures were 25 out of 
67 (37%) and 42 of 67 (63%), respectively. Following selection in 
0.125 mg/l penicillin G broth cultures (excluding the survival of 
isolates exposed to the addition of 5 mg/l gentamicin), 14 out of 
19 surviving strains (74%) had penicillin V MBCs >_0.125 mg/l 
(corresponding figures for amoxycillin were 12 out of 19; 63%).
Selection at 0.125 mg/l penicillin G yielded fewer isolates (6 of 
19; 32%) with penicillin V MBCs . 0 mg/l compared with 27 out of 
67 (40%) at the 1.0 mg/l penicillin G selection level. The cor­
responding figures for amoxycillin were 4 of 19 (21%) and 25 of 
67 (37%), respectively, at the low and high selection concentra­
tions
11.3.5 Selection in penicillin G broth of strains with high 
MBC levels: comparison between E-group and UE-group 
isolates
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11.3.5.1 Comparison between E-group and UE-group according to 
individual selection procedures
A clear trend showing a higher proportion of isolates with 
penicillin V and amoxycillin MBCs >_1 .0 mg/1 in the E-group com­
pared with the UE-group, was evident following the various selec­
tion procedures (Table 11.1). This finding applies to the higher 
selection concentration (25 of 55; 45%) in the E-group vs 2 of 12 
(17%) in the UE-group (p=0.03) for penicillin V and 23 of 55 vs 2 
of 12 in the case of amoxycillin (not significant). However, at 
the lower penicillin selection concentration, 5 of 10 (50%) in
the E-group had MBCs >1.0 mg/1 as opposed to the 1 of 9 (11%) in 
the UE-group. The respective amoxycillin figures were 3 out of 10 
(30%) and 1 of 9 (11%). The numbers in this comparison are too 
low for statistical analysis. When the corresponding figures in 
the penicillin G (0.125 mg/1) plus gentamicin selection broth 
were compared, the difference between the E- and UE-groups ac­
cording to previous antibiotic exposure was significant (3/9 and 
33% vs 3/45 and 7% giving a p-value of 0.05 (Fisher Exact test). 
THe corresponding figures for amoxycillin were 2 of 9 (22%) as
opposed to 1 of 45 (2.2%)
11.3.5.2 Comparison between E-group and UE-group according to 
the two penicillin G—only selection procedures
Comparison of resistance at MBCs _>1 •0 mg/1 according to the two 
penicillin G only selection procedures (Table 11.1) showed that 
more strains in the E-group had penicillin V MBCs H .0 mg/1 than 
in the UE-group (30/65 vs 3/21; p<0.02, chi-squared test with
Yates modification). For amoxycillin, statistical analysis indi­
cates a difference which approaches significance; the correspond­
ing figures being 26/65 vs 3/21; p=0.06 (chi-squared test, Yates 
modification)
11.3.5.3 Comparison according to all selection procedures 
combined
When the UE- and E-groups are compared (Table 11.1), considering 
all the selection procedures, significantly more strains had MBCs 
>J . 0 mg/1 antibiotic for both penicillin V and amoxycillin in the 
E-group compared with the other (33/74 vs 6/66; p<0.00001 and
28/74 vs 4/66; p<0.00002)
11.4 Effect of previous B—lactam antibiotic exposure on 
streptococcal species
11.4.1 Distribution of streptococcal species according to 
previous antibiotic exposure
S. oralis, S. mitis biovar 1 and S. mitis biovar 2 were the 
predominent species found in both the UE-group and E-groups, and 
S. oralis and S. mitis biovar 2 were the only species isolated 
from the ampicillin-exposed (A-) subgroup. S. mitis biovar 1 was 
common in the UE-group but only four strains were recovered from 
B-lactam exposed individuals, all receiving rheumatic fever 
prophylaxis. Less common isolates belonged to S. sanguis biovar 
4, S. vestibularis and biovars 2 or 3 of S. qordonii species (the 
latter two biovars were not distinguished from one another), 
while other S. sanguis strains were distinctly uncommon (Table 
11.2a)
Very similar trends were observed when selection in the penicil­
lin G-only concentrations were analysed (see Table 11.2b)
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11.4.2.1 Differences related to antibiotic exposure following
selection procedures in penicillin G and in penicillin 
G plus gentamicin
MICs and MBCs of both penicillin V and amoxycillin were clearly 
higher in the E-group of 74 isolates compared with 66 strains in 
the UE-group as reflected in the MIC 50 and the peak MIC and MBC 
levels (Table 11.3a). This was also the case when individual 
species were considered (Table 11.3a), except for S. mitis biovar 
2 MIC 50 levels of penicillin V which were the same as in the 
two exposure groups. Similar trends could be observed when the 
findings were presented according to susceptible, intermediately 
resistant and resistant categories (Table 11.4a)
11.4.2 Effect of previous exposure to B—lactam antibiotics on
levels of resistance in viridans streptococi as a group
11.4.2.2 Differences related to antibiotic exposure following 
selection procedures in penicillin G alone
The findings when the selection process involved penicillin G- 
only and penicillin G plus gentamicin are given in Tables 11.3b 
and 11.4b, and Tables 11.3c and 11.4c, respectively. They show 
similar trends as the results of the selection procedures 
described under Section 11.4.2.1. However, the differences of the 
proportion of susceptible strains in the UE-group compared with 
the E-group were less pronounced in the isolates from the 
penicillin G-only selection process
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11.4.2.3 Relative susceptibility to the B-lactam antibiotics of 
viridans streptococci in E-subgroups and UE-group 
based upon MIC 50/MBC 50 and MIC 90/MBC 90 levels
The MIC 50 and MBC 50 levels of penicillin V and amoxycillin 
against isolates from the two E-subgroups consisting of 
hospitalised patients exposed to high doses of ampicillin over 
relatively short periods (ampicillin (A)-subgroup; 9 patients, 12 
isolates) and rheumatic fever patients with prolonged low-level 
exposure to penicillin V (rheumatic fever (RF)-subgroup; 41 in­
dividuals, 62 isolates) are given in Table 11.5a (including iso­
lates processed in penicillin G plus gentamicin selection broths) 
and Table 5b (penicillin G only selection broth). MIC 50/MIC 90 
and MBC 50/MBC 90 levels of both penicillin V and amoxycillin 
were, with the exception of the three S. mitis biovar 2 strains, 
higher in the A-subgroup than the RF subgroup which, in turn, 
were higher than those in the UE-group, especially as indicated 
by the MIC 90 and MBC 90 figures of the latter. These findings 
applied to both the penicillin G plus gentamicin selection broth 
procedures and the penicillin G only procedure (see Table 11.5a 
and Table 11.5b)
11.4.2.4 Relative susceptibility of viridans streptococci to the 
B—lactam antibiotics of E—subgroup and UE-group strains 
based on resistance breakpoints
Numbers of isolates in the different susceptibility categories 
are shown in Table 11.6a and Table 11.6b and an analysis of the 
statistical significance of the effect of in vivo exposure to B- 
lactam antibiotics on resistance to penicillin V and amoxycillin 
is presented in Table 11.7a and Table 11.7b. A significantly 
greater number of isolates resistant to either penicillin V 
(p=0.012) or amoxycillin (p=<0.001) was encountered in the E-
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group compared with the UE-group (Table 11.7a). Both short-term 
ampicillin therapy and long-term penicillin V prophylaxis also 
resulted in significantly larger proportions of penicillin V- 
resistant and amoxycillin-resistant isolates compared with those 
susceptible to these agents. P-values ranged from <0.0001 for the 
A-subgroup vs UE-group in the case of amoxycillin, to p=0.012 for 
A-subgroup vs UE-group against penicillin V (Table 11.7a). In 
Table 11.7b, the equivalent figures are shown after selection in 
the absence of gentamicin and no significant difference was evi­
dent between any of the respective groups. No significant dif­
ference was detected between the two E-subgroups irrespective of 
whether gentamicin was present in the penicillin G broths or not
However, when isolates obtained from the penicillin plus gen­
tamicin selection procedure in the UE-group were compared with 
those of the E-group, 32 of 45 (71%) of isolates were susceptible 
to penicillin V in the UE-group compared with 5 of 9 in the E- 
group. The difference was not significant but the respective 
figures for amoxycillin (44 of 45 vs 6 of 9) yielded a p-value of 
0.03 (Fisher Exact test). Furthermore, when, as shown in Tables 
11.4b and 11.6b, high level resistance (>_4 mg/1) strains were 
compared with less resistant and sensitive strains in the three 
antibiotic exposure groups (2 and 3 out of 12, respectively, for 
penicillin V and amoxycillin in the A-subgroup and 6 and 5 of 53 
in the RF-subgroup, respectively, were highly resistant while no 
highly resistant strains were encountered in the UE-group). When 
the A-subgroup was compared with the UE-group, p-values (using 
the Fisher Exact test), were 0.12 and 0.04 for penicillin V and 
amoxycillin, respectively, and 0.17 and 0.3 when the RF-subgroup 
was compared with the UE-group. Thus, only in the case of 
amoxycillin in the A-subgroup could a significant difference be­
tween prior antibiotic exposure and non-exposure be demonstrated 
- and even then, small numbers of isolates involved render 
statistical analysis uncertain
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11.4.3 Effect of exposure to fi-lactam antibiotics on levels of
resistance in streptococcal species
S- oralis and S. mitis biovar 2 exhibited the highest MIC and MBC 
levels to the two 6-lactam antibiotics in the E-group, ranging 
from 4-32 mg/1. The corresponding peak MICs and MBCs in the UE- 
group were much lower and ranged from 0.25-1 mg/1 antibiotic 
(Table 3a). MIC 50 figures of S. oralis and S. mitis biovar 1 
were approximately 8-fold higher in the E-group compared with the 
UE-group but no difference in MIC 50 figures of S. mitis biovar 2 
figures were observed. Similar trends, based on amoxycillin MIC 
50 figures, were demonstrated (Table 11.3a), as were those ap­
parent after selection in in penicillin G alone (Table 11.3b), 
albeit with fewer available UE-isolates
Comparison of MICs 50/MBCs 50, MICs 90/MBCs 90 and peak MICs/MBCs 
of strains from the A- and RF-subgroups and the UE-group (Table 
11.5a) clearly shows that the resistance concentrations to both 
penicillin V and amoxycillin were consistently highest in the A- 
subgroup followed by the RF-subgroup. This trend was more clearly 
shown in S. oralis strains than in S. mitis biovar 2 strains 
(Table 11.5a)
With all isolates distributed into susceptible, intermediately 
resistant and resistant categories (Table 11.4a and Table 11.6a), 
only strains of S. oralis and S. mitis biovar 2 were found to be 
resistant to the 6-lactams (MICs ^4.0 mg/1). All highly resistant 
strains were limited to specimens which originated in the dental 
plaque of E-group volunteers: 16.7% of 12 isolates and 9.7% of 62 
strains which were resistant to penicillin V came from the A- 
subgroup and RF-subgroup respectively, while the corresponding 
percentages for amoxycillin were 25 and 6.5 in the two respective
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subgroups
When the relative activities of penicillin V and amoxycillin were 
compared in the various streptococcal species, the latter an­
tibiotic was found to be generally more active than penicillin V. 
This was also apparent when the UE- and E-groups were considered. 
With the exception of relatively small numbers of S. mitis biovar 
2 strains in the E-group (12 isolates) and unnamed species in the 
UE-group, the amoxycillin MIC 50 levels were approximately 4-fold 
lower than the corresponding MICs 50 of penicillin V in the 
species and biovars listed according to B-lactam exposure groups 
in Table 11.3a, with very similar trends in Tables 11.3b and 
11.3c. Table 11.4a also shows that more isolates were susceptible 
to amoxycillin than penicillin V amongst S. oralis and S. mitis 
(both biovars) isolates as well as amongst the total number of 
strains in the UE-group. A similar but less pronounced trend was 
seen amongst strains in the E-group. The same trends were ob­
served in Tables 11.4b and 11.4c concerning penicillin G-only and 
the combination selection procedures. However, more S. oralis 
strains in the high ampicillin exposure group showed higher MBC 
90 and peak MBC values of amoxycillin compared with penicillin V. 
This was also an overall finding in the 12 isolates in the A- 
subgroup as well as in the 62 isolates of the RF-subgroup (Tables 
11.5a and 11.5b)
11.5 Discussion
Although the findings in the in vitro penicillin G selection 
model exclude the de novo susceptibility status of streptococci 
in dental plaque and does not indicate how many of the originally 
susceptible streptococci in the plaque were killed in the process 
of selection, it does provide the relative numbers of phenotypi- 
cally tolerant streptococci with MBCs below the equivalent
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penicillin G selection concentrations, as well as resistant 
streptococci surviving the in vitro selection procedure
The most important aspect of this model is however that it should 
give an indication of the phenotypically tolerant or resistant 
status of dislodged streptococci from dental plaque which may en­
ter the blood stream during B-lactam prophylaxis
11.5.1 MICs vs MBCs
MICs and MBCs for the E-group and UE-group isolates are recorded 
in Table 11.1. The MIC findings are interesting as they express 
the conventional assessment of susceptibility of organisms to an­
tibiotics. However, in the context of the present study, MBC 
findings are more relevant as they more appropriately reflect the 
potential for survival of the streptococci to the two B-lactam 
antibiotics tested. This is obviously important in the 
prophylaxis of IE where killing (MBCs) of organisms is of 
paramount importance as opposed to mere inhibition (as reflected 
by the MICs) where surviving bacteria may still be able to 
colonise the endocardium after the antibiotic effect has waned
11.5.2 Comparison between the activities of penicillin V and 
amoxycillin
Comparatively few studies have been conducted in which the rela­
tive activities of penicillin G, amoxycillin and penicillin V 
have been compared (Garrod, 1960a; Garrod 1960b; Coulter et al, 
1990). The present study clearly shows that amoxycillin is some­
what more active against viridans streptococci than penicillin V, 
regarding both their relative bacteriostatic and bactericidal 
potential against these bacteria. These findings are in accord-
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ance with findings of the quoted authors
11.5.3 The effect of selection in penicillin G plus gentamicin 
broth on the susceptibility to penicillin V and 
amoxycillin according to previous 6-lactam exposure
The addition of gentamicin to 0.125 mg/1 penicillin G in broth 
resulted in ratios of phenotypic tolerance to resistance (T/R) 
ratios of surviving strains that resemble selection at 1.0 mg/1 
concentrations more closely than the 0.125 mg/1 penicillin-only 
selection process - but only in the case of amoxycillin. For 
penicillin V the T/R ratios resemble more closely the selection 
that occurred at 0.125 mg/1 penicillin G only
The gentamicin plus penicillin G selection process in the case of 
UE-group isolates resulted in a much higher amoxycillin T/R ratio 
of 39/45 (87%) compared with 3/9 (33%) when the selection broth 
contained only penicillin G (p=0.015, Fisher exact test). No 
meaningful difference was, however, observed when the penicillin 
V T/R ratios of penicillin G plus gentamicin (14/45; 31%) were
compared with those of penicillin alone (2/9; 22%) (p=0.71,
Fisher Exact test). Thus while exposure of isolates to selection 
in the penicillin plus gentamicin broth resulted in little dif­
ference between isolate sensitivity to penicillin V compared to 
selection in penicillin G only (0.125 mg/1), this was not the 
case for amoxycillin where this combination resulted in the 
selection of appreciably fewer resistant isolates with MBCs 
greater than the selection concentration of penicillin G at 0.125 
mg/1 in the combination. These findings suggest that the addition 
of gentamicin to penicillin G in the selection process in the 
case of UE-group isolates rendered the organisms more phenotypi- 
cally tolerant to amoxycillin compared with penicillin V. A high 
proportion of phenotypically tolerant isolates was also seen in
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the UE-group when selection took place at the high penicillin G 
concentration of 1.0 mg/1 without gentamicin: 10 out of 12 (83%) 
were phenotypically tolerant to amoxycillin and 2 out of 12 (17%) 
had MBCs >10 mg/1 (Table 11.1). However, at this concentration 
the proportion of strains phenotypically tolerant to penicillin V 
was similar to that of amoxycillin. The trend of a preponderance 
of amoxycillin-tolerant (phenotypic) strains relative to penicil­
lin V was also seen, with this one exception, in the other selec­
tion exercises in the UE- and E-groups, but much less so and cer­
tainly not statistically important (Table 11.1). In the case of 
selection at 10 mg/1 penicillin G-only in the UE-group, however, 
there was no difference between penicillin V and amoxycillin T/R 
ratios (Table 11.1)
The high proportion of isolates phenotypically tolerant to 
amoxycillin in the penicillin plus gentamicin selection process 
may be partly due to the greater activity of amoxycillin compared 
with penicillin V under the conditions pertaining to MIC/MBC 
determinations which are designed to prevent the expression of 
phenotypic tolerance (inocula for MIC/MBC determinations contain 
cells from fresh isolates in the very active logarithmic growth 
phase - see later). Under these laboratory conditions the same 
cohort of streptococcal isolates will show proportionally more 
strains to be susceptible to amoxycillin, by virtue of its 
greater activity, than to penicillin V
It is possible that the higher concentrations of penicillin G, 
and the addition of gentamicin to the lower penicillin G con­
centration, may enhance the expression of phenotypic tolerance 
over and above the role growth conditions may play in dental 
plaque - which probably also favour phenotypic tolerance (see 
later). In the case of a possible gentamicin effect, it is con­
ceivable, but highly speculative, that its action on protein syn­
thesis may result in defective enzymes which could slow down or
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halt metabolic processes reversably, thus facilitating phenotypic 
tolerance. Furthermore, one could speculate that previous ex­
posure to 6-lactam antibiotics (E-group subjects) may have 
eliminated some strains susceptible to such effects of gentamicin 
or high levels of penicillin G which may operate during the 
selection process. Alternatively, previous antibiotic exposure 
may have selected mutants not affected in this manner by these 
selection procedures. A more plausable explanation, however, is 
that previous antibiotic exposure may have affected the physical 
formation of the dental plaque or changed its integrity and com­
position, resulting in modified bacterial films which are more 
likely to promote phenotypic tolerance than undisturbed films
The similarity between the T/R ratios amongst the survivors of 
the high penicillin G and the low penicillin G plus gentamicin 
selection concentrations, respectively, could at least in part, 
be explained by synergy between gentamicin and penicillin G. The 
premise that synergy may play a role is based upon the following 
assumptions: a) Susceptible cells that are not phenotypically 
tolerant will be killed by both penicillin G alone and by the an­
tibiotic combination but the number of cells killed are not 
known; b) Phenotypically tolerant cells will be refractory to 
killing; c) More genetically-based resistance cells will be 
killed if there is synergy between the drugs in the combination 
compared with the bactericidal effect of penicillin G alone and 
d) The T/R ratio will therefore tend to be greater if synergy is 
present (see Table 11.1)
This argument is corroborated by the presence of a high percent­
age of susceptible strains with MICs £0.12 mg/1 (and therefore 
phenotypically tolerant) following selection by this combination 
amongst the UE-group individuals: 71% against penicillin V and 
98% against amoxycillin amongst 45 isolates, as opposed to 52% 
and 57% respectively amongst 21 isolates selected by the equiv­
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alent penicillin G concentration only. A similar but less 
pronounnced trend was evident in the E-group: 56% and 67% for 
penicillin V and amoxycillin out of the small number of 9 iso­
lates from the penicillin G plus gentamicin broth, compared with 
35% and 42% out of 65 isolates from the penicillin G-only broths 
(see Tables 11.4b and 11.4c)
Similar trends were noticed when the MICs 50 of strains surviving 
the various selection procedures were examined. Thus, in the case 
of penicillin V, no change occurred in the MIC 50 values of the 
viridans streptococci in the UE-group (0.12 mg/1) when selection 
in penicillin G-only broths (Table 11.3b) was compared with the 
penicillin G plus gentamicin selection procedure (Table 11.3c). 
There was, however, a decrease in the MICs 50 of E-group strains 
from 0.5 mg/1 in the penicillin G-only broths to 0.12 mg/1 in the 
penicillin G plus gentamicin strains (Tables 11.3b and 11.3c). 
For amoxycillin, there was a similar 4-fold decrease in MICs 50 
in both the E- and UE-groups (Table 11.3b and 11.3c)
11.5.4 Pooling of findings obtained from different in vitro 
selection concentrations
As the selection procedures could all reflect what may happen in 
vivo in patients exposed to prophylactic 6-lactam antibiotics 
(also keeping in mind that selection patterns of 0.125 mg/1 
penicillin G plus gentamicin resemble those of selection by the 
higher concentration of 1.0 mg/1 penicillin G), the findings of 
resistance to both 6-lactams of all three selection procedures 
were combined for statistical analysis of the exposure groups 
even though the differences described above appear to be real. 
However, although there may have been justifiable grounds for the 
combination of data, it was decided to also analyse the findings 
separately for the three selection procedures
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11.5.5 The effect of penicillin G-only selection on exposure 
group susceptibility to penicillin V and amoxycillin
More isolates were found to be phenotypically tolerant at 1.0 
mg/1 concentrations in the UE-group (10/12: 83%, both agents, see 
Table 11.1) as opposed to the E-group where the amoxycillin 
figures were 32/55; 58% and those of penicillin V 30/55; 55% (see 
Table 11.1). Possible reasons for this finding were discussed in 
Section 11.5.9.2. In the lower 0.125 mg/1 selection concentration 
of penicillin G-only very little difference can be observed be­
tween the two exposure groups but numbers were too small for any 
valid conclusions to be drawn
Examination of the penicillin G-only selection model (without the 
addition of gentamicin) shows very little difference between the 
phenotypic tolerance to resistance (T/R) ratios of penicillin V 
and amoxycillin in both groups as reflected in the MBC values: 
UE-group, 10/12 for both antibiotics at the 1.0 mg/1 penicillin G 
selection concentration and 2/9 and 3/9 for the two respective 
agents at the lower 0.125 mg/1 selection. For the E-group, the 
equivalent T/R ratios for penicillin V and amoxycillin at 1.0 
mg/1 are 30/55 and 32/55 (1.0 mg/1), and 3/10 and 4/10 for the 
same two at 0.125 mg/1 antibiotic. It is worth noting again that 
the higher T/R ratios at the 1.0 mg/1 selection concentration are 
demonstrated in both the E-group and UE-group but this trend in 
T/R ratios is reversed in these two groups at the lower 0.125 
mg/1 selection concentration. The proportionately fewer resistant 
survivors at the high selection concentration can be partly ex­
plained on the assumption that of the metabolically active strep­
tococci from the dental plaque exposed to the selection con­
centration, a smaller proportion would be resistant and survive 
at he higher compared with the lower selection concentrations.
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Unfortunately, the relative proportions of resistant cells with 
higher MBCs that were metabolically inactive in the plaque 
samples, were not known. Such phenotypically tolerant cells 
would, of course, have survived the selection process irrespec­
tive of the level of the selection concentration or the strain 
MBC. It is, however, reasonable to assume that the mix of suscep­
tible and resistant cells in the plaque samples submitted to the 
various selection concentrations were similar in each of the UE- 
and E-groups groups
11 .5.6 Summary of main findings of in vitro selection 
affecting plaque streptococci in general
Selection in penicillin G broth results in the survival of both 
resistant strains and phenotypically tolerant forms. The addition 
of gentamicin in the selection process failed to abolish either 
phenotypically tolerant or resistant strains and may result in 
the development of proportionally more phenotypically tolerant 
bacteria, but not to penicillin V. It would also appear that the 
state of phenotypic tolerance is not due to traditional 
(genetically-based) tolerance phenomena and finally, and not 
unexpectedly, that previous 6-lactam exposure results in the 
selection of proportionally more resistant forms
11.5.7 Effect on species of broth selection procedures
The overall effects of the three selection procedures on the 
various streptococcal species are given in Tables 11.3a and 11.4a 
while the effects of penicillin G-only selection and that of 
penicillin G plus gentamicin are given in Tables 11.3b and 11.4b 
and 11.3c and 11.4c, respectively
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11.5.7.1 Relative activites of penicillin V and amoxycillin 
amongst streptococcal species
As pointed out earlier (Section 11.3.3), amoxycillin showed 
greater activity amongst the more common S. oralis, S. mitis 
biovar 1 and 2 strains. In the UE-group proportionately more S . 
oralis strains were susceptible to penicillin V (81% overall; 
Table 11.4a) than S. mitis biovar 1 (53%) and biovar 2 (56%).
This was not demonstrated in the E-group (41%, 0% and 47%,
respectively), nor in the case of amoxycillin in either of the 
exposure groups. Similar trends were seen in the penicillin G 
plus gentamicin selection group (Table 11.4c) but not in the 
penicillin G-only selection groups (table 11.4b) where the dif­
ference in susceptibility to penicillin V between S. oralis and 
S. mitis biovar 2 was reversed (43% vs 55%) compared with the 
data in the other two selection groups. The numbers of isolates 
belonging to these two species in the penicillin G-only selection 
groups were, however, too small for valid comparisons to be made
11.5.7.2 Effect of selection procedures on streptococcal
species in relation to previous antibiotic exposure
Except for S. mitis biovar 2, there was a clear trend amongst S . 
oralis and S. mitis biovar 1 isolates of larger numbers of sus­
ceptible strains in the UE- as opposed to the E-group when selec­
tion groups were combined (Table 11.4a), as well as in the 
penicillin G plus gentamicin selection group. This pattern was, 
however, not as pronounced in the penicillin G-only selection 
groups where the total number of isolates in the UE-group was 
only 21 with 5, 4 and 9 strains respectively in the three most
common species/biovars, respectively (S. oralis, S. mitis biovar 
1, S. mitis biovar 2). In the E-group, there was a total of 57
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isolates of these species/biovars with a respective species dis­
tribution of 41, 5 and 11 isolates (Table 11.4b)
With regard to MICs 50 (see Tables 11.3a, 11.3b and 11.3c), the 
values (with exception of S. mitis biovar 2) were generally 
higher in the E-group than in the UE-group amongst the species. 
This was exemplified in S. oralis and S. mitis biovar 1 strains, 
the latter biovar showing somewhat higher MICs 50 (but not peak 
MIC or MBC levels) compared with the other species/biovars 
(penicillin V MICs 50 of the three combined selection procedures 
of 0.12 and 1.0 mg/1 in the UE- and E-groups, respectively, in 
contrast to 0.06 and 0.5 mg/1 for S. oralis strains). When the 
MICs 50 of both penicillin V and amoxycillin in the penicillin G 
plus gentamicin selection group were compared, they were 
generally the same or one serial concentration lower than in the 
penicillin G-only selection group
More striking were the differences between the peak MIC and MBC 
levels of penicillin V and amoxycillin which were, with the ex­
ception of S. mitis biovar 2 strains, appreciably lower in the 
penicillin G plus gentamicin selection category than was the case 
with the penicillin G-only selection procedures (see Tables 
11.3a, 11.3b and 11.3c). This finding may, however, be fortuitous 
as 45 isolates from the penicillin G plus gentamicin selection 
process came from the UE-group (from which lower peak levels 
would be expected) while only 9 isolates from this combination 
selection procedure came from the E-group and only 2 of these had 
MICs or MBCs higher than 1.0 mg/1 (see Table 11.1). On the other 
hand, 65 isolates from the E-group (55 from the high penicillin G 
concentration selection procedure) compared with 21 from the UE- 
group (12 of these in the high penicillin G concentration 
procedure) came from the two penicillin G-only selection process, 
thus increasing the likelihood of selecting strains with high 
MIC/MBC values
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11.5.7.3 Summary of main species—related findings in the 
in vitro selection model
a) S. oralis and S. mitis biovars 1 and 2 were the most common 
survivors in this model
b) Amoxycillin was more active than penicillin V in viridans 
streptococci in general and the differences between the ac­
tivities of these antibiotics was most marked in S. mitis biovar 
1 and S. mitis biovar 2 strains
c) There was a larger proportion of susceptible strains of S . 
oralis and S. mitis biovar 1 in the UE-group than the E-group 
(Tables 11.4a, 11.4b and 11.4c) but this trend was less marked in 
strains surviving the penicillin G-only selection broth procedure 
(Table 11.4b)
d) Peak MICs/MBCs were highest in the E-group isolates and were 
most clearly observed in S. oralis and S. mitis biovar 2 strains
11.5.8 Comparative effects of exposure to high 6—lactam
concentrations (A-subgroup), prolonged low fi—lactam 
concentrations (RF-subgroup) and absence of prior 
B-lactam exposure (UE—group)
In vivo exposure to high concentrations of ampicillin (A- 
subgroup) resulted in the selection of viridans streptococci with 
higher penicillin V and amoxycillin MICs and MBCs compared with 
streptococci selected from those exposed to prolonged administra­
tion of penicillin V in rheumatic prophylaxis individuals. The 
latter, in turn, had higher MICs/MBCs than oral streptococci
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selected from the UE-group (Tables 11.5a, 11.5b, 11.6a and
11.6b). This pattern was most clearly shown in S. oralis strains
These findings not only show that prior antibiotic exposure does 
affect the susceptibility of viridans streptococci in plaque, but 
also demonstrates that exposure to high concentrations of B- 
lactam antibacterial agents would tend to select for strains with 
higher levels of resistance. They also suggest that selective 
pressures affect some species more than others and that S. oralis 
selected in the process had higher MICs/MBCs than S. mitis biovar 
2 strains
It is interesting to note (but difficult to explain) that prior 
exposure to B-lactam antibiotics also led to the selection of 
strains that were resistant to antibiotics other than B-lactams 
(see Chapter 9). It is possible that transposons coding for 
resistance eg. to erythromycin and clindamycin by Tn 917 and Tn 
1545 (Leclerq and Courvalin, 1991) may play a role. But, these 
latter transposons do not, however, code for resistance to B- 
lactam aaents
11.5.9 Summary of, and concluding comments on, the most
salient features of the in vitro selection model in 
relation to amoxycillin and penicillin V prophylaxis
11 .5.9.1 Validity of model
The experimental model used in this study has a number of poten­
tial shortcomings viz:
a) the original composition of the streptococcal species in 
plaque transferred to the penicillin G selection cultures and 
their susceptibility patterns were not determined
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b) dental plaque specimens could not, for practical reasons, be 
standardised with regard to size. However, the same site was used 
to collect dental plaque whenever possible (upper first or second 
molars, see Section 8.4)
c) the antibiotic chosen for selection was penicillin G 
(supplemented with gentamicin in one selection process) rather 
than amoxycillin which is used in practice for IE prophylaxis 
(and penicillin V in the past). The author feels that the case 
of penicillin G is justified by the fact that it is an agent of 
choice - "the mainstay of therapy" (Johnson and Tunkel, 1995) - 
either as a single agent or in combination with an 
aminoglycoside, in the treatment of cases of IE caused by 
viridans streptococci
The choice of the low concentration of penicillin G in the in 
vitro model is a compromise but can be justified on the grounds 
that the end result (death of the bacteria) after the duration of 
exposure is likely to be the same at 0.125 mg/1 or 1.0 mg/1 as it 
is with much higher concentrations such as 20 mg/1, as these are 
all in excess of the MBCs of susceptible viridans streptococci. 
Very high serum levels of 20 mg/1 and greater are achievable in 
practice following amoxycillin prophylaxis at high (3g) doses 
(Shanson et al, 1984). Furthermore, the long-term consequences of 
selection of resistant strains relate to the resistant strep­
tococci in dental plaque where the antibiotic concentrations are 
much lower, probably approximately 10% of the blood levels, ie. 
in the range of selection concentrations used in the present 
model (Sukchotiratana and Linton, 1975)
d) The decision to expose the plaque-derived bacteria to an an­
tibiotic selection period of 18 hours (overnight incubation) may 
also be a matter for debate. The British Society for An­
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timicrobial Chemotherapy (BSAC) recommended 3g amoxycillin 1 hour 
before the dental procedure giving an exposure time of a few 
hours only while the American Heart Association (AHA) recommended 
an additional 1.5g 6 hours later resulting in an adeguate ex­
posure time of approximately 12 hours. This study, therefore, had 
an exposure time of bacteria to antibiotic activity which was 
somewhat longer than that achievable by the AHA schedule. Workers 
who studied prophylaxis in in vivo experiments (Phillips et al, 
1976; Shanson et al, 1978; Hess et al, 1983) have suggested that 
the failure to show killing of susceptible bacteraemic organisms 
by prophylactic antibiotics in their studies may be as a result 
of the short exposure of the bacteria to the antimicrobial agents 
at the time of taking blood samples (approximately 10 minutes) 
and diluting out of the antibiotic during the blood culture 
process. These problems have been eliminated in the present model
Deficiencies and debatable aspects of the model described in the 
dissertation would have been costly to rectify. They do not, 
however, appear to have markedly compromised the validity of the 
findings presented here. The model finally employed in this study 
attempted to mimic IE prophylaxis in persons at risk who are 
about to undergo dental procedures. It includes important fea­
tures such as removal of plaque material containing biofilms of 
bacteria which are likely to be prone to phenotypic tolerance and 
to harbour amongst them, resistant strains selected by previous 
antibiotic usage. Furthermore, streptococci from dental plaque 
are subjected to antibiotic pressures likely to obtain at the 
dental plaque sites as well as the blood of persons following ad­
ministration of a prophylactic 6-lactam antibiotic (even though 
concentrations in the blood are greater than in the model) fol­
lowing administration of a prophylactic 6-lactam antibiotic. Sur­
viving bacteria would therefore tend to include those which may 
cause IE should prophylaxis fail. The model could also be of 
value as a screening procedure in experiments to predict the
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potential efficacy of antibiotics that are candidates for IE 
prophylaxis, also in persons previously exposed to antibiotics
The rationale for the use of penicillin G plus gentamicin in the 
selection model is based upon the known synergistic action of 
this combination on viridans streptococci and further studies 
using such combinations were recommended by Hess et al (1983) 
following failure of penicillin G to destroy bacteraemic strep­
tococci in their in vivo investigations. However, the selection 
of strains in the presence of penicillin G plus gentamicin intro­
duced a confounding aspect to the model. When all three selection 
processes (ie. high and low penicillin G levels and penicillin G 
plus gentamicin) were considered together statistically, sig­
nificant differences in resistance frequencies to penicillin V 
and amoxycillin in the antibiotic exposure groups, compared with 
unexposed individuals, were demonstrated (Table 11.7a). Such dif­
ferences could, unfortunately, not be shown when the penicillin 
G-only selection procedures were considered (Table 11.7b) except 
when an MBC level of ^1.0 mg/1 was taken as the breakpoint for 
resistance (see footnote Table 11.7b). Were similar models to be 
designed in future, it may be wise to use an agent or combination 
of agents which is/are actual candidates for prophylaxis rather 
than a surrogate compound such as penicillin G
11 .5.9.2 Demonstration of phenotypic tolerance
Phenotypic tolerance was clearly demonstrated in the in vitro 
model and this is entirely in keeping with those reported in 
early in vivo studies (Phillips et al, 1976; Shanson et al, 1978; 
Hess et al, 1983; Hall et al, 1993), the latter of whom showed 
that bacteraemic viridans streptococci survive amoxycillin and 
penicillin V prophylaxis despite bactericidal antibiotic levels 
obtained in the blood of subjects in the study
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The model described here suggests that phenotypic tolerance is 
more likely to be operative with amoxycillin prophylaxis, espe­
cially in individuals not previously exposed to 13-lactam an­
tibiotics. This form of tolerance may be associated with 
prophylaxis failure (although not necessarily so as tolerant 
strains subjected to /3-lactam antibiotics may possibly fail to 
adhere to platelet vegetations at the initiation of IE - see Sec­
tion 2.3.2). On the other hand, phenotypically tolerant strains 
demonstrated in vivo and in this model, would probably become 
susceptible to this type of antibiotic agent in the IE setting. 
Here metabolically active non-tolerant bacteria susceptible to 
the bactericidal action of the antibiotic are likely to prevail - 
at least during stages of the disease when vegetations are 
developing or maintained as "active" entities. Degrees and/or 
phases of phenotypic tolerance may indeed be responsible for the 
prolonged therapy that is required for cure of the disease
Results of the study recorded here also showed that previous ad­
ministration of antibiotics to individuals affected their plaque 
streptococci in such a way that when these organisms were exposed 
to high penicillin G-only concentrations or low penicillin G plus 
gentamicin they were less likely to exhibit phenotypic tolerance 
to amoxycillin than in persons not recently given antibiotic. 
This may be as a result of altered biofilm caused by prior ex­
posure to antibiotics and this phenomenon may well apply to IE 
prophylaxis with B-lactam agents
11 .5.9.3 Selection of resistant strains
The model strongly suggests that /3-lactam-resistant strains may 
be selected during IE prophylaxis with penicillin V or amoxycil­
lin. Furthermore, such strains would more likely be present in
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individuals previously exposed to 6-lactam agents (see Table 
11.7a) while the highest levels of resistance can be expected 
when high-dose 6-lactam therapy had been given recently to 
hospitalised patients (Tables 11.3a and 11.5a). The results are 
in accordance with previous publications relating to the effect 
of antibiotic exposure on viridans streptococci in the oral 
cavity (see Section 1.2.2 and Section 5.2.3)
This study shows that S. mitis biovar 1 strains are more likely 
than other viridans streptococci to be resistant to penicillin V 
and amoxycillin based upon MIC 50/MBC 50 values (Table 11.3a). S . 
oralis strains, on the other hand, exhibited the highest resis­
tance levels to amoxycillin (peak MBCs; 32 mg/1) while S. oralis 
and S. mitis biovar 2 strains displayed increased levels of 
resistance to both amoxycillin and penicillin V (peak MBCs; 16 
mg/1; see Table 11.3a). Thus, high-level resistance with MBCs >4 
mg/1 were only encountered in S. oralis and S. mitis biovar 2 
isolates (Tables 11.3a and 11.5a)
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Table 11.1 Effect of in vitro antibiotic selection on susceptibility of streptococcal isolates from p-lactam-exposed (E-group) and p-lactam- 
unexposed individuals (UE-group)
Selection broths
______________________________________ (mg/l penicillin G)__________________________________
Susceptibility ranges (mg/l)
of surviving streptococci 0.125 1.0 0.125 + 5 mg/I gentamicin
(10 isolates)
a) E-group isolates (74)
MIC
Pt
MBC MIC
A
MBC
<0.125 3* 3 4 4
>0.125-0.9 3 2 3 3
> 1.0 4 5 3 3
b) UE-group isolates (66)
(9 isolates)
<0.125 4 2 4 3
>0.125-0.9 5 6 5 5
> 1.0 0 1 0 1
(55 isolates) (9 isolates)
P A P A
MIC MBC MIC MBC MIC MBC MIC MBC
11 9 16 14 4 4 5 5
20 21 18 18 2 2 2 2
24 25 21 23 3 3 2 2
(12 isolates) (45 isolates)
3 2 5 5 21 14 39 39
7 8 5 5 24 28 6 5
2 2 2 2 0 3 0 1
Underlined figures denote number of isolates with MIC's lower than the selection concentrations
t  P = penicillin V & A = amoxycillin
Table 11.2(a) Num ber and identity of viridans streptococcus isolates speciated according to Kilian et al (1989) in d iffe rent b-lactam exposure
groups follow ing selection in penicillin  G only and penicillin G plus gentam icin
Species according to antibiotic exposure
Unexposed, Unexposed, Exposed to i+ieumatic Exposed to ampicillin
speciation only also susceptibility tested fever prophylaxis treatment
(n = 67)* (n = 54) (n = 41) (n = 9)
Streptococcus oralis 31 26 40 9
S. mitis biovar 1 22 15 5 0
S. mitis biovar 2 18 18 9 3
S. sanauis biovar 4 2 2 2 0
S. vestibularis (CovkendalH 2 2 2 0
S. sanauis biovar 1 or 3 t 1 1 0 0
S. aordonii biovar 2 or 3 t 2 1 4 0
S. sanauis biovar 2 1 1 0 0
Total 79 66 62 * 12 t
* n = number of subjects in each group
t  Range of identification tests used did not allow for differentiation between biovars 1 and 3 of S. sanguis or biovars 2 and 3 of S. gordonii
respectively
t  The respective subgroups together form the E-group: 62 + 12 = 74 isolates
NOTE: This table is identical to Table 9.1
Table 11.2(b) Num ber and identity of v iridans streptococcus isolates speciated according to K ilian et al (1989) in d ifferent b-lactam exposure
groups fo llow ing selection in penicillin  G only broth
Number of isolates within species according to antibiotic exposure
Unexposed, 
speciation only 
(n = 67)*
Unexposed,
also susceptibility tested 
(n = 18)
Exposed to rheumatic 
fever prophylaxis 
(n = 33)
Exposed to ampicillin 
treatment 
(n = 9)
Streptococcus oralis 31 5 (21) f 32 (8) 9(0)
S. mitis biovar 1 22 4(11) 5(0) 0(0)
S. mitis biovar 2 18 9(9) 8(1) 3(0)
S. sanauis biovar 4 2 1 (1) 2(0) 0(0)
S. vestibularis || 2 0(2) 2(0) 0(0)
S. sanauis biovar 1 or 3 ± 1 1 (0) 0(0) 0(0)
S. aordonii biovar 2 or 3 ± 2 0(1) 4(0) 0(0)
S. sanauis biovar 2 1 1 (0) 0(0) 0(0)
21 (45) 53(9) 12(0)
Total number of isolates 79 66 § 62§
* n = number of subjects in each group
t  Numbers in parenthesis denote the total number of isolates recovered from penicillin plus gentamicin selection broth
$ Range of identification tests used did not allow for differentiation between biovars 1 and 3 of S. sanguis or biovars 2 and 3 of S. qordonii res
§ Total number of isolates identified in UE-group = 21 + 45 = 66; E-group = 53 + 9 + 12 = 74
|| Coykendall (1989) classification
Table 11.3(a) p-lactam  susceptib ility ranges o f streptococcal species, selected in penicillin  G broth only and in com bination with gentam icin, from
plaque o f participants w ith in antib io tic exposed (E) and unexposed (UE) groups
Classification of Kilian et al (1989) Penicillin V Amoxycillin
_________________(mg/l)_________________ ________________ (mg/l)
Species Group No. (%) MIC-range MIC-50 MBC-range MIC-range MIC-50 MBC-range
S. oralis UE 26 (39.4) 0.03-1 0.06 0.03-1 <0.007-0.25 0.03 <0.007-0.5
E 49 (66.2) 0.003-8 0.5 0.003-16 0.007-16 0.25 0.007-32
S. mitis b/v 1 UE 15 (22.7) 0.03-2 0.12 0.06-2 <0.007-2 0.03 0.015-2
E 5 (6.8) 0.5-1 1 1-2 0.25-2 1 0.25-2
S. mitis b/v 2 UE 18 (27.2) 0.015-0.5 0.12 0.015-1 <0.007-0.5 0.06 0.015-1
E 12 (16.2) 0.003-8 0.12 0.003-16 0.03-4 0.12 0.03-4
Other species* UE 7 (10.6) 0.03-0.5 0.12 0.03-1 0.007-0.5 0.12 0.007-1
E 8 (10.8) 0.06-1 0.25 0.06-2 0.03-1 0.12 0.06-2
All species UE 66 (100) 0.015-2 0.12 0.015-2 <0.007-2 0.03 <0.007-2
E 74 (100) 0.003-8 0.25 0.003-16 0.007-16 0.25 0.007-32
* S. sanguis biovar 2 (1 isolate in UE-group, 0 in E-group); S. sanguis biovars 1 or 3 (1,0); S. sanguis biovar 4 (2,2); S. vestibularis (2,2) 
S. gordonii biovars 2 or 3 (1,4)
Table 11.3(b) p-lactam  susceptib ility ranges o f streptococcal species, selected in penicillin G only broth, from  plaque participants in antib iotic
exposed (E) and unexposed (UE) groups
Classification of Kilian et al (1989) Penicillin V Amoxycillin
_________________(mg/l)_________________ ________________ (mg/l)
Species Group No. (%) MIC-range MIC-50 MBC-range MIC-range MIC-50 MBC-range
S. oralis UE 5 (23.8) 0.06-1 0.06 0.06-1 0.015-0.25 0.06 0.015-0.5
E 41 (63.1) 0.015-8 0.5 0.015-8 0.007-16 0.5 0.007-32
S. mitis biovar 1 UE 4 (19.0) 0.12-2 0.25 0.25-2 0.015-2 0.12 0.015-2
E 5 (7.7) 0.5-2 1 1-2 0.25-4 1 0.25-4
S. mitis biovar 2 UE 9 (42.9) 0.03-0.5 0.12 0.03-1 <0.007-0.5 0.06 0.015-0.5
E 11 (16.9) 0.003-8 0.12 0.003-16 0.03-4 0.12 0.03-4
Other species* UE 3 (14.3) 0.06-0.5 0.12 0.12-0.5 0.12-0.5 0.25 0.12-1
E 8 (12.3) 0.06-1 0.25 0.06-2 <0.007-2 0.12 <0.007-2
All species UE 21 (100) 0.03-2 0.12 0.03-2 <0.007-2 0.12 0.015-2
E 65 (100) 0.003-8 0.5 0.003-16 0.007-16 0.25 0.007-32
* S. sanguis biovar 2 (1 isolate in UE-group, 0 in E-group); S. sanguis biovars 1 or 3 (1,0); S. sanguis biovar 4 (1,2); S. vestibularis (0,2) 
and/or S. aordonii biovars 2 or 3 (0,4)
Table 11.3(c) p-lactam  susceptib ility ranges o f streptococcal species, selected in penicillin G plus gentam icin only broth from  plaque participants w ithin
exposed (E) and unexposed (UE) groups
Classification of Kilian et al (1989) Penicillin V Amoxycillin
_________________(mg/l)_________________ ________________ (mg/l)
Species Group No. (%) MIC-range MIC-50 MBC-range MIC-range MIC-50 MBC-range
S. oralis UE 21 (47) 0.03-0.25 0.06 0.03-1 <0.007-0.12 0.015 <0.007-0.12
E 8 (89) 0.003-4 0.25 0.003-4 <0.007-2 0.06 <0.007-2
S. mitis b/v 1 UE 11 (24) 0.03-0.5 0.12 0.06-0.5 <0.007-0.06 0.03 0.015-2
E 0 (0) - - - - - -
S. mitis b/v 2 UE 9 (20) 0.015-0.5 0.12 0.015-1 0.015-0.12 0.06 0.015-1
E 1 (11) (0.06)f - (0.06) (0.06) (0.06)
Other species* UE 4 (9) 0.03-0.25 0.25 0.03-0.25 0.007-0.25 0.06 0.007-0.25
E 0 (0) - - “ “ “
All species UE 45 (100) 0.015-0.5 0.12 0.015-1 <0.007-0.25 0.03 <0.007-1
E 9 (100) 0.003-4 0.12 0.003-4 <0.007-2 0.06 <0.007-2
*
t
S. sanguis biovar 2 (0 isolate in UE-group, 0 in E-group); S, sanguis biovars 1 or 3 (0,0); S. sanguis biovar 4 (1,0); S. vestibularis (2,0) 
and/or S. qordonii biovars 2 or 3 (1,0)
Respective MIC or MBC value
Table  11.4(a) Susceptib ility  in MICs to penicillin V  and am oxycillin  o f isolates selected in penicillin G only and penicillin plus gentam icin
broth from  dental plaque o f subjects exposed o r unexposed to p-lactam  antibiotics
Species Unexposed to p-lactams 
(n = 66 isolates)
Exposed to p-lactams 
(n = 74 isolates)
Kilian et al (1989) susceptible* intermediately
classification resistant f
P§ A P A
Streptococcus oralis 21 (81%) 25(96) 5 1
S. mitis biovar 1 8(53) 13(87) 7 2
S. mitis biovar 2 10 (56) 14(78) 8 4
S. sanauis biovar 4 1 0 1 2
S. vestibularis || 2 2 0 0
S. sanauis biovar 1 or 3 0 1 1 0
S. aordonii biovar 2 or 3 0 1 1 0
S. sanauis biovar 2 1 0 0 1
Total 43 56 23 10
(%) (65.1) (84.8) (34.8) (15.2)
resistant t susceptible * intermediately 
resistant t
resistant %
P A P A P A
0 18 (37) 22 (45) 23 21 8 6
0 0 0 5 4 0 1
0 7(58) 7(58) 4 4 1 1
0 1 0 1 2 0 0
0 0 1 2 1 0 0
0 0 0 0 0 0 0
0 2 2 2 2 0 0
0 0 0 0 0 0 0
0 28 32 37 34 9 8
(37.8) (43.2) (50) (45.9) (12.2) (10.8)
* MIC < 0.12 mg/l for both penicillin V and amoxycillin
t  MICs; 0.25-2 mg/l for both penicillin V and amoxycillin
t MIC > 4.0 mg/l fo r both penicillin  V  and am oxycillin
§ P = penicillin V, A  = am oxycillin
|| Coykendall (1989) c lassification
T ab le  11.4(b) Susceptib ility in MICs to  penicillin  V  and am oxycillin  o f streptococcal species selected in penicillin G only broth from
dental plaque o f subjects exposed or unexposed to p-lactam  antib iotics
Species Unexposed to p-lactams 
(n = 21 isolates)
Exposed to p-lactams 
(n = 65 isolates)
Kilian et al (1989) susceptible * intermediately resistant $ susceptible * intermediately resistant $
classification resistant t resistant t
P§ A P A P A P A P A
Streptococcus oralis 3 (60%) 4(80) 2 1 0 13(32) 17(41) 21 18 7 6
S. mitis biovar 1 1 (25) 2(50) 3 2 0 0 0 5 4 0 1
S. mitis biovar 2 5(56) 5(56) 4 4 0 7(64) 6(55) 3 4 1 1
S. sanauis biovar 4 1 0 0 1 0 1 1 1 1 0 0
S. vestibularis || 0 0 0 0 0 0 1 2 1 0 0
S. sanauis biovar 1 or 3 0 1 1 0 0 0 0 0 0 0 0
S. aordonii biovar 2 or 3 0 0 0 0 0 2 2 2 2 0 0
S. sanauis biovar 2 1 0 0 1 0 0 0 0 0 0 0
Total 11 12 10 9 0 23 27 34 30 8 8
(%) (52.4) (57.1) (47.6) (42.9) (35.4) (41.5) (52.3) (46.2) (12.3) (12.3)
* MIC < 0.12 mg/l for both penicillin V and amoxycillin
t  MICs; 0.25-2 mg/l for both penicillin V and amoxycillin
t M IC > 4.0 mg/l fo r both penicillin V and am oxycillin
§ P = penicillin V, A  = am oxycillin
|| Coykendall (1989) classification
Tab le  11.4(c) Susceptib ility to penicillin V  and am oxycillin  o f isolates selected in penicillin G plus gentam icin only broth from  dental plaque
of subjects exposed or unexposed to p-lactam  antibiotics
Species Unexposed to p-lactams 
(n = 45 isolates)
Exposed to p-lactams 
(n = 9 isolates)
Kilian et al (1989) 
classification
susceptible * 
P§ A
intermediately 
resistant t  
P A
Streptococcus oralis 18 (86%) 21 (100) 3 0
S. mitis biovar 1 7(64) 11 (100) 4 0
S. mitis biovar 2 5(56) 9 (100) 4 0
S. sanauis biovar 4 0 0 1 1
S. vestibularis || 2 2 0 0
S. aordonii biovar 2 or 3 0 1 1 0
Total 32 44 13 1
(%) (71) (98) (29) (2)
resistant t susceptible * intermediately 
resistant t
resistant t
P A P A P A
0
0
5(63) 5(63) 2 3 1 0
0
0
0
0
0 1 1 0 0 0
0 5 6 3 3 1 0
(55.6) (66.7) (33.3) (33.3) (11.1) (0)
* MIC < 0.12 mg/l for both penicillin V and amoxycillin
t  MICs; 0.25-2 mg/l for both penicillin V and amoxycillin
t M IC > 4.0 mg/l fo r both penicillin V  and am oxycillin
§ P = penicillin  V, A  = am oxycillin
II Coykendall (1989) classification
Table 11.5(a) Susceptib ility patterns of viridans streptococci selected in penicillin G and penicillin G plus gentam icin broth from  subjects
(a) on high-dose p-lactam  treatm ent, (b) on penicillin V  rheum atic fever prophylaxis and (c) unexposed to  p-lactam  antibiotic
Isolates from p-lactam exposed groups MIC50/MBC50 MIC90/MBC90
(mg/l) (mg/l)
Penicillin V Amoxycillin Penicillin V Amoxycillin
MIC/MBC range 
(mg/l)
Penicillin V Amoxycillin
High p-lactam exposure group 
12 isolates (9 subjects)
1/2 0.5/1 4/4 8/16 0.12/0.12-4/4 0.06/0.06-16/32
S. oralis I subarouo 
9 isolates
2/2 1/1 4/4 8/16 0.12/0.12-4/4 0.06/0.06-16/32
S.mitis II subarouo 
3 isolates
0.12/0.12 0.25/0.25 1/2 2/2 0.12/0.12-1/2 0.12/0.12-2/2
Rheumatic fever prophylaxis group 
62 isolates (41 subjects)
0.25/0.5 0.25/0.25 4/4 4/4 0.003/0.003-8/16 0.007/0.007-8/16
Unexposed group 0.12/0.12 0.03/0.03 0.5/0.5 0.25/0.25 0.015/0.015-2/2 <0.007/<0.007-2/2
66 isolates (54 subjects)
Table  11.5(b) Susceptib ility patterns of viridans streptococci selected in penicillin G only broth from  subjects (a) on high-dose am picillin
treatm ent, (b) on penicillin V  rheum atic feve r prophylaxis and (c) unexposed to p-lactam  antib iotics
Isolates from p-lactam exposed groups MIC50/MBC50
(mg/l)
MIC90/MBC90
(mg/l)
MIC/MBC range 
(mg/l)
Penicillin V Amoxycillin Penicillin V Amoxycillin Penicillin V Amoxycillin
a) High p-lactam exposure group 
12 isolates (9 subjects)
1/2 0.5/1 4/4 8/16 0.12/0.12-4/4 0.06/0.06-16/32
S. oralis 
9 isolates
2/2 1/1 4/4 8/16 0.12/0.12-4/4 0.06/0.06-16/32
S.mitis biovar2 
3 isolates
0.12/0.12 0.25/0.25 1/2 2/2 0.12/0.12-1/2 0.12/0.12-2/2
b) Rheumatic fever prophylasis group 
53 isolates (33 subjects)
0.25/0.5 0.25/0.25 4/4 2/4 0.003/0.003-8/16 0.007/0.007-8/16
c) Unexposed group
21 isolates (18 subjects)
0.12/0.25 0.12/0.12 0.5/0.5 0.5/1 0.03/0.03-2/2 <0.007/0.015-2/2
Table  11.6(a) Susceptibility (based on MICs) and numbers within susceptibility categories of streptococcal species from dental plaque 
of patients selected in penicillin G and penicillin G plus gentamicin broth from patients on (a) high ampicillin doses and 
(b) on penicillin V rheumatic fever prophylaxis
(a) Short-term high-dose ampicillin recipients 
(n = 12 isolates)
(b) Prolonged penicillin V prophylaxis recipients 
(n = 62 isolates)
Species susceptible 
(<0.12 mg/l)
intermediate 
resistance 
(0.25-2 mg/l)
resistant 
(>4 mg/l)
susceptible 
(<0.12 mg/l)
intermediate 
resistance 
(0.25-2 mg/l)
resistant 
(>4 mg/l)
P A P A P A P A P A P A
Streptococcus oralis 1 2 6 4 2 3 17 20 17 17 6 3
S. mitis biovar 1 0 0 5 4 0 1
S. mitis biovar 2 2 1 1 2 0 0 5 6 3 2 1 1
S. sanauis biovar 4 1 1 1 1 0 0
S. vestibularis (Covkendall) 0 1 2 1 0 0
S. sanauis biovar 1 or 3 0 0 0 0 0 0
S. aordonii biovar 1 or 3 2 2 2 2 0 0
S. sanauis biovar 2 0 0 0 0 0 0
Total 3 3 7 6 2 3 25 30 30 27 7 5
(%) (25) (25) (58) (50) (17) (25) (40.3) (48.4) (58.4) (43.5) (11.3) (8)
Table 11.6(b) Susceptibility (based on MICs) and numbers within susceptibility categories of streptococcal species from dental plaque 
of patients selected in penicillin G only broth on (a) high ampicillin doses and (b) on penicillin V rheumatic fever prophylaxis
(a) Short-term high-dose ampicillin recipients 
(n = 12 isolates)
(b) Prolonged penicillin V prophylaxis recipients 
(n = 53 isolates)
Species susceptible 
(<0.12 mg/l)
intermediate 
resistance 
(0.25-2 mg/l)
resistant 
(>4 mg/l)
susceptible 
(<0.12 mg/l)
intermediate 
resistance 
(0.25-2 mg/l)
resistant 
(>4 mg/l)
P A P A P A P A P A P A
Streptococcus oralis 1 2 6 4 2 3 12 15 15 14 5 3
S. mitis biovar 1 0 0 5 4 0 1
S. mitis biovar 2 2 1 1 2 0 0 5 5 2 2 1 1
S. sanauis biovar 4 1 1 1 1 0 0
S. vestibularis (Covkendall) 0 1 2 1 0 0
S. sanauis biovar 1 or 3 0 0 0 0 0 0
S. aordonii biovar 1 or 3 2 2 2 2 0 0
S. sanauis biovar 2 0 0 0 0 0 0
Total 3 3 7 6 2 3 20 24 27 24 6 5
(%) (25) (25) (58) (50) (17) (25) (37.7) (45.3) (50.9) (45.3) (11.3) (9.4)
Table 11.7(a) S ignificance o f in v ivo  exposure to p-lactam antib iotics on susceptib ility o f dental plaque streptococci a fte r selection in
penicillin  broth including the procedure involving penicillin  G plus gentam icin
p-lactam exposure Penicillin V Amoxycillin
S * R * (%) Significance 
(p-value) t
S R (%) Significance
(p-value)
Short-term ampicillin 
(Subgroup A)
3 9 (75) A vs UE (0.012) 3 9 (75) A vs UE (<0.0001)
Rheumatic fever prophylaxis 
(Subgroup RF)
25 37 (60) A vs RF (NS t) 30 32 (52) A vs RF (NS)
p-lactam exposure 
(Group E)
28 46 (62) RF vs UE (0.008) 32 42 (57) RF vs UE (<0.0001)
Not exposed 
(Group UE)
43 23 (35) E vs UE (0.001) 56 10 (15) E vs UE (0.001)
*
t
t
S = susceptible and R = resistant, including intermediately resistant
p-values are based on either Fisher Exact tests or Yates' correction of Chi-squared
NS = not significant
T ab le  11.7(b) S ignificance o f in v ivo  exposure to p-lactam  antib iotics on susceptibility of dental plaque streptococci a fte r selection in penicillin
broth (w ithout gentam icin)
p-lactam exposure Penicillin V Amoxycillin
S * R* (%) Significance 
(p-value) |
S R (%) Significance
(p-value)
Short-term ampicillin 
(Subgroup A)
3 9 (75) A vs UE (NS t; 0.24) 3 9 (75) A vs UE (NS; 0.16)
Rheumatic fever prophylaxis 
(Subgroup RF)
20 33 (62) A vs RF (NS) 24 29 (55) A vs RF (NS)
p-lactam exposure 
(Group E)
23 42 (65) RF vs UE (NS; 0.37) 27 38 (58) RF vs UE (NS; 0.51)
Not exposed 
(Group UE)
11 10 (48) E vs UE (NS; 0.26) § 12 9 (43) E vs UE (NS; 0.32)
* S = susceptible and R = resistant, including intermediately resistant
t  p-values are based on either Fisher Exact tests or Yates' correction of Chi-squared
% NS = not significant
§ Comparison of E-group vs US-group using MBCs >1.0 mg/l as a criterion of resistance yielded a statistically significant p-value of 0.02
in the case of penicillin V and approached significance in the case of amoxycillin (p = 0.06) as given in Section 11.3.5.2
C h a p te r  12
GENERAL DISCUSSION AND CONCLUSIONS
This chapter will be devoted to the discussion of selected topics 
relating to the present field and will include a substantial sec­
tion on phenotypic tolerance with respect to biofilms in dental 
plaque and its relation to IE prophylaxis. It will conclude with 
a summary of the main findings produced by the in vitro selection 
model and suggest further studies emanating from the findings re­
corded in this dissertation
12.1 Rationale and candidate antibiotic agents for prophylaxis
"... Guidelines are not based on any controlled studies: there 
have never been a placebo-controlled human study on antibiotic 
prophylaxis for the prevention of IE" (Wahl, 1994)
None-the-less, guidelines have been proposed for the administra­
tion of prophylactic antibiotic cover prior to clinical proce­
dures which may produce bacteraemia in persons regarded as being 
susceptible to the development of IE (BSAC, 1982; Special Report, 
1984; BSAC, 1986; BSAC, 1990; Van der Bijl, 1992; AHA, 1990). 
Both parenteral and oral preparations of penicillin are widely 
used as IE-prophylaxis. Amoxycillin is the most commonly recom­
mended /3-lactam agent and is administered orally in large doses 
pre-operatively (3 g for adults) with or without an additional 
post-operative administeration (Van der Bijl, 1992. Penicillin V
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was in vogue in the 1970's and early 1980's but is no longer 
recommended as it offers no advantage over the better absorbed 
and more active amoxycillin. Before the inclusion of clindamycin 
in IE-prophylaxis recommendations, erythromycin was the only 
suitable alternative oral agent in patients allergic to penicil­
lin. Recent efforts by the British Society for Antimicrobial 
Chemotherapy, the American Heart Association and others have 
simplified and standardised prophylaxis regimens (Van der Bijl, 
1992; Wahl, 1994). In this study, the susceptibility to penicil­
lin V, amoxycillin, erythromycin, roxithromycin, clindamycin and 
vancomycin of dental plague-derived streptococci which survived 
selection in overnight broth culture, was determined and the iso­
lates speciated
Various in vivo studies have shown that after the administration 
of most of the candidate antibiotics for purposes of prophylaxis, 
not only does bacteraemia still occur (Phillips et al, 1976; 
Shanson et al, 1978; Hess et al, 1983a), but that bacteria are 
viable (Phillips et al, 1976) and still sensitive to the ad­
ministered antibacterial agent (Hall et al, 1993). The latter 
authors noted that administered prophylactic penicillins 
(penicillin V and amoxycillin) do not prevent the occurrence of 
post-extraction bacteraemia by highly susceptible organisms 
despite the fact that more than adequate blood levels were ob­
tained. The present in vitro model, the validity of which was 
discussed in Chapter 11.5.9, clearly demonstrated the phenomenon 
of phenotypic tolerance. Furthermore, it offers a means for the 
evaluation of candidate antibiotics for IE prophylaxis
12.2 Spectrum of streptococcal species from the oral cavity
The streptococcal species isolated in this study have also been 
recovered from similar sites by other researchers (Longman et
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al, 1991). S. oralis was found to be the predominant species in 
plaque that survived in vitro exposure to penicillin G (Tables 
11.2a and 11.2b). S. sanguis and S. oralis are commonly found on 
(smooth surface enamel of) caries-inactive teeth (Marsh, 1992). 
Of note was the failure to demonstrate in plaque specimens the 
important oral streptococci S . mutans and S. milleri which are 
recognised causes of IE (Bayliss et al, 1983; Young, 1987; 
Franklin, 1992). The absence of hydrogen peroxide-negative 
colonies on the hydrogen peroxide indicator plates (Muller, 1984) 
lends credence to reports that at least one of these species, S . 
mutans, does not commonly colonise smooth dental surface sites 
sampled in this study but rather inhabits retentive (occlusal) 
surfaces (Ellen, 1982). An increase in numbers of this species 
has, however, been reported to be associated with dental caries 
(Marsh, 1992). Additionally, the presence of S . mutans is known 
to be rare in those with a reduced dietary intake of sucrose 
(Hardie, 1983) - a situation which may apply to many subjects who 
participated in this study. While our laboratory approach allowed 
for the identification of alpha-haemolytic S. milleri strains, 
none was found. However, any 13-haemolytic forms of this species- 
complex which includes strains of S . anqinosus, S. intermedius 
and S . constellatus (Kilian et al, 1989; Facklam, 1984; French et 
al, 1989) would have been missed in the present study. S. milleri 
species were identified in another study (Longman et al, 1991) 
from plaque specimens gathered from similar areas, although their 
method of collection differed markedly from that employed in this 
study. The latter researchers were unable to culture S. mutans 
from gingival sulcus material. As its typical habitat was not 
sampled, the failure to isolate S. salivarius was not unexpected. 
Although in vitro exposure to penicillin G and this antibiotic 
plus gentamicin may have affected the isolation of this strep­
tococcal species in the present study, it is likely that 
phenotypically- or genotypically tolerant bacterial cells from 
these species would have survived the selection procedure
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12.3 Phenotypic tolerance
12.3.1 Definition and origin of term
Explanations of the survival phenomenon of susceptible strains in 
the presence of B-lactam and other antibiotics have been offered 
by a number of authors (Hobby et al, 1942; Bigger, 1943; Green­
wood, 1972; Tuomanen, 1986; Gilbert et al, 1990; Shockman et al, 
1979; Brown et al, 1988). The response of bacterial clones to an­
tibiotic pressure may be related to the growth status of the 
original (parent) streptococci within the plaque inoculum. Hobby 
et al noted in 1942 that the antibacterial action of penicillin 
only appeared to occur when "active multiplication" occurred. 
Gilbert et al (1990), in a minireview, postulated that 
asynchronous populations of bacteria contain balanced proportions 
of organisms in the various stages of growth associated with the 
normal cell cycle. As penicillin G and other B-lactam antibiotics 
presumably affect only growing cultures (Tuomanen, 1986; Shockman 
et al, 1979), dormant or near-dormant bacteria in mitotic inter­
phase would remain largely unaffected when subjected to these an­
tibacterial agents, while those which were growing actively would 
either have survived their effects and multiplied if resistant, 
or have been destroyed if susceptible. Toumanen (1986) used the 
term "phenotypic tolerance" to describe this form of bacterial 
behaviour which allows what appears to be "susceptible" bacteria 
survive in the presence of antibiotic agents
12.3.2 Biolayers and biofilms
In a leading article, Brown, Allison and Gilbert (1988) suggested 
that slowly growing organisms within what was termed "biolayers"
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may exhibit phenotypic tolerance. Evans and Holmes (1987) 
described these as being "microbial biofilms" consisting of 
"adherent, dense populations of micro-organisms and their as­
sociated exopolysaccharides...". Gilbert et al, 1990, who widened 
this concept to include chronic infections, called them 
"functional bacterial concortia which grow as adherent biofilms 
within extended polysaccharide glycocalices" and which are able 
to "condition their environment" within this "glycocalyx 
barrier". Although unintended, Gilbert's description of chronic 
infection would serve usefully as one of mature ("chronic") bac­
terial accumulations on dental hard tissue. Marsh (1992) termed 
dental plaque simply as "film(s) of micro-organisms found on the 
tooth surface embedded in a matrix of polymers of salivary and 
bacterial origin" while Hardie (1983) called this material a 
"soft, non-calcified accumulation of bacteria and their products" 
associated closely with the tooth surface and the gingival sulcus
Extracellular glycocalyx barriers synthesised by micro-organisms 
may protect susceptible bacteria by means of two mechanisms. 
Directly, by restricting or preventing the penetration into 
plaque of antibiotic agents (Gilbert et al, 1990; Nickel et al, 
1985; Dali et al, 1987; Dali et al, 1990), or indirectly, by 
slowing cell growth-rate to reduce bacterial sensitivity to par­
ticular agents (Brown et al, 1988). Growth-rate and nutrient 
limitation or deprivation are "fundamental modulators of drug 
activity" (Brown et al, 1988). Glycocalyces may also shield bac­
teria from host defence mechanisms in vivo (Ashby et al, 1994). 
Similar conditions within residual material carried over in 
plaque specimens, existed in the artificial broth-culture selec­
tion system employed in this study ("captive" bacteria enclosed 
within bacterial glycocalyx polymers and adherent salivary 
proteins etc.)
However, Nickel et al (1985) expressed certain reservations about
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the protection supposedly granted to biofilm bacteria as a result 
of cellular dormancy. They stated that an increased degree of 
"metabolic inactivity" (and antibiotic resistance) need not exist 
in bacteria within biofilms when compared to their planktonic 
(free-floating) counterparts. They also propose that (the bac­
teria within) biofilms may actually be more active biochemically 
than planktonic forms but support other workers by emphasising 
that decreased antibiotic susceptibility of biofilms (and in 
their experiment there appeared to be strong evidence for this) 
may be far more as a result of protection granted by the inter- 
celluar exopolysaccharide matrix than that as a result of the 
role played by cellular metabolic activity. If this were to be 
the case in this in vitro ex vivo study, one would have to postu­
late that exopolysaccharide matrix protected bacterial cells in 
the in vitro situation where these bacteria were exposed to an 
active /3-lactam agent in the test tube. It would be interesting 
to explore whether mechanical shearing of matrix may reduce 
phenotypic tolerance in viridans streptococci
Supporting the concept of the importance of dormancy, it has been 
demonstrated in chemostat experiments that killing of certain 
bacteria by 8-lactam antibiotics may vary and that the 
availability of specific nutrients any affect growth rate (Cozens 
et al, 1986. Although the latter authors found that the elimina­
tion of E. coli by amoxycillin was not markedly affected in such 
a system compared with a number of other 6-lacatm antibiotics, 
the effect of this antibiotic on nutrient-deprived viridans 
populations eg. within (mature) "plaque-biofilm" environments, is 
undocumented
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12.3.3 Antibiotic insensitivity of bacteria within plaque 
(biofilm) deposits
As bacteria which enter the blood-stream during surgical and 
other dental procedures originate from dislodged colonies of 
plaque-embedded viridans and other bacteria, the initial metabo­
lic status of the organisms would presumeably reflect both the 
(mitotic) asynchronicity and variable antibiotic sensitivity to 
the administered antibiotics of the original plaque populations 
themselves. Consequently, a /3-lactam antibacterial agent may be 
incapable of destroying simultaneously all plaque-derived or­
ganisms in the blood-stream as dormant or near-dormant subpopula­
tions of phenotypically tolerant organisms would survive its ac­
tion - the presence also of protective extra-cellular substances 
(noted above) notwithstanding. This concept, which is cor­
roborated by our findings (Tables 1, 3-6), questions the postu­
lated efficacy of prophylactic antibiotic regimens used at 
present, irrespective of whether or not the organisms are 
labelled susceptible according to conventional in vitro testing 
criteria
Differing isolate susceptibilities and the selection which oc­
curred within specific groups of isolates described previously 
would tend to support reservations about the effectivity of 
prophylaxis. Hall et al (1993) reported on the apparent inability 
of either penicillin V or amoxycillin to eliminate post­
extraction streptococcal bacteraemia. In their ex vivo study, 
they (as in this investigation), found susceptible strains which 
survived the effects of the two /3-lactams. More than 90% of 
their 126 surviving strains had MICs _£0.125 mg/1 antibiotic
But IE prophylaxis does appear, somehow, to bestow significant 
clinical protection on experimental animals (Bernard et al, 1981; 
Glauser et al, 1983; Pujadas et al, 1986; Moreillon et al, 1986).
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Mechanisms other than bactericidal efficacy are necessary to as­
sist in the protective role (Hall et al, 1993; Glauser et al, 
1982; Berney and Francioli, 1990) and are reported to include the 
sensitisation by antibiotics (penicillin) of bacteria to the ac­
tion of certain protective host factors (Horne and Tomasz, 1980), 
bacterial growth inhibition (Moreillon et al, 1986; Brown et al, 
1988) and the ability of certain antibiotics to interfere with 
bacterial adhesion to tissues (Scheld et al, 1981; Lowy et al, 
1983). Other factors include antibiotic dose and frequency 
(Pujadas et al, 1987; Berney and Francioli, 1990), and bacterial 
inoculum size (Pujadas et al, 1986; Berney and Francioli, 1990; 
Pujadas et al, 1987)
Durack (1995) summarised the rationale for prophylaxis against 
endocarditis simply (? simplistically) as follows: "endocarditis 
usually follows bacteraemia; bacteraemia with organisms which may 
cause endocarditis follows certain health care procedures; these 
bacteria are usually sensitive to antibiotics; therefore, these 
agents should be given to those susceptible to the infection"
Hall et al (1993), in an effort to explain the unexpected sur­
vival of bacteria after the antibiotic prophylaxis, wrote that 
"the protective effect of prophylactically administered penicil­
lins must be due to interference with crucial steps in the 
development of endocarditis - other than the transient bac­
teraemia that occurs"
12.3.4 Use of animal models
It is worth noting that inocula of fresh, actively growing bac­
teria (only) are administered in animal models used to assess the 
potential efficacy of agents employed in prophylaxis regimens 
(Dali et al, 1987; Dali et al, 1990; Bernard et al, 1981; Glauser
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et al, 1983; Pujadas et al, 1986; Moreillon et al, 1986). Animal 
trials using bacteria in the exponential growth phase of their 
cell-cycle would be unable to adequately mimic clinical condi­
tions which might prevail during dental procedures in humans. 
Dental biofilm is likely to contain the metabolically mixed, dor­
mant and asynchronously mutiplying bacterial populations dis­
cussed above
Elements of bacterial populations which originate elsewhere in 
the body and find their way into the blood-stream would be 
similarly constituted (see below)
Microbiological properties of importance during the sterilisation 
of cardiac vegetations in IE-patients under treatment (intact, 
sessile bacterial colonies within enveloping matrices; Gilbert et 
al, 1990) differ materially and physically from those which 
prevail during prophylaxis in susceptible patients of 
bacteraemia-producing events (Brown et al, 1988) - although meta­
bolically dormant or inactive bacteria would occur within both 
vegetations (Cremieux and Carbon, 1992) and suspended bacteraemic 
plaque fragments. To improve success of treatment of valvular in­
fection, infected prostheses and other devices involving vascula­
ture, some understanding of factors affecting bacterial con­
stituents associated with conditions above may be useful (Ashby 
et al, 1994)
Incongruities of the sort raised by Hall et al (1993) remain un­
resolved in the case of IE prophylaxis. Fang et al (1993), in a 
prospective multicentre study, found that lengthened duration of 
antimicrobial therapy failed to prevent the development of en­
docarditis in bacteraemic patients with prosthetic valvular im­
plants. Perhaps dormancy of existing subpopulations within estab­
lished colonies of bacteria (biofilms) adherent to valve pros­
theses - and resistant to the onslaught of normally effective an­
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tibiotics as a result of phenotypic tolerance - played a pivotal 
role in the progression to IE amongst their patients?. And how 
would these dormant subpopulations be able to actively infect 
these patients over a prolonged period while still in the 
presence of antibiotic?. Possibly enveloping serum-protein 
deposits on bacterial colonies may have slowed or hampered at­
tempts at chemotherapeutic sterilisation of IE cardiac vegeta­
tions in a manner which was additional to and separate from that 
exerted by other (unrelated) protective films of an extracellular 
bacterial nature. Or factors such as the paradoxical effect 
(Handwerger and Tomasz, 1985) may have played a meaningful role. 
It is interesting that Tuomanen et al (1986) noted that the most 
abundant sources in the body of tolerant bacteria are those in­
fection sites not easily accessible to the immune system. They 
give the deep seated infections, valvular endocarditis and menin­
gitis as examples - all infections of sites in the body where 
some form of nutrient restriction to infecting organisms occurs 
(see below)
Generally, however, the desired result in compromised patients of 
antibiotic prophylaxis against bacteraemic elements involving a 
growing population of bacteria from any site in the body ought, 
by the very nature of the pathogenic mechanism involved, to be 
similar. Fragments in the blood of suspended asynchronous 
(mature) populations originating from mucosal surfaces of the 
gastro-intestinal, respiratory or female genital tracts 
(Wehrmacher, 1994), as examples, would be subject to the same 
fundamental objectives and principals of prophylaxis as those 
from within the oral cavity itself. On the basis of current con­
cepts and practice, the origin within the body of culprit bac­
teria ought to be of little consequence when appropriate antibac­
terial agents and prophylaxis protocols are employed
The metabolic state of blood-borne or invasive bacteria, and
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their reaction to antibacterial agents, is difficult to simulate 
in artificial (in vitro) systems as noted previously. In a mini­
review, Gilbert et al (1990) highlighted possible behavioural 
properties of bacterial populations involved in chronic infec­
tions (as noted above, dental plaque accumulations fit the 
description of chronic infections admirably - especially long­
standing ones). These cells often exhibit phenomema associated 
with starvation and dormancy under certain biological/ 
physiological conditions. Bacteria in infected valvular vegeta­
tions, for example, - and which exhibit stationary phase cultures 
(Brown et al, 1988), could react unpredictably to antibiotic ac­
tivity and may also be tolerant (Tuomanen et al, 1986) in any 
event (see above)
Besides the effect which cellular metabolic activity may have on 
efficiency of antibiotic activity, the precise mechanism(s) of 
protection exerted by prophylactic agents themselves in the 
development of IE, and discussed in earlier chapters, are confus­
ing and often contradictory. Tuomanen et al (1986) commented on 
the fact that although only bactericidal antibiotic agents are 
acceptible for the successful treatment of endocarditis, studies 
into the prevention of this disease have revealed that the 
prophylaxis process appeared to be far more complex than was 
originally supposed - especially when nonbactericidal concentra­
tions of antibiotic were shown to have the desired protective ef­
fect as well. However, genetic tolerance to certain agents was 
also found to markedly lessen the effectivity of these agents 
when this factor was taken into account. Hess et al (1983), in 
their study on rabbits, found failure of penicillin to protect 
the animals to be closely related to the MBC of penicillin for 
each isolate. But, in 1973, Durack and Petersdorf were the first 
to show that bactericidal action appeared not to be essential in 
prophylaxis - subinhibitory concentrations of streptomycin 
successfully prevented the development of experimental IE. Later
208
in 1981, Bernard et al (1981) published similarly favourable 
results using vancomycin against a tolerant viridans strain. The 
latter authors were able to identify inhibition of bacterial ad­
herence by vancomycin as a mechanism of protection rather than 
its notable killing action
12.3.5 The role of adhesion in the prevention of IE by 
antibiotics
Much of the confusion, some of which is highlighted above, was 
resolved to some degree in the in vitro and in vitro plus in vivo 
experiments of Scheld et al (1981) and Lowy et al (1983), respec­
tively. The former worked on adherence of bacteria to fibrin- 
platelet complexes in the presence of vancomycin, penicillin and 
three other antibacterial agents, whilst the latter studied ad­
herence behaviour to scarred heart tissue of tolerant S. sanguis 
pretreated with penicillin (with the resultant loss of 
lipoteichoic acid). Mechanisms explained by the latter two publi­
cations were noted by Tuomanen et al (1986) to apply to bacteria 
irrespective of their tolerance status, noting further that loss 
of adhesins occurs at concentrations above MICs and that these 
adhesin-related concentrations remain unchanged after the 
development of tolerance
Findings in this dissertation suggest that certain strains 
"primed" for antibiotic resistance in the E-group as a result of 
previous B-lactam exposure, may flourish in the presence of addi­
tional antibiotic pressure at the time of IE prophylaxis. It is 
unlikely that such genotypically resistant strains will lose 
their adherence potential when exposed to antibiotics to which 
they are truly resistant
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12.4 Some conclusions arising from the present in vitro selection
model
12.4.1 Phenotypic tolerance
/3-Lactam antibiotics exert an irregular and unpredictable killing 
effect on metabolically non-uniform or mixed populations of nor­
mally sensitive bacteria. Only dividing cells are killed in such 
populations while nondividing or dormant cells would survive ex­
posure to these agents to exhibit normal sensitivity patterns 
when re-exposed later to the same agents. This appears to be the 
case in the present study. The in vitro results here are in ac­
cordance with the presence of fully susceptible bacteraemic oral 
viridans streptococci in the ex vivo study conducted by Hall et 
al (1993)
12.4.2 Effect of previous antibiotic exposure on genotypic 
resistance
However, the study was able to go further. Bacterial selection in 
B-lactam broths or broths with a /3-lactam plus gentamicin 
produced susceptibility behaviour which differed dependant upon 
the history of the original isolates with regard to prior contact 
with antibiotic agents. This was observed in the UE and E-group 
isolates recovered from penicillin G and gentamicin broth which 
exhibited greater resistance penicillin V and amoxycillin in the 
E-subgroups
12.4.3 Relative merits of candidate drugs for IE prophylaxis
The two macrolides, erythromycin and roxithromycin, plus clin­
damycin appeared to be the most active purely on MBCs alone, fol-
lowed by the two B-lactam agents tested, and vancomycin. However, 
and this is especially important when the bactericidal action of 
agents is explored, when the emergence of persisters and the 
development of tolerance is taken into account, the rankings are 
reversed. On in vitro data alone, vancomycin would appear to be 
an ideal candidate. Its killing of non-growing Streptococcus 
pneumoniae (and therefore probably other alpha-haemolytic 
streptococci) may prove a great advantage (Tuomanen, 1986) and 
needs to be verified
Based on in vitro data, there appears to be little to choose be­
tween the macrolides and clindamycin for IE prophylaxis. The su­
perior pharmacokinetic properties of roxithromycin would be very 
useful in the clinical situation where its far higher serum 
levels, increased activity in macrophages and fewer side-effects 
at therapeutic dosages are apparent
Other apparently useful information emerged from the study. In­
terestingly, with regard to the history of prior 13-lactam an­
tibiotic exposure of a patient at risk of IE, penicillin V ap­
peared to be a better candidate for IE prophylaxis use than 
amoxycillin in patients who had not had 13-lactams in the previous 
three months because of a lesser chance of persisters developing. 
On the other hand, in someone who had had antibiotics during this 
time, amoxycillin would appear to be the wiser choice for the 
same reason
12.5 Concluding remarks
The in vitro model used in the present studies demonstrated 
selection of both phenotypically tolerant and genotypically 
resistant strains of viridans streptococci. The findings gen­
erated by the model are likely to reflect the status of bac-
teraemic streptococci following procedures which would disturb 
dental plaque and lead to plaque-derived bacteria entering the 
blood circulation where they are exposed to candidate /3-lactam 
(or other) prophylactic agents. Some modifications to the model 
which are mooted in Chapter 11 (Section 11.5.9) may be considered 
in future studies
Because of their bactericidal activity against streptococci, the 
macrolides - especially roxithromycin based on its improved phar­
macokinetics - and clindamycin would be good candidates for study 
in the model. Newer macrolides such as clarithromycin and azith­
romycin, with their superior pharmacokinetic properties, could 
also be studied, while vancomycin is perhaps the most deserving 
candidate for further investigation. Evidence reported by 
Tuomanen (1986) that this agent may be active against metabo- 
lically inactive streptococci can be tested in this model which 
hopefully will show reduced phenotypic tolerance against van­
comycin
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